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Abstract 
Background 
Pancreatic cancer has the lowest survival rate of all cancers in Australia, with an estimated five-year 
relative survival of 6%. Screening for early pancreatic cancer is currently not feasible and at present 
there are no new systemic treatment regimens on the horizon that will radically alter prognosis. 
Therefore, in the short-term, the largest improvements in patients’ outcomes will be gained through 
ensuring that all patients receive optimal (or best-practice) care. 
International evidence suggests that some evidence-based treatments for pancreatic cancer are 
under-utilised and that there is inequitable access to high-quality care. In Australia, there is very 
little current population-based information on the types of care that patients with pancreatic cancer 
receive, nor the factors that influence the care provided. Given Australia’s unique geography and 
health-system, local information is required to understand patterns-of-care for patients with 
pancreatic cancer as well as the sociodemographic and health-service factors associated with receipt 
of optimal care in this country.  
Aims 
The aims of this work were to: 
1. Identify indicators of care that clinicians believe important in the management of patients 
with pancreatic cancer 
2. Describe the proportions of pancreatic cancer patients who receive different treatment 
modalities. 
3. Identify determinants of variability in delivery of cancer-directed therapies. 
4. Determine if patient, tumour or health service factors influence survival of patients with 
non-metastatic disease. 
5. Develop a quality-of-care score based on the indicators of care identified by clinicians and 
(a) investigate factors associated with the quality-of-care score; and (b) examine the 
association between the quality-of-care score and overall survival. 
Methods 
The research described in this thesis was nested within a population-based study of patterns of care 
for Australian patients with pancreatic cancer. The study was a retrospective comprehensive 
medical record review of all patients diagnosed with pancreatic cancer in Queensland (QLD) and 
New South Wales (NSW) between July 2009 and December 2010 (NSW) or June 2011 (QLD).  
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We used a Delphi process with a range of clinical specialists to identify indicators of optimal care. 
We applied the mean score of importance to the clinical data to calculate a quality-of-care score for 
patients in the patterns-of-care study. 
Data from the patterns-of-care study were also used to describe management and treatment patterns, 
and survival outcomes. Factors related to the quality-of-care score and receipt of surgery were 
investigated. 
Statistical analyses included multivariable logistic regression, Kaplan-Meier methods to construct 
survival curves and estimate survival times, and Cox proportional hazards models.  
Results 
The NSW and QLD cancer registries identified 2090 patients as potentially eligible for inclusion in 
the patterns-of-care study cohort. Records were reviewed for 2003 (96%) patients and 140 (7%) of 
these were found to be ineligible for the study. The median age of the 1863 eligible patients was 72 
years, 54% were men and over half had metastatic disease at diagnosis. 
The Delphi process included responses from 63 participants (66% of those sent the final 
questionnaire; 25% of those initially invited). Specialties of the participants invited included 
surgery, medical oncology, allied health and nursing, gastroenterology, palliative care, radiation 
oncology, interventional radiology, general practice, gerontology and medicine. Consensus was 
reached for many items, such as the need for patients to be assessed by a hepatobiliary surgeon, for 
surgery to occur in a high-volume centre and the importance of management by a multidisciplinary 
team, but there was some variability according to the specialty of the clinician. Surgeons tended to 
prioritise surgical factors and, compared with other clinicians, considered supportive care less 
important. 
Among the patients in the patterns-of-care study, the median survival was 4.5 months and 22% 
were alive at least one year after diagnosis. Consistent with the international literature, 
approximately 15% of patients underwent resection of their primary tumour and three quarters of 
these received adjuvant chemotherapy. Less than half of the patients were reviewed by a 
multidisciplinary team, and only 51% of patients who did not have metastatic disease were 
reviewed by a specialist hepatobiliary surgeon.  
Age, comorbidities, tumour stage and increasing remoteness of residence were significantly 
associated with poorer survival in patients without metastatic disease at diagnosis. This is likely to 
have been at least partially influenced by access to surgery, with patients from rural areas being less 
likely to be offered resection of their tumour than those living in cities.   
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For the quality-of-care scores derived from the Delphi process, the scores for patients living in rural 
or more socio-economically disadvantaged areas were statistically significantly lower than for 
patients living in major cities or least disadvantaged areas. Quality-of-care scores were higher for 
patients who were younger, with better performance status, or who first presented to a hospital with 
a high pancreatic-cancer-case volume. Higher scores were associated with better survival. 
Conclusions 
This research emphasised the importance of highly expert care in the management of patients with 
pancreatic cancer, but found that care was highly variable and dependent on a range of factors, 
including region of residence.  Implementing strategies to ensure equitable access to optimal care 
for all patients diagnosed with pancreatic cancer, may improve outcomes for people diagnosed with 
this devastating disease. 
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1.1. INTRODUCTION 
In developed nations pancreatic cancer is the 10th most common cancer.1 However it has the worst 
survival of any cancer type so it is the 5th most common cause of cancer death in men and the 4th 
most common in women. Current statistics suggest that one out of every 72 people in Australia is 
likely to die from pancreatic cancer before the age of 85- a total of about 2800 deaths per year.2  
Currently the only potentially curative treatment is resection of the pancreatic lesion. Patients who 
undergo a completed resection have five-year survival of approximately 15-20% compared to less 
than 5% for the 80% of patients who are diagnosed at a stage when resection is not possible due to 
invasion of nearby blood vessels or the presence of distant metastases. There are a variety of 
chemo- or radio-therapeutic options available for use in either adjuvant or palliative settings. These 
treatments provide only modest survival gains but can offer improvements in quality of life.3 
Ensuring best practice care for all patients may lead to improvements in survival and/or quality of 
life. Recommendations regarding diagnosis, staging and treatment of pancreatic cancer arose from 
the World Congress on Gastrointestinal Cancer (Barcelona 2006)4 in 2006, and a 2012 meeting led 
to additional recommendations for management of metastatic cancer.5 The United States National 
Comprehensive Cancer Network (NCCN)6 has also published guidelines. Despite these 
publications there is evidence from a range of countries that there is variability in management and 
under-use of treatment for patients diagnosed with pancreatic cancer.7-9 Rurality of residence, 
socio-economic status, marital status and age have all been shown to influence the treatment and 
management of care that patients receive.10-13 
In Australia there appears to be variability in survival according to location of residence, with 
people living in rural areas having poorer survival than those in cities.14, 15 The reasons for survival 
disparities are unclear, although differences in access to treatment have been suggested.16, 17 
There have been few attempts to describe management of pancreatic cancer in Australia. A 
population-based study in Victoria described under-utilisation of treatments but, apart from 
examining the association with age, they did not explore patient or health system factors that might 
influence treatment decisions.18 In addition, the situation may have changed in the decade since the 
data for that study were collected and patterns observed in Victoria, a small and relatively 
urbanised state, may not be generalisable to other states. Describing patterns of care is important to 
identify avenues for ensuring that all patients receive optimal care.19 
This literature review provides background information pertinent to my doctoral research project. It 
includes information regarding the anatomy and function of the pancreas and the epidemiology of 
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pancreatic cancer. It then describes risk factors and symptoms of pancreatic cancer and approaches 
to management including diagnosis, staging and treatment. Patterns-of-care studies are reviewed 
including the methods used, the quality of the studies and the key results found. The variations in 
receipt and quality of care are described, as are the determinants of access and the relationships 
between management and care received and patients’ outcomes.  
1.2. OVERVIEW OF THE THESIS 
This thesis entitled “Patterns of care in patients with pancreatic cancer” includes a review of current 
literature; methods; three published manuscripts and one accepted manuscript as results chapters; 
followed by a discussion and conclusion of the findings of this research.  
Chapter 1 includes an appraisal of the literature associated with the research aims, with a focus on 
the epidemiology of pancreatic cancer, optimal care for patients with pancreatic cancer, current 
patterns of care and factors associated with care and management, both in Australia and 
Internationally. 
Chapter 2 states the aims and hypotheses of the research. 
Chapter 3 provides an overview of the methods and includes a description of my contribution to 
the research. Further details, particularly of analytical methods, are shown in the methods section of 
each published manuscript. 
The results are presented in Chapters 4 to 7 (all published or in press manuscripts). 
Chapter 4 identifies factors of care that pancreatic cancer clinicians identified as important in the 
care of patients with pancreatic cancer. This was completed using a Delphi process which enabled 
each factor to be quantified. The factors and scores are presented in a published manuscript.  
Chapter 5 includes a publication which presents an overview of patterns of care for patients with 
pancreatic cancer in NSW and QLD.  
Chapter 6 presents mortality and survival rates for patients diagnosed with non-metastatic disease 
and factors associated with 1) survival; 2) determinants of classification as potentially resectable; 
and 3) determinants of attempted resection. 
Chapter 7 shows the development of an overall quality-of-care score based on the factors 
identified during the Delphi process.  Factors associated with the score and the association of the 
score with survival are presented.  
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Chapter 8: offers a comprehensive discussion of the research, including an overview of the 
significant findings, how the findings relate to other recently published literature and the strengths 
and limitations of the research. The implications of the results, including future issues to be 
considered to improve outcomes for patients diagnosed with pancreatic cancer are also discussed, 
followed by a conclusion. 
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Literature review 
1.3. ANATOMY AND FUNCTION OF THE PANCREAS 
The pancreas lies across the back and centre of the abdomen behind the stomach and close to the 
kidneys, spleen and liver. It is a long tapered organ with the widest part (the head) near the 
duodenum, extending through the body to the tail, which is situated near the spleen. It is 
surrounded by major arteries and veins as shown in Figure 1-1.20  
 
Source: The Pancare Foundation20 
Figure 1-1: Anatomy of the pancreas in the abdomen 
The pancreas is a glandular organ, vital to metabolism, made up of two types of glands: exocrine 
glands which secrete digestive enzymes used by the body to break down fats, proteins and 
carbohydrates; and endocrine glands that secrete hormones, most notably insulin and glucagon, 
which regulate blood glucose levels.  
1.4. PANCREATIC CANCER CHARACTERISTICS 
Almost 95% of all pancreatic cancers arise in pancreatic exocrine tissue and are classified as 
exocrine tumours, usually invasive ductal adenocarcinomas. Other pancreatic cancers include 
slower-growing neuroendocrine tumours, rarer acinar cell carcinomas which are associated with the 
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release of digestive enzymes into the bloodstream, and low-grade solid-pseudopapillary neoplasms 
which mainly arise in young women.21  About 75% of pancreatic cancers arise in the head of the 
pancreas, 15-20% in the body and 5-10% in the tail of the pancreas.22 The most frequent site of 
metastases from pancreatic adenocarcinomas is the liver (~75%), but spread to the peritoneum, 
lymph nodes, bone, lung and pleura also occurs.23  
The focus of this thesis will be on pancreatic adenocarcinoma. The term pancreatic cancer from 
here-on will refer to pancreatic adenocarcinoma unless otherwise stated. 
1.5. BIOLOGY OF PANCREATIC CANCER 
Pancreatic cancer is genetically highly heterogeneous, but mutations in a number of key driver 
genes have been identified.24 The most common of these are activating mutations in the KRAS 
oncogene, which is mutated in over 90% of all pancreatic cancers. Inactivating mutations in three 
tumour suppressor genes (CDKN2A, TP53, SMAD4) have been identified in over 30% of all 
pancreatic cancers.25 In addition to these genes there are many more that are mutated at low 
frequency, some of which will also be driver genes. 
The most widely accepted model of pancreatic carcinogenesis is that the tumour originates in well-
defined precursor lesions called pancreatic intra-epithelial neoplasms (PanINs). These progress 
from low-grade PanIN-1A lesions through to high-grade Pan-IN-3 lesions over a period of at least 
10 years.26  KRAS appears to be the earliest mutation, with other genes becoming mutated during 
the progression to neoplasia. After the founder cell is originated it takes approximately a further 
five years for the development of metastatic potential.27 Thus, a long window exists during which 
early detection could potentially reduce the risk of metastatic pancreatic cancer.21 
Pancreatic cancer is characterised by the presence of dense collagenous stromal tissue.  The stroma 
contains a variety of cells, including pancreatic stellate cells (PSCs). There is a complex interplay 
between PSCs and pancreatic cancer cells.28 Pancreatic cancer cells release chemokines that recruit 
PSCs to their vicinity and promote their activation. The PSCs then participate in pancreatic cancer 
progression by stimulating proliferation, inhibiting apoptosis and promoting cancer cell 
migration.29 This, along with the challenges of drug delivery through the dense surrounding tissue, 
is thought to contribute to the highly aggressive nature of pancreatic cancer. However, two recent 
studies have suggested that the stroma may actually protect against progression, raising the 
possibility that the role of PSCs may be context dependent.30, 31 
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1.6. EPIDEMIOLOGY OF PANCREATIC CANCER 
1.6.1. Incidence 
Pancreatic cancer is the 10th most commonly diagnosed cancer in Australia (Figure 1-2).32 Current 
statistics estimate that one out of every 65 people are likely to develop the disease before the age of 
85 years.2 The age-standardised incidence rate is 6.6 per 100,000. This is consistent with figures 
from other more developed countries in the world.1 
  
Source: Australian Institute of Health and Welfare32 
Figure 1-2: The estimated 10 most commonly diagnosed cancers, Australia, 2014 
The incidence of pancreatic tumours has been gradually rising in Australia, particularly in women, 
with an age-standardised incidence rate per 100,000 population of 7.5 in 1980, rising to 9.8 in 2012 
(Figure 1-3).32   
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Source: Australian Institute of Health and Welfare32 (Age-standardised to the 2001 Australian standard population) 
Figure 1-3: Australian age-standardised (per 100,000 population in Australia 2012) incidence 
rate of pancreatic cancer by year 
Pancreatic cancer is predominantly a disease of older age. The median age at diagnosis is about 70 
years and it is rarely diagnosed in patients under the age of 40 years (Figure 1-4).2, 33 
  
Source: Australian Institute of Health and Welfare32, 34 
Figure 1-4: Age-specific incidence rate by age group, for 2012 
Developed regions of the world have a much higher age-standardised incidence rate of pancreatic 
cancer than less developed regions (7.2 and 2.8 per 100,000 population respectively) (Figure 1-5).1 
It is likely that this is at least partly related to differences in diagnosis and cancer registration. 
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Figure 1-5: World Areas, estimated age-standardised (per 100,000 world population 2012)  
Incidence and Mortality rates of pancreatic cancer by gender. 
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1.6.2. Mortality and Survival 
People diagnosed with pancreatic cancer have the poorest prognosis compared with people 
diagnosed with any other cancer and it is thus the fourth leading cause of cancer-related death in 
Australia.35 One-year overall survival is currently 20%, and 6% of patients survive five years 
following diagnosis, which mirrors survival estimates from other western countries.32, 36, 37 Despite 
some modest improvement in five-year relative survival (Figure 1-6),38, 39,  unlike some cancers that 
have experienced dramatic recent reductions in mortality rates such as breast and colorectal 
cancers,35 current projections suggest that pancreatic cancer will be the second leading cause of 
cancer death in the United States (USA) before the year 2030.40 
 
Figure created with data sourced from references32, 34, 39  UK: United Kingdom; USA: United States America 
Figure 1-6: Five-year relative survival over time in Australia, United Kingdom and United 
States 
1.7. RISK FACTORS ASSOCIATED WITH PANCREATIC CANCER 
A number of factors have been consistently associated with risk of pancreatic cancer. These 
include:  
 Cigarette smoking: Current smokers are almost twice as likely to develop pancreatic 
cancer as non-smokers.41, 42 It has been estimated that 23% of pancreatic cancers 
diagnosed in Australia have cigarette smoking as a contributing risk factor.43 
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 Obesity: People with a body mass index of > 25kg/m2 have a 25% increase in risk of 
pancreatic cancer compared to those ≤ 25 kg/m2,42, 44 and for each 5-unit increase in body 
mass index there is a 10% increase in risk.45 Approximately 8% of pancreatic cancers in 
Australia are attributable to being overweight or obese.46  
 Alcohol consumption: Heavy alcohol consumption (three or more alcoholic drinks per 
day) compared to low consumption increases the risk of pancreatic cancer by about 
40%.42, 47 More modest alcohol intake does not appear to influence the risk of developing 
pancreatic cancer. 
 Race: More African Americans develop pancreatic cancer than white Americans but this 
increased risk may be due to differences in smoking status or other lifestyle factors.48 
 Diabetes: Long-standing diabetes increases the risk of pancreatic cancer. Onset of diabetes 
within 2-8 years prior to study entry has been associated with an 80% increase in the risk 
of pancreatic cancer.49, 50 Patients with diabetes and chronic pancreatitis are more than 
twice as likely to develop pancreatic cancer as diabetics without chronic pancreatitis.51 
 Genetic factors: Approximately 10% of pancreatic cancer cases occur in high-risk 
families. Known genetic syndromes, such as Peutz-Jeghers account for a small proportion 
of these, with the underlying mutations unknown for a high proportion of familial cases. 
The standardized incidence ratio can be as large as 17 for people with three or more first-
degree relatives who developed pancreatic cancer.52-54 
 Diet: The role of diet in risk of pancreatic cancer is not entirely clear although there is 
some evidence that fruit consumption can reduce risk 42 and consumption of red meat and 
nitrosamines can increase risk.55 
1.8. SYMPTOMS OF PANCREATIC CANCER 
Symptoms of pancreatic cancer are often non-specific and this possibly contributes to the late stage 
of presentation. Symptoms can include vague abdominal discomfort, nausea, anorexia, weight loss, 
changed bowel habits, fatigue and lethargy. There are some more specific symptoms including 
jaundice, epigastric pain, diabetes and pancreatitis and it is often these that will trigger clinical 
presentation.  
Jaundice: If the tumour arises in the head of the pancreas the common bile duct is often blocked 
causing increased levels of bilirubin in the blood. This in turn leads to jaundice (yellow 
pigmentation of the skin and eyes), dark urine and pruritus (itchy skin). Jaundice occurs in up to 
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70% of patients with cancer of the head of the pancreas,56 but is less frequent if the tumour occurs 
more distally. 
Epigastric pain: The coeliac plexus is a group of nerves very close to the pancreas, and as the 
disease spreads patients are often troubled by severe pain due to involvement of these nerves. This 
pain is usually described as epigastric pain but often radiates through to the back and shoulder, 
particularly if the liver is involved.  
Diabetes: Diabetes or hyperglycaemia is found in up to 85% of patients diagnosed with pancreatic 
cancer.57 It has been suggested that newly diagnosed diabetes could be indicative of a pancreatic 
cancer diagnosis.58 Recognition of newly diagnosed diabetes as an early manifestation of pancreatic 
cancer could be exploited as a screening tool, although this may be unfeasible due to the large 
number of people diagnosed with diabetes and the relatively rare diagnosis of pancreatic cancer.59 
Pancreatitis: Occasionally pancreatic cancer can also cause acute pancreatitis60 which is 
characterised by severe abdominal pain.61  
1.9. CLINICAL MANAGEMENT OF PATIENTS WITH PANCREATIC CANCER 
1.9.1. Diagnosis and staging of pancreatic cancer 
Accurate diagnosis and staging in patients with a differential diagnosis of pancreatic cancer is 
difficult due to the anatomic location of the pancreas.  Recent developments in medical imaging 
have made diagnosis and staging less complex, but these investigations often require specialised 
equipment and expertise.62 There are various investigations that can be used to assist diagnostic 
confirmation and staging of the disease. 
Computed tomography (CT): Non-contrast CT scans have poor sensitivity and specificity for 
pancreatic cancers and evaluation of the extent of  tumours, thus are only recommended for patients 
unable to tolerate iodine contrasts.63 However, a multiphase CT scan with contrast provides high 
image resolution and information on tumour extent, organ and vascular involvement, lymph node 
and hepatic metastases. It is the primary method for evaluating resectability,60 and is able to predict 
surgical resectability with about 85% accuracy.58 It is generally accepted that the optimal test for 
diagnosis and staging is a contrast-enhanced CT scan64 and that expertise in interpreting these 
pancreas-protocol scans in high-volume specialist centres improves staging accuracy and 
management in patients with pancreatic cancer.65  
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Endoscopic ultrasound (EUS) and endoscopic retrograde cholangio-pancreatography (ERCP) are 
used to assess the tumour, vascular invasion (particularly the portal and splenic vein), tissue 
diagnosis, lymph node disease (reliably identifying disease in coeliac and mediastinal nodes), small 
volume liver disease, peritoneal ascites and to visualize the pancreatic ducts, all of which help to 
ascertain the resectability of the tumour. If a mass is observed during the EUS a fine needle 
aspiration (FNA) is performed with the sensitivity for diagnosing pancreatic cancer by EUS-FNA 
being approximately 85%.66 The main limitation of EUS is its functional dependence on the 
expertise of a gastroenterologist, but with the increasing use and accuracy of pancreas-protocol CTs 
to assess resectability, the need for EUS is declining.63  ERCP is predominately used for palliation 
of biliary obstruction and has a limited role in defining resectability of the tumour.63 
Magnetic resonance imaging (MRI) [and magnetic resonance cholangiopancreatogram (MRCP)] 
enables clinicians to investigate the extent of the pancreatic tumour and the biliary and pancreatic 
ducts in patients who have equivocal findings following a pancreas-protocol contrast CT and/or 
following endoscopic ultrasound. MRCP provides better imaging of the pancreaticobiliary tree than 
other imaging modalities, requires no administration of contrast and can identify liver metastases 
but is dependent upon availability of the resource and relevant expertise.63 
Positron emission tomography (PET) is a nuclear medicine imaging technique which produces a 
three dimensional image and is able to distinguish between normal cells and rapidly dividing cancer 
cells. Sensitivity of PET for pancreatic cancer ranges from 73% to 92% and specificity from 68% to 
86%.63 It can detect pancreatic metastases with about 80% reliability.67  For this reason it is often 
used for patients with potentially resectable disease to detect small metastases in the liver or lymph 
nodes that would suggest resection is an inappropriate course of management.  
At the time this patterns-of-care study was completed PET scanning facilities were rarely available 
in rural or remote areas due to the necessity to regularly transport radioactive material for their use 
and the extensive requirements and costs of establishing specialised facilities. The number of PET 
facilities has since increased, with approximately 15 facilities in both QLD and NSW in 2016.68 
Laparoscopy/laparotomy: A laparoscopy (keyhole surgery) or a laparotomy (open surgery) can be 
performed by a surgeon to obtain a tissue diagnosis and investigate the resectability of the tumour. 
This is particularly useful if the imaging is unclear regarding major arterial blood vessel 
involvement and can prevent the morbidity associated with major surgery. Laparoscopy has been 
shown to be less reliable than a full laparotomy to predict distant metastases.69 Although previous 
reports suggest laparoscopy is able to identify occult metastases in up to 50% of cases, it has been 
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argued more recently that this proportion has fallen and laparoscopies are no longer required due to 
the increasing sensitivity of CT scans.70  
Biomarkers: There are no accurate or tumour-specific diagnostic blood tests available for 
pancreatic cancer although the carbohydrate antigen 19-9 (CA 19-9) test is widely used. A meta-
analysis reported that elevation of CA 19-9 has both a sensitivity and specificity of 80%.71  CA 19-
9 has limited diagnostic use as approximately 10% of the population is unable to synthesise CA 19-
9, and levels may also be elevated in patients with other benign pancreatic diseases,72 and with 
other gastrointestinal cancers.73 It should therefore be used alongside other diagnostic techniques in 
the diagnosis of pancreatic cancer.60 It is the only biomarker recommended for routine use as an 
indicator of treatment response and for disease monitoring.74, 75 
Ongoing investigations and clinical trials are being conducted to determine the clinical significance 
of screening and diagnostic biomarkers, such as the S100 and MUC proteins,76, 77 to enable early 
detection, prognostic biomarkers to predict survival patterns78 and predictive biomarkers to 
personalise treatment regimens,75 Further trials are investigating diagnostic tests to identify 
circulating tumour cells, although these cells are only likely to be found in patients with metastatic 
disease, or to detect circulating DNA which has been detected in 43% of patients with localised 
pancreatic cancer.79 
1.9.2. Stages of pancreatic cancer 
The extent of a pancreatic cancer’s  growth  and spread is routinely classified using the TNM 
coding system.80, 81 This was developed by the International  Union Against Cancer (UICC)82 and 
the American Joint Committee  on Cancer (AJCC).83 The T refers to the size of the primary tumour 
and whether it has infiltrated to adjacent vessels or organs; the N refers to involvement of regional 
lymph nodes; and the M refers to whether the cancer has metastasised to distant organs such as the 
liver or lungs (Table 1-1).81 
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Table 1-1: Current (7th edition) TNM classification for pancreatic cancer 
Primary Tumour (T) 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour limited to the pancreas, ≤ 2 cm in greatest dimension 
T2 Tumour limited to the pancreas, > 2 cm in greatest dimension 
T3 Tumour extends beyond the pancreas but without involvement of the celiac axis or the superior 
mesenteric artery 
T4 Tumour involves the celiac axis or the superior mesenteric artery (unresectable primary 
tumour) 
Regional lymph nodes (N) 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
 
Classification of the TNM stage for pancreatic cancer is problematic, mainly due to the lack of 
definition for “extending beyond the pancreas” in the classification of T3. Clinicians debate 
whether the involvement by tumour of: (1) peri-pancreatic soft tissue or (2) the common bile duct 
which extends from the pancreas, are classified as “confined to the pancreas” or “extended beyond 
the pancreas”. These issues result in a highly subjective classification of T3.84 Until recently all T3 
tumours were thought to be unresectable, but with the improvement in surgical techniques, 
resectability of the main blood vessels may be viable;85, 86 hence the T-stage no longer determines 
resectability and there is a need to redefine a "T" for such cases.87 
From the TNM coding the overall stage of the disease can be determined from stage 0 to stage IV 
with stage IV cancers having the worst prognosis (Table 1-2).  
Pancreatic cancer has often progressed to become locally advanced or metastatic at the time of 
diagnosis.60 Approximately half of all pancreatic cancer patients are diagnosed with metastatic 
disease, 10-20% are found to have localised disease confined to the pancreas and 20-30% with 
locally advanced disease.12, 33, 58 Large proportions of patients (20 - 50%) have unstaged disease in 
most population-based studies.12, 33 In NSW, as recorded by the NSW Cancer Registry, in 2006 
17% were diagnosed with localised, 13% with regional disease, 44% had metastatic disease, and 
26% unknown stage.88 
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For patients diagnosed with disease confined to the pancreas, median survival is approximately 15-
20 months, compared with 10 months for patients with locally advanced disease and 3-6 months for 
patients with metastatic disease.21, 89-91  
Table 1-2: Stage of disease according to TNM and clinical classification and United States estimated 
five-year survival 
Stagea       TNMa Clinical disease status Resectability classification  5-year  survival92 
0 Tis, N0, M0 Carcinoma in situ Resectable n/a 
IA T1, N0, M0 Localised Resectable 14% 
IB T2 ,N0, M0 Localised Resectable 12% 
IIA T3, N0, M0 Locally advanced Potentially resectable 7% 
IIB T1 - T3, N1, M0 Locally advanced Potentially resectable 5% 
III T4, Any N, M0 Locally advanced Potentially resectable 3% 
IV Any T, Any N, M1 Distant metastases Non-resectable 1% 
a Stage and TNM classification of disease according to UICC, 7th edition  
1.9.3. Treatment 
Accurate staging provides the foundation for optimal treatment.93-95 For patients with stage I and 
stage IIa disease complete resection of the tumour is advised followed by adjuvant chemotherapy or 
adjuvant chemoradiation therapy,6, 96 while for patients with locally advanced or potentially 
resectable stage IIb or III disease, neoadjuvant treatment is often recommended.  Neo-adjuvant 
treatment enables the latency of the tumour to be observed, preventing needless costs and resultant 
morbidity of surgery if progression of the tumour occurs, or facilitates surgical resection and 
improves surgical margins if the tumour responds to treatment.6, 97-104 The survival benefit of neo-
adjuvant treatment is unproven so its use should be restricted to clinical trials,6 particularly in the 
absence of agreed criteria to select patients who may become operable. Adjuvant treatment usually 
consists of chemotherapy alone, although radiation therapy is occasionally prescribed for patients at 
high-risk of local recurrence (for example if surgical margins were involved) following resection.  
Chemotherapy is recommended for patients with Stage IV disease if they have adequate 
performance status. If patients are unable to receive systemic therapy, have poor performance status 
or if they have recurrent or metastatic disease, supportive care which includes palliative care and 
symptom management, should be provided.6, 21, 105 Palliative radiation therapy is used for patients 
who have symptomatic local disease or distant metastases.  
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1.9.4. Surgery 
Surgical removal of the pancreatic neoplasm remains the only reliable curative treatment modality 
but is only possible in about 15-20% of cases.10, 106 Population-based studies have shown that 
surgical resection of the primary tumour is under-utilised.12, 106, 107 Almost a third of all planned 
pancreatectomies commence but are then abandoned due to the cancer being more extensive than 
suggested by imaging.100 Of those patients receiving a complete resection, 70% survive more than 
one year.98, 100, 101 Five-year survival among patients who have surgery is approximately 20-25% 
compared to less than 5% for patients with no resection of their primary tumour.32, 33, 108  
Depending on the location of the tumour in the pancreas various surgical procedures are performed. 
For tumours arising in the head or body of the pancreas, a Whipple’s procedure 
(pancreaticoduodenectomy) is usually performed, or occasionally a total pancreatectomy. Tumours 
in the tail of the pancreas require a distal pancreatectomy, often including removal of the spleen.109 
Distal pancreatectomy is now often performed laparoscopically which results in a decrease in 
length of hospital stay as well as a decrease in surgical complications. 110 Surgical post-operative 
complications, including pancreatic fistula, anastomotic leak, blood loss, pancreatic enzyme 
insufficiency and wound infection, occur in approximately 35-65% of patients following 
pancreaticoduodenectomy.111-113 
Systematic reviews and international studies suggest that patients who undergo surgery in a high-
case-volume or tertiary academic hospital with an experienced surgeon are more likely to receive 
optimal care and have better outcomes including longer overall survival (meta-analysis of 5-year 
survival for high-case volume compared with low-case volume hazard ratio (HR) 0.79; 95% 
confidence interval (CI): 0.70 - 0.89),114 lower readmission and mortality rates (meta-analysis of 
hospital mortality for high compared with low volume (odds ratio (OR) 0.32; 95% CI 0.16 – 
0.64),114 and lower surgical complication rates following surgery.13, 85, 106, 114-135  
Guidelines are inconsistent about what constitutes a high-case-volume hospital, with the NCCN 
recommending a minimum of 15 resections per year,6 the National Cancer Institute Guidelines 
recommending five136 and the British Society of Gastroenterology not specifying a particular 
number.137 A systematic review of general surgeon case volume suggested that surgeons should 
perform at least four pancreatic cancer resections each year to maintain expertise and associated 
better outcomes.119, 138, 139 
The volume of pancreatic surgery undertaken at the hospital has also been shown to be associated 
with outcomes for patients in Australia.140, 141 There is evidence that surgical inexperience, not 
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solely for the surgeon but for the entire surgical team, for complex surgeries including pancreatic 
surgery, is detrimental to patient survival outcomes.142  
1.9.5. Chemotherapy 
Chemotherapy can be prescribed as a cytotoxic agent or radio-sensitiser in the adjuvant setting or to 
relieve symptoms and improve quality of life (QOL) in the advanced disease setting.8, 143-145  The 
administration of chemotherapy has increased over time and improves survival and QOL.3, 12, 91, 124, 
146 
Clinical practice guidelines recommend adjuvant chemotherapy to reduce the risk of recurrence 
following resection of the primary pancreatic tumour.6, 147 Gemcitabine has been standard 
chemotherapy administered as adjuvant therapy since the publication of the CONKO-O01 trial 
which showed an increase in median disease-free survival of 13.4 months for patients receiving 
gemcitabine compared to 6.9 months for those in the observation alone arm.143 A recent trial 
(JASPAC-01) of adjuvant S-1, (an oral 5-fluorouracil drug) versus gemcitabine conducted in Japan 
was discontinued early on the recommendation of the independent data monitoring committee due 
to significant results in favour of the S-1 treatment. Follow-up data from the study has shown a 
statistically significant improvement in survival for patients who received the S-1 compared to 
those receiving gemcitabine (HR 0.57; 95% CI: 0.44 – 0.72) associated with 24% five-year overall 
survival for the gemcitabine group compared to 44% for the S-1 group. S-1 is now recommended 
as the standard of care for resected pancreatic cancer in Japanese patients.148 
For patients with advanced disease there are limited curative treatment options and symptom 
control has been the primary aim of management. In 1997 a landmark randomised controlled trial 
showed that gemcitabine resulted in a modest survival benefit over 5-fluorouracil but it delivered 
substantial improvements in pain and performance status.149 Gemcitabine subsequently became the 
standard of care for first line treatment in patients with advanced disease. There are attempts to find 
new drug combinations to further improve survival and QOL for patients with advanced pancreatic 
cancer. A randomised controlled trial in patients with metastatic disease comparing FOLFIRINOX 
(a combination of fluorouracil, folinic acid, irinotecan and oxaliplatin) to gemcitabine 
chemotherapy showed an improvement in survival with median survival of 11.1 months compared 
to 6.8 months.150 Nab-paclitaxel (Abraxane), paclitaxel bound to the protein albumin, has recently 
been shown to increase the survival of patients with metastatic pancreatic cancer with 35% 
surviving 12 months when used in conjunction with gemcitabine, compared to 22% receiving 
treatment with gemcitabine alone.151 These more recent chemotherapy regimens with greater 
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impacts on survival and QOL are now recommended for treatment of advanced pancreatic cancer in 
patients with good performance status.151-153  
Side effects of chemotherapy for pancreatic cancer can include nausea and vomiting, bowel 
changes, mouth ulcers, anorexia, bruising and nerve changes, depending upon which drugs are 
received.92 Supportive care only is a feasible option for patients who decide that the 
treatment:benefit ratio is unacceptable, although it is important that patients reach this decision 
following discussion with a specialist oncologist. 
1.9.6. Radiation Therapy 
Radiation oncology is a rapidly advancing field with new modalities and technology being 
introduced world-wide, such as intensity modulated radiation therapy (IMRT) and volumetric-
modulated arc therapy (VMAT) which are able to deliver high-precision radiotherapy, allowing for 
higher doses to the pancreatic tumour while minimising the dose to surrounding critical structures. 
Clinical benefits include reduced side-effects of treatment but the use of VMAT and IMRT in place 
of standard three-dimensional radiotherapy has not been tested in pancreatic cancer randomised 
clinical trials.154, 155 
Radiation Therapy is often prescribed in the adjuvant setting following incomplete resection of the 
tumour or where there are involved margins following surgery although there is little evidence to 
suggest the use of adjuvant radiation is beneficial in terms of patient survival.156-158  
Radiation Therapy also has a recognised role in the treatment of patients with locally advanced 
disease but who are unsuitable for surgery either as neo-adjuvant treatment with the aim of 
shrinking the tumour to increase the potential for surgery or as a definitive treatment for patients 
unsuitable for surgery.159 Neoadjuvant chemoradiation therapy provides appropriate treatment 
while allowing identification of patients who develop early metastatic disease who can be spared 
the morbidity resulting from surgery. A study from the United States using decision tree modelling 
suggests that neoadjuvant chemoradiation therapy is associated with improved survival and QOL 
(18.8 quality-adjusted life-months) with lower cost than a surgery first approach (8.7 quality-
adjusted life-months) for patients with pancreatic cancer.97 
For patients with advanced disease or metastases, a meta-analysis has shown that 60% of patients 
have pain control in response to palliative radiotherapy for pain management.160 
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1.9.7. Supportive Care 
Supportive care is primarily targeted at symptom control and improving QOL. Palliative care is an 
integral part of this support with clinical evidence suggesting that most cancer patients are only 
referred to palliative care at the end stage of their life; adequate attention to QOL and patient care 
preferences often occur only days to weeks from the patient's death.161 This may be important, as a 
trial of patients with lung cancer showed that early palliative care intervention significantly 
improved QOL, fewer patients had depressive symptoms (16% early intervention versus 38%) and 
survival improved (median early intervention 12 months versus 9 months) despite the use of less 
aggressive care.162 These results have been confirmed for patients with advanced pancreatic cancer 
where more intense palliative care has also been shown to diminish the use of chemotherapy within 
14 days of death. Hospitalisations, emergency unit or intensive care admissions within 30 days of 
death were also reduced.163 Survival benefits of early referral (63% one-year survival for early 
palliative care intervention versus 48% in the delayed group) to palliative care have also been 
reported, although the reasons for this are, as yet, unexplained.164 
Pain is the most frequent symptom for patients with pancreatic cancer but despite the availability of 
opioids and coeliac plexus blocking, a systematic review suggested that 43% of patients with 
cancer are undertreated for pain control.165 Recent data have suggested that Australian patients with 
pancreatic cancer have high supportive care needs with higher levels of pain, (OR 6.1; 95% CI 2.4 
– 15.3), anxiety (OR 3.3; 95% CI 1.5 – 9.3) and depression (OR 3.2; 95% CI 1.7 – 6.0) associated 
with higher unmet supportive care needs.166, 167  
1.9.8. Multidisciplinary care 
Multidisciplinary care by a team of clinical specialists provides comprehensive and coordinated 
evaluation and treatment and is suggested as the most effective way to improve the quality of care 
and manage patients with pancreatic cancer,21, 130, 168 leading to changes in clinical diagnoses, and 
improved treatment recommendations in approximately 25% of patients.169-171 Early review of 
patients by an expert multidisciplinary team (MDT) in a high-volume hospital following diagnosis 
of pancreatic cancer enables accurate staging, comprehensive and coordinated evaluation and 
optimal management.21, 94, 126, 172, 173 Patients were more likely to receive treatment, multimodality 
therapy and participate in a clinical trial if evaluated by a MDT at a tertiary centre.122, 130 In the 
United States, implementation of a hepatobiliary (HPB) surgeon-led MDT meeting in regional 
areas suggested that the general quality of care provided improved, increasing regional referrals 
from 17% to 44% and tripling the number of HPB surgical procedures.174  A systematic review of 
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international literature and a Canadian pilot project found that multidisciplinary care should be 
managed by MDTs at large tertiary hospitals but smaller or regional centres can benefit by 
improving access to expert staging, treatment management plans and palliative care by having 
MDT meetings via telehealth with high-volume tertiary centres.175, 176  
The European Partnership Action Against Cancer consensus group formulated and approved a 
policy statement on multidisciplinary cancer care.90 This document identifies MDTs as essential 
instruments of effective cancer care and describes the key elements of the MDT including the MDT 
care objectives, organisation, clinical information, patient-centred approach, and policy support.94 
While there is some debate about what constitutes a MDT,177-179 it has been suggested that an MDT 
for the management of patients with pancreatic cancer should include at least one each of; 
hepatobiliary (HPB) surgeon, medical oncologist, radiation oncologist, interventional radiologist, 
allied health practitioners including dieticians, social workers, care-coordinator / nurse / General 
Practitioner, and pathologist.94, 180-182 Palliative care specialists are often included as their role in 
supportive care and their ability to provide a continuum of care is realised.94  
Communication is a major contributor to the care of the patient, with patients stating that they 
require clear communication and for their clinicians to be on the “same page”, not being given 
contrary advice by different care givers.183 Bringing clinicians together in multidisciplinary 
meetings facilitates and encourages inter-clinician communication as well as patient-clinician 
communication and ensures all care givers have the same information, improving the consistency 
of care plus MDT and patient collaboration.184, 185 
Currently in Australia MDTs are recognised as providing optimal quality care by Cancer 
Australia,180 but are unregulated and are not a necessary requirement as a clinical standard by 
National Safety and Quality Health Service Standards for health service organisation 
accreditation.186 A survey completed by 267 MDT attendees across Australia revealed that 86% 
agreed that MDTs improved the outcomes and quality of care received by patients.172   
1.9.9. Clinical practice guidelines 
While there are no comprehensive clinical practice guidelines for the management and treatment of 
patients with pancreatic cancer in Australia, such guidelines exist from Europe and the United 
States. However, a recent consensus review of existing guidelines indicated that there is 
considerable disagreement regarding guideline recommendations primarily due to the lack of high-
level evidence available.187 
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Current expert opinion and recommendations from the World Congress on Gastrointestinal Cancer 
(Barcelona 2006)4 provide recommendations including the use of appropriate diagnostic tests, 
adequate staging, multidisciplinary team decisions about resectability, adjuvant treatment and for 
patients with unresectable disease, chemotherapy with or without radiation. The European Society 
for Medical Oncology and European Society of Digestive Oncology (ESMO-ESDO) guidelines 
were updated in 2010 and describe guidelines for care from diagnosis until supportive care.5, 105, 188 
There are also comprehensive guidelines available through the National Comprehensive Cancer 
Network (NCCN)  in the United States6 for the management of pancreatic cancer from diagnosis, 
staging, treatment to follow up. Less detailed guidelines are available from the United States 
government’s National Cancer Institute.189 Some details of guidelines are provided in the table 
below (Table and Table 1-4). 
In Australia, the State of Victoria’s Department of Health and Human Services has published a 
practical optimal care pathway for people with pancreatic cancer which summarises steps from 
prevention and detection, through treatment to communication and end-of-life care.95 This pathway 
was developed by the National Cancer Expert Reference Group established by the Council of 
Australian Governments in 2010. The NSW Government with the Cancer Institute NSW have 
several clinical evidence-based, quality controlled cancer treatment protocols on-line (eviQ).  
Chemotherapy treatment regimens for pancreatic cancer and links to the Cancer Institute NSW are 
available through the eviQ website and are accessible to anyone following registration.190 
The Australian Gastro-Intestinal Trials Group (AGITG) has recently published a set of consensus 
guidelines defining surgical resectability, calling for MDT assessment prior to surgery, structured 
pathology reports and discusses the use of neo-adjuvant therapy.159 
  
  
Table 1-3: American and European Guidelines for the diagnosis, staging and management of resectable or locally advanced pancreatic cancer  
Guidelines Diagnostic and Staging Investigations Surgery Chemotherapy Radiation Other 
Resectable disease      
ESMO-ESDO 
105    
 
Pancreas protocol CT 
Selected cases MRI and 
laparoscopy. 
CA 19.9- limited use.  
Small tumours EUS + FNA. 
Pathological proof is mandatory 
except for radical surgical cases. 
Staging using  AJCC-UICC 
classification. 
MRCP. 
EUS. 
Not PET. 
ERCP only therapeutic use. 
Radical for early 
stage. 
Margins clear to 1mm. 
LNR should be 
reported. 
Adjuvant- 6 cycles 5FU or gemcitabine. 
 
Neoadjuvant in trial setting only. 
 
Should only give adjuvant RT 
in trial setting. 
 
NCCN6  
Pancreas-protocol CT. 
MRI. 
ERCP- if clinically indicated or 
MRI/CP. 
    EUS.   Chest CT. 
Biopsy. 
Staging laparoscopy. 
PET only to detect mets in 
high-risk patients. 
Complete guidelines 
re surgical procedure 
and pathology 
reporting. 
Adjuvant, Gemcitabine or 5FU before 
or after CRT or  Gemcitabine. 
5FU. Capecitabine. 
Single agents. 
CRT followed by 5FU or 
Gemcitabine 
Chemo then CRT 
 
With surgery 6-8 weeks after 
CRT. 
 
Locally advanced disease      
ESMO-
ESDO105 
Pancreas protocol CT. 
MRI 
EUS 
MRCP 
Pathological proof is 
mandatory.  
 
Neoadjuvant: either chemo then CRT or 
direct CRT. 
Gemcitabine 3 months. 
Should only give 
neo/adjuvant RT in trial 
setting. 
 
NCCN6 
 
Pancreas protocol CT. 
MRI 
EUS. Chest CT. 
ERCP- if clinically indicated 
or MRI/CP. 
Biopsy. 
 
Neoadjuvant 
CRT or chemo then CRT 
Gemcitabine, capecitabine, 
5FU 
Neoadjuvant 
CRT or chemo then CRT 
36 - 54 Gy 
Biliary bypass or stent 
Coeliac plexus block 
 
Table 1-4: American and European Guidelines for the diagnosis, staging and management of metastatic pancreatic cancer 
Guidelines Clinical work-up Chemotherapy Radiation Other 
Metastatic/unresectable disease     
ESMO5  
 
CT, MRI, biopsy 
PS, Comorbidities,  
Geriatric assessment. 
 
Gemcitabine, 5FU, Oxaliplatin, abraxane in 
combination preferably on trial. 
Pain control only. 
Endoscopic stenting- metal if life expectancy 
> 3 months. 
Pain- opioids, coeliac axis block. 
NCCN6 
 
Pancreas-protocol CT. 
MRI, 
PS, Biopsy  
 
 
 
Depending on performance status. Trial preferred 
Gemcitabine, Capecitabine, Oxalyplatin, FOLFIRINOX, 
Abraxane in any combination. 
Trial preferred.  30-36 Gy for palliation. 
Palliative RT for patients suitable for definitive 
treatment but have poor  PS or comorbidities 
Pancreatic enzyme replacement. Biliary 
bypass or stent. Coeliac plexus block. Poor 
performance status - best supportive care 
 
ESMO: European Society for Medical Oncology; ESDO: European Society for Digestive Oncology; NCCN: National Comprehensive Cancer Network; CT: computerised tomography; 
MRI : magnetic resonance imaging,  EUS: endoscopic ultrasound; ERCP endoscopic retrograde cholangio-pancreatography;  FNA: fine needle aspiration;  LNR: lymph node ratio; CRT: 
chemo-radiation therapy;  PET: positron electron tomography; PS: Performance status; CRT : chemoradiation therapy;  5FU: 5-Flourouracil   RT: radiotherapy;  Gy: Gray (radiation dose) 
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1.10. VARIABILITY IN CARE OF PATIENTS WITH PANCREATIC CANCER 
Research on patterns of care describes clinical practice and explores variability in care. It can be 
used to inform educational programs designed to improve the quality of care at the patient, clinician 
or policy level.191 To investigate the current receipt of therapies and patterns of care internationally 
and in Australia for patients with pancreatic cancer I undertook a search of PubMed to find relevant 
articles and identified 29 patterns-of-care studies, excluding small single centre studies with 
samples of less than 200; these are shown in Appendix C, Table 9-1.  
Most of these studies were completed in the United States (n=18), with seven from Europe and 
Scandinavia, one from Canada and three from Australia.  Sample sizes for the studies ranged from 
219 patients in Norway to over 300,000 in the United States. The earliest data collected was from 
1983 in the United States and the most recent from 2012 in Norway. Some studies focussed on sub-
groups of patients, with four studies focussed on patients with metastatic disease, three describing 
care of patients following resection, three on patients with non-metastatic disease and one on 
patients with locally advanced disease. The studies varied in quality with most unable to adjust for 
known confounders such as receipt of chemotherapy and performance status, while some studies 
were not specific for pancreatic adenocarcinoma.62, 192-195 
Only four studies did not identify patients using cancer registry notifications.196-199 Most of the 
studies, especially those from the United States used electronic administrative datasets containing 
information on the patients’ diagnosis, treatment and management to provide results, including the 
National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database and the  
National Cancer Data Base (NCDB). The NCDB collects data on approximately 70% of all new 
invasive cancer diagnoses each year200 and the SEER database collects data from geographical 
areas covering approximately 28% of the United States population.201 Procedures and treatments 
are generally under-recorded in administrative databases.202 For example, the SEER database does 
not release data on chemotherapy receipt due to a recognised incompleteness of the data.203 Another 
deficiency of administrative data is the lack of reporting of some patient factors, including 
performance status which is a known determinant of active treatment such as surgery and 
chemotherapy due to the increased risks of morbidity.151, 204, 205 Performance status is also a major 
prognostic factor for survival for all stages of pancreatic cancer.206, 207  
Cohort characteristics and overall receipt of treatment reported in the included studies are 
summarised in Table 1-5. Approximately 50% of all patients were diagnosed with metastatic (Stage 
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IV) disease and this is relatively consistent across all studies. Fewer than 15% of all patients
proceeded to surgical resection, with an average of 7% (range 3% - 11%) in Europe, and 15% in the 
United States (range 9% – 22%). The studies suggest that the use of adjuvant chemotherapy has 
increased in more recent years; studies published from 2013 onwards report that 75% or more of 
patients received adjuvant chemotherapy compared with approximately 40% of patients in studies 
including patients diagnosed and treated prior to 2005. Reports suggest between 20% and 42% of 
patients received palliative chemotherapy. All treatments were administered to a greater proportion 
of patients in the United States than in Europe, in particular radiation therapy (United States 25% 
compared to 8% in Europe). 
1.10.1. Care of pancreatic cancer patients in Australia 
Australian health care is unique in terms of geographical complexity and the mix of public and 
private facilities. The Australian government supports care in both public and private facilities. 
Care is provided free in public hospitals while care in private facilities is co-funded by 
contributions from private health insurance companies and patients. In Australia in 2007-2008 
approximately 95% of outpatients occasions of service occurred in public hospitals and 60% of all 
surgery was completed in private hospitals.208 Hospitals are accredited by the government to 
provide medical services. Large metropolitan hospitals usually have a full range of services 
compared to smaller regional hospitals which often primarily provide aged or supportive care. 
Despite some degree of regulation, a lack of centralisation of cancer care exists. Between 2005 and 
2008 in NSW pancreatic cancer surgery took place at 37 hospitals with almost half of them (n = 15, 
41%) undertaking fewer than two procedures each year.209 For patients diagnosed with pancreatic 
cancer in QLD, only three formal MDT meetings are held weekly throughout the state, all in 
metropolitan tertiary hospitals.  
Few Australian population-based studies describing the care of patients with pancreatic cancer were 
identified. A QLD government report described pancreatic surgery, showing that 
pancreaticoduodenectomy was performed on 12% of patients diagnosed during 2009-2011.192 A 
NSW government report described the hospital volume of facilities providing pancreatic surgery, 
observing that 41% of hospitals performing pancreatic resections between 2005 and 2008, 
undertook two or less pancreatic resections annually.209 A population-based Victorian research 
study reported that during 2002 and 2003 11% of patients had a complete resection, 52% of these 
had adjuvant chemotherapy and that 16% of the cohort had radiation therapy and 32% palliative 
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chemotherapy. This study found that only 6.8% of patients diagnosed with pancreatic cancer were 
managed by a MDT.18 
  
 
Table 1-5: Pancreatic cancer stage and receipt of treatment reported in identified patterns-of-care studies  
First author, 
year 
Data 
Country 
N 
                           Disease stage (%) 
%  
surgery 
% 
chemotherapy 
% adjuvant 
chemotherapy 
% 
radiotherapy 
% palliative 
chemotherapy 
% MDT  
review 
   
Localised or 
stage I / II 
Regional or 
Stage III 
Distant or 
stage IV 
Unknown All patients 
Surgical 
resection 
  
 
United States             
Wolfson,  
2015123 
All  
1998 - 2008 
United States, 
Los Angeles 
2,317 
22 15 56        
Abraham,  
201310 
All 
1994 - 2008 
United States, 
California  
20,312 
  46  15  
Any adjuvant 
treatment 
83 
12 
Unresectable 
42 
 
Oberstein, 
2013210  
Distant disease 
> 65 years 
1998 - 2005 
United States, 
SEER and 
Medicare 
3,094 
        42  
DaCosta,  
2013196 
All 
2001 - 2010 
United States  
Managed care 
5,262 
  50  16 47 41    
Singal, 
2012211 
Non-metastatic 
1998 - 2008 
United States, 
SEER data 
16,282 
20-25 75-80 -     19-22   
Gong,  
201133 
All 
1995 - 1999 
United States, 
San Francisco 
1,954 
7 27 47 7 11 
Chemo or 
radiotherapy 
21 
- 
Chemo or 
radiotherapy 
21 
-  
Davila,  
2009212 
Resected and > 
65 years 
1992 - 2002 
United States, 
SEER- 
Medicare data 
1,383 
70 3 - 25 - - 40 
Adjuvant 
39 
-  
Shavers, 
2009213 
All  
1998 
United States, 
SEER data 
697 
  62  14 42  20  10 
Bilimoria,  
200713 
All 
1985 - 2003 
United States 
301,033 
32 13 55  13 8 
1995 -2003 
Stage I and II 
40 
1995 -2003 
Stage I and II 
36 
  
Cress,  
200689 
All 
1994 - 2000 
United States 
10,612 
7 34 51 9 16 - 
 
Any adjuvant 
treatment 
58 
Adjuvant 
39 
-  
Eloubeidi, 2006195 
All  
1996 - 2000 
United States, 
Alabama  
2,230 
12 30 35 23 22 31  14  
 
 
  
 
First author, 
year 
Data 
Country 
N 
                           Disease stage (%) 
%  
surgery 
% 
chemotherapy 
% adjuvant 
chemotherapy 
% 
radiotherapy 
% palliative 
chemotherapy 
% MDT  
review 
   
Localised or 
stage I / II 
Regional or 
Stage III 
Distant or 
stage IV 
Unknown All patients 
Surgical 
resection 
  
 
Krzyzanowska, 
2003214 
Unresected, 
LAD 
1991 - 1996 
United States, 
SEER and 
Medicare 
1,696 
  -  - 31 - 37 -  
Senner, 
1999215 
All 
1985 - 1995 
United States, 
NCDB 
100,313 
20 12 33 34 9 30 33 23 30  
Janes, 
1996197 
All 
1983 - 1985 + 
1990 
United States 
16,942 
26 16 57 25 10 37  26 
Stage IV 
26 
 
Wade,  
1996199 
All 
1989 - 1994 
United States,  
698 
    16      
Canada             
Kagedan,  
2016216 
All 
2005 -2010 
Canada, 
Ontario 6,296 
    13  
Any adjuvant 
treatment 
75 
   
Europe             
Jooste, 
2016217 
All  
2009 - 2011 
 France 
554 
  54        
HajMohammad, 
2016131 
Metastatic   
2007 - 2011 
Netherlands 
5,385 
  54 of all PC      24  
Bernards,  
2015 
Metastatic 
1993 - 2010 
Netherlands 
1,494 
  
2009-2010 
59 
     27  
Sharp,  
200912 
All 
1994 - 2003 
Ireland 
3,173 
5 13 46 37 7 12 39 7 20  
David,  
200962 
All 
2001 - 2005 
France,  
2,986 
9 6 86  11 42 40 9 42  
Bramhall,  
1995193 
All 
1957 - 1986 
UK, West 
Midlands  
13,560 
    
1977 -1986 
3 
     
Australia             
Queensland 
Health, 
2015192 
All  
2009 - 2011 
Australia, QLD 
664 
    13      
Jefford, 2010,18 
Speer, 2012107 
All 
2002 - 2003 
Australia, VIC 
765 
20 4 76  11 36 52 16 32 7 
 
Missing data indicates that the % of patients is unable to be determined from publication results.  
PC: Pancreatic cancer; SEER: Surveillance; Epidemiology and End Results program; NCDB: National Cancer Database; LAD: Locally advanced disease; UK:United Kingdom.  
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1.11. DETERMINANTS OF ACCESS TO CARE 
Access to treatment for patients diagnosed with pancreatic cancer is not always equitable. Factors 
associated with being less likely to receive surgery are shown in Table 1-6 and with receipt of 
chemotherapy or radiotherapy in either the adjuvant or palliative setting are shown in Table 1-7.  
These studies suggest that elderly patients with pancreatic cancer are less likely to receive surgery 
(approximate OR: 0.20 for each increasing decade) or any chemotherapy (approximate OR of 0.40 
for each increasing decade) than younger patients, although there is evidence of benefit of treatment 
in selected older patients.218-220 The presence of a higher number of co-morbidities also reduces the 
likelihood of receiving surgery (comparing increasing number of comorbidities with none) (OR 
0.26; 95% CI: 0.08 – 0.83) or chemotherapy (0.79; 95% CI 0.66 - 0.93).210, 213  Pancreatic cancer 
treatment poses significant morbidity, so taking patient factors such as age, co-morbidities and 
patient preferences into account may be appropriate. The lower use of surgery or chemotherapy in 
patients living in lower socio-economic areas or more rural areas indicates inequitable access to 
treatment. A recent Canadian study estimated the odds of receiving surgery decreased with 
decreasing socio-economic status (SES) (comparing the lowest SES quintile with the highest OR 
0.49; 95% CI 0.37 – 0.64) although it found no statistically significant difference in the receipt of 
chemotherapy.216 Other international studies have estimated significant differences with 
approximately twice the odds of receiving surgery or chemotherapy for patients in patients with 
high SES as those with low SES.11, 210, 221 
Patients who presented to or received treatment in larger or specialised cancer centres were more 
likely to receive surgery or chemotherapy (OR range: 1.20 to 2.20).13, 131 Due to the increasing 
evidence that better outcomes are achieved for patients with pancreatic cancer if they receive their 
staging and treatment at specialised high-volume centres, there have been efforts to centralise care 
in the last five years.121, 129  
Although there are indications that centralisation of care has been occurring in Australia, recent 
government reports indicate some surgery is still performed in low-case-volume hospitals.192, 209 A 
QLD report indicates that between 2002 and 2011, 23 hospitals performed 
pancreaticoduodenectomies but this number had dropped to 13 by 2011.192 Of the 37 hospitals in 
NSW that performed pancreatic resection for cancer in the period 2005-2008, only six (16%) 
performed more than six procedures on average each year. There were also 15 (41%) hospitals 
undertaking two or fewer procedures annually on average during this period.209 NSW surgeons 
performing between four and six pancreaticoduodenectomies each year within a hospital with a 
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high-volume of upper-gastrointestinal surgery have comparable outcomes to those achieved by 
high-case-volume international centres.141 We found no Australian studies describing the 
determinants of pancreatic surgery or receipt of chemotherapy for patients diagnosed with 
pancreatic cancer.  
 
  
  
 
Table 1-6: Review of factors associated with receiving surgery for pancreatic cancer 
First author Data 
Country 
N 
Facility Case 
Volumea 
Race Age Sex / comorbidities Rural SES b 
    Black vs White  Men vs. Women Urban vs. Rural Lowest vs. highest quintile 
Kagedan, 
2016216 
All 
2005 -2010 
Canada, Ontario  
6,296 
    
Rural vs. Urban 
OR: 0.68, 0.51–0.91 
OR: 0.49 (0.37–0.64) 
Queensland 
Health, 
2015192 
All  
2009 - 2011 
Australia, QLD 
664 
 
17% (Indigenous) vs. 
13% (Non) 
20%(<65 yrs)  vs. 
4% (75+ yrs)  
15% vs. 10% 13% vs. 11% 
15% (affluent) vs. 
12%(disadvantaged) 
Abraham, 
201310 
All 
1994-2008 
United States, 
California 
20,312 
 OR: 0.66 (0.54-0.80) 
75-79 yrs  vs. <65   
OR: 0.26 (0.22-0.31) 
OR: 0.95 (0.85-1.1)  
No Medicaid vs. Medicaid  
OR: 1.7 (1.4-2.2) 
Seyedin, 
201211 
Non-metastatic 
1998-2002 
United States, 
SEER data 
5,908 
- OR: 0.65 (0.52-0.82)  
Women vs. Men  
OR: 0.82 (0.72-1.01) 
 OR: 0.52 (0.35-0.78) 
Singal, 
2012211 
Non-metastatic 
disease 
1998-2008 
United States  
16,282 
 19% vs. 18%       
Sharp, 
200912 
All 
1994-2003 
Ireland 
3,173 
  
75+ yrs vs. <65   
OR: 0.18 (0.11–0.28) 
   
Shavers, 
2009213 
1998 
United States, 
SEER data 
697 
 n/s 
Increasing year 
OR: 0.98 (0.95–1.00) 
Charlson score 2+ vs. 
score 0   
OR: 0.26 (0.08 – 0.83) 
 
Uninsured  vs. Insured 
OR: 0.09 (0.01–0.62) 
Bilimoria, 
200713 
Stage I&II: 
1985-2003 
United States 
301,033 
Highest vs. 
 Lowest quartile 
OR: 1.45 (1.35–1.55) 
   OR: 1.26 (1.1 –1.36)  
Eloubeidi, 
2006195 
All patients 
1996-2000 
United States, 
Alabama 
2,230 
 
14% vs. 17%, 
 p=0.09 
    
Cress, 
200689 
All 
1994-2000 
United States 
10,612 
 
13% vs. 17%, 
p=0.03 
   
48% (High) vs. 
 44% (Low), p= 0.02 
Janes, 
1996197 
All 
1983-1985, 1990 
United States 
16,942 
14%(< 10 cases) vs. 
17% (>20 cases) 
12% vs.15%  
22% (<50 yrs) vs. 
8% (80+ yrs) 
  
17% (Highest income) vs. 
 13% (Lowest) 
a Facility case volume = pancreatic cancer surgery or pancreatic cancer caseload volume, higher academic or tertiary facility if no facility volume recorded.  
 b based on socio-economic status (SES) or insurance status  
  
 
Table 1-7: Review of factors associated with receiving chemotherapy or radiotherapy treatment for pancreatic cancer. 
First author Data 
Country 
N 
Facility Case Volumea Race Age Sex/ Comorbidities Rural SESb 
   
Highest vs. Lowest 
quartile 
Black vs White years (yrs) Men vs. Women Urban vs. Rural 
Highest vs. Lowest 
 quintile 
Any adjuvant treatment        
Kagedan,  
2016216 
All 
2005 -2010 
Canada, Ontario  
6,296 
 OR: 0.98 (0.78–1.22)    
Increasing deprivation 
OR: 0.95 (0.70–1.28) 
Abraham,  
201310 
All 
1994-2008 
USA, California 
20,312 
 OR: 0.75 (0.58-0.98) 
75-79 vs. <65 yrs 
OR: 0.29 (0.23-0.37) 
OR: 1.1 (1.0-1.2)  
Uninsured vs. Insured 
OR: 0.54 (0.30- 0.98) 
Davila, 
2009212 
> 65, post-op  
1992-2002 
USA, SEER data 
1,383 
OR: 1.85 (1.20–2.86) OR: 0.61 (0.38–0.99) 
75 + vs. 65-75 yrs 
OR: 0.43 (0.34-0.54) 
OR: 1.17 (0.93–1.47) 
Rural vs. Urban 
OR: 0.92 (0.23–3.76) 
OR: 1.64 (1.10–2.47) 
Bilimoria,  
200713 
 Stage I&II: 
1985-2003 
USA 
301,033 
OR:1.20 (1.10–1.32)    OR:0.89 (0.79–1.01)  
Chemotherapy         
HajMohammad 
2016131 
Metastatic 
2007-2011 
Netherlands 
5,385 
OR: 2.20 (1.85–2.61)      
Bernards,  
2015221 
Metastatic 
1993-2010 
Netherlands 
1,494 
  
80+  vs. 60-69 yrs 
OR: 0.04 (0.01–0.18) 
Women vs. Men 
OR: 0.91 (0.67–1.24) 
 OR: 2.05 (1.34–3.13) 
Vijayvergia, 
2015198 
Metastatic 
2000-2010 
USA, 
579 
  
75% (<65 yrs) vs. 
 65% (65+ ), p <0.001 
   
Oberstein, 
 2013210 
Metastatic  
1998 -2005 
USA, SEER data  
3,094 
 OR: 0.73 (0.57–0.93) 
85+ vs. 65-69 yrs 
OR: 0.20 (0.14–0.27) 
Women vs. menc 
OR: 0.80 (0.70-0.93) 
OR: 1.07 (0.84–1.38) OR: 2.14 (1.66 -2.76) 
Sharp, 
200912 
All 
1994-2003 
Ireland 
3,173 
  
75+ vs. <65 yrs 
OR: 0.04 (0.02-0.07) 
OR: 1.11 (0.85–1.46)   
Shavers, 
2009213 
1998 
USA, SEER data 
697 
 OR 0.61 (0.37–0.95) 
Increasing year  
OR: 0.94 (0.92–0.96) 
  
Uninsured vs. Insured 
OR: 0.36 (0.11–1.21) 
Eloubeidi,  
2006195 
All patients 
USA, Alabama 
2,230 
 
27% vs. 32%, 
 p = 0.02 
    
Radiation therapy        
Shavers, 
2009213 
1998 
USA, SEER data 
697 
 OR 0.74 (0.42–1.30) 
Increasing year  
OR: 0.97 (0.95–0.99) 
  
Uninsured vs. Insured 
OR: 1.82 (0.56–5.96) 
Combined modality treatment or cancer directed therapy      
Krzyzanowska, 
2003214 
Unresected, 
LADd 
1991-1996 
USA, SEER data 
1,696 
Teaching 
OR: 1.26 (1.01–1.57) 
 
Increasing decade 
OR: 0.43 (0.37–0.51) 
Increasing 
Comorbidities 
OR: 0.85 (0.75–0.96) 
Midwest United States 
(West United States 
ref) 
OR: 1.60 (1.26–2.03) 
Increasing quintile 
OR:1.15 (1.06–1.24) 
Janes,  
1996197 
All 
1983-1985, 1990 
USA 
16,942 
 45%(< 10 cases) vs. 
55% (>20 cases) 
47% vs. 54% 
70% (< 50 yrs) vs. 
25% (80+ yrs) 
  
58% (High) vs. 
 48% (Low) 
 
a Facility case volume= pancreatic cancer surgery or pancreatic cancer caseload volume, or academic or tertiary facility status; b Based on socio-economic status (SES), material 
deprivation or insurance status; c Comorbidities also reported: 2+ comorbidities (0 ref) OR: 0.79 (0.66 - 0.93) ; d LAD locally advanced disease;  OR: Odds ratio (95% confidence interval)  
 62 
 
1.12. QUALITY OF CARE 
Evidence-based care that is in accordance with guidelines is generally accepted as high-quality 
care.119 Indicators based on the receipt of guideline-recommended care222 provide benchmarks to 
facilitate the measurement of the quality of care delivered.134  
Quality indicators for pancreatic cancer care have been developed in the United States by reviewing 
the literature, consensus guidelines and expert interviews. These indicators include quality 
indicators measured at both the hospital and the patient level.119 Similar to clinical guidelines from 
the United States, these indicators are primarily associated with pancreatic surgery and include 
monitoring the hospitals and surgeons’ case volume, recording clinical or histological stage, 
provision of care in an intensive care unit, access to interventional radiology, radiation and 
chemotherapy services if performing pancreatic surgery and monitoring stage-specific survival. 
When these quality indicators were measured, compliance with guidelines at the individual patient 
level ranged from 50% to 97% and at the hospital level compliance ranged from 7% to 100%.119 
A United States study of 3,706 patients in 50 hospitals found patients with pancreatic cancer had a 
reduced likelihood of death from any cause (OR 0.64; 95% CI 0.53 – 0.77), after controlling for 
patient and hospital factors, if they received care compliant with the NCCN guidelines.222 Patients 
with lower SES (comparing the lowest SES quintile with the highest OR 0.61; 95% CI 0.47 - 0.80), 
who were older in age (comparing patients aged 75-84 years with aged <45 years OR 0.30; 95% CI 
0.20 – 0.44) and seen in lower case-volume hospitals were less likely to have care compliant with 
NCCN guidelines. 
While the measures of quality of care for patients are linked to clinical practice guidelines they do 
not necessarily reflect all aspects of care relevant to optimising the patient experience. Quality 
indicators are best derived by experts in the field and a Delphi process is one established method to 
harness these experts’ opinions.223 
1.13. DELPHI PROCESS 
The Delphi process was first developed in the 1950s224 and has been used in a wide-range of fields 
including the military service, medicine and education to elucidate experts’ views regarding their 
specialty.225 The value of the Delphi process for developing expert consensus on clinical health-
related decisions and for selecting healthcare quality indicators has been demonstrated through its 
extensive use in Australia and internationally.226-230   
 63 
 
1.13.1. Delphi process characteristics 
A Delphi process is iterative, consisting of approximately three rounds.231 The first round generally 
asks experts an open-ended question and subsequent survey questions are based on the responses to 
this. The experts are asked to rank or score each questionnaire item. The results of this scoring 
process are compiled. Participants are then asked to re-score the items with knowledge of the mean 
score elicited in the previous questionnaire round. The process is repeated until consensus (see 
below) with item scores, between the panel participants is reached.  
Advantages of the Delphi process are that it enables group communication that might otherwise 
have been impossible due to time, geography or other constraints.232 It also draws together existing 
knowledge and pinpoints areas of agreement or disagreement.232 Furthermore, the anonymity of 
participants provides them with the opportunity to freely express opinions and positions.233  
Disadvantages include a potentially high attrition rate as the process is time-consuming and 
requires active participant engagement over several weeks or even months.234 Potential costs of 
producing surveys and correspondence have been reduced by the use of the eDelphi process which 
uses online surveys and electronic correspondence rather than the traditional written paper 
method.235 
1.13.2. Delphi participants 
The Delphi process has been criticised for its lack of definition of an expert and for the impact on 
the reliability and accuracy of the outcomes by including non-experts on panels.236 Others have 
suggested that a heterogeneous group of participants increases the variety of opinions and is 
beneficial to the outcomes of the Delphi process and that participants with diverse perspectives 
produce more accurate judgements.237, 238 
The sample size used in surveys varies from 2 to 1000. The general consensus is that between 20 
and 50 is adequate to develop reliable criteria that inform judgment and support effective decision 
making,233 but that the larger the participant group the more reliable the collective outcomes will 
be.232 
1.13.3. Delphi consensus and results 
The Delphi process aims to bring participants to consensus, stopping when further rounds are 
unlikely to change the results.  However, there is no standard method for determining consensus.  A 
study to compare methods of declaring consensus analysed data from a Delphi process using the 
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Pearson correlation coefficient, F-test and the coefficient of variation. It found that the coefficient 
of variation was the most reliable method for predicting consensus and that, in general, two  rounds 
of scoring was sufficient to reach consensus, with negligible improvement thereafter.231 The 
coefficient of variation is a standardised measure of dispersion and is useful for the comparison of 
distributions of Delphi scores. It is the ratio of the standard deviation to the mean for each item 
score and is usually reported as a percentage by multiplying the ratio by 100. In Delphi research, 
assorted studies have used the coefficient of variation as a measure for consensus as it allows for a 
direct comparison between rounds and also of the stability of results amongst groups or 
individuals.226, 239 A high degree of consensus is generally accepted as represented by a coefficient 
of variation of ≤ 0.5, 0.5 to ≤ 0.8 indicate less than satisfactory consensus and > 0.8 a low degree of 
consensus.226 
1.13.4. Application of the Delphi Process to Pancreatic cancer  
Recently, a core set of patient-reported outcomes for patients with pancreatic cancer was compiled 
using a two-round Delphi process in the Netherlands. The 150 patients and 78 health care 
practitioners, reached consensus for 17 patient-reported outcomes which included general quality of 
life, physical ability, negative feelings and satisfaction with services.240 Bilimoria used an 
adaptation of the Delphi process to develop clinical quality indicators to evaluate pancreatic cancer 
care and to identify potential quality improvement opportunities. A two-round Delphi process, with 
an expert panel of 20 specialist clinicians, rated 43 out of 50 potential indicators as valid. These 
included measures of clinical processes of care, treatment appropriateness, efficiency, structural 
factors and outcomes.119 The Delphi method was also used to develop research priorities for 
pancreatic cancer in Australia in 2010.184 While these Delphi processes did harness opinions 
regarding pancreatic cancer care they did not determine which aspects of care or management were 
most important, and they did not evaluate the effectiveness of adherence to the indicators with 
patient outcomes. 
With the diversity of Australian geography and health-care a Delphi process is an optimal method 
for determining aspects of care important in the care and management of patients diagnosed with 
pancreatic cancer.  
1.14. LITERATURE REVIEW SUMMARY  
Clinical management of pancreatic cancer is complex and challenging. Patients with pancreatic 
cancer have poor survival with mortality rates similar to incidence rates, and there has been little 
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improvement in survival over the past several decades. While there is increasing research into new 
screening tests, diagnostic investigations and treatments, improving the quality of care and ensuring 
equitable access to that care could deliver improved outcomes even in the absence of new treatment 
options. Enabling all patients to be managed by high-performing multidisciplinary teams will also 
enable full realisation of benefits expected to accrue from the development of new therapies over 
the coming decades. 
This literature review has described current clinical practice guidelines and described appropriate 
care for patients diagnosed with pancreatic cancer. Randomised trials and a population-based study 
have found that survival outcomes can be improved by increasing the proportion of patients 
undergoing resection and chemotherapy.12, 124, 146 In Australia there are no national clinical 
guidelines and, with the diverse socio-demographic characteristics in Australia and a unique health-
service system, definition of optimal care for patients diagnosed with pancreatic cancer is required. 
Australian quality indicators are also required to help identify where changes in policy and/or 
practice could be implemented to improve patient outcomes.  
Population-based studies have provided evidence that care of patients with pancreatic cancer is 
varied, effective treatments are under-utilised and that compliance with recommended clinical 
guidelines is sporadic. International pancreatic cancer clinical guidelines are inconsistent, but even 
in countries where there are clear guidelines evidence suggests that the care and management of 
patients with pancreatic cancer varies according to patient, socio-demographic and health-service 
factors. Accurate staging and evidenced-based treatment is most likely to be achieved by 
experienced multidisciplinary teams specialised in caring for patients with pancreatic cancer at a 
high-volume hospital. How often this occurs in Australia is unknown.  
Australian data, on a population-level, are needed to generate information about the management of 
patients with pancreatic cancer and to identify factors determining variability in that management. 
Data are also needed to describe evidence-based optimal care and to evaluate the benefits of this 
care. Knowledge of the patient, socio-demographic or health-service factors associated with access 
to this care is also required for Australia. 
These data will provide a baseline against which the effect of changes in policy and practice can be 
measured. By improving management of the disease and by providing all patients with equitable 
access to optimal care, we can almost certainly have an impact on survival and quality of life for 
patients diagnosed with pancreatic cancer. 
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2.1. RESEARCH AIMS 
The over-arching aim of this research was to gain an in-depth understanding of the management 
and care of patients diagnosed with pancreatic cancer in Australia, thereby identifying avenues for 
improvement.  
The specific research aims were to: 
1. Identify indicators of care that clinicians believe important in the management of patients 
with pancreatic cancer 
2. Describe the proportions of pancreatic cancer patients who receive different treatment 
modalities. 
3. Identify determinants of variability in delivery of cancer-directed therapies. 
4. Determine if patient, tumour or health service factors influence survival for patients with 
non-metastatic disease. 
5. Develop a quality-of-care score based on the indicators of care identified by clinicians and 
(a) investigate factors associated with the quality-of-care score; and (b) examine the 
association between the quality-of-care score and overall survival. 
2.2. HYPOTHESES 
The overall hypothesis of this research was that the quality of care and outcomes for patients 
diagnosed with pancreatic cancer in NSW and QLD varies according to patient, tumour and health-
service factors. Specific alternative hypotheses include: 
A. Clinical specialists in pancreatic cancer management throughout Australia can identify and 
reach consensus regarding factors required to provide optimal care for patients diagnosed 
in Australia. 
B. Management of pancreatic cancer patients in NSW and QLD varies and is influenced by 
patient, tumour and/or health-system factors. 
C. Patient, tumour and/or health-system factors influence the overall quality-of-care score. 
D. The quality-of-care score is associated with survival. 
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A variety of processes and analytical methods was employed to investigate the patterns and 
determinants of care, including the development of clinical quality indicators and a quality-of-care 
score, for patients diagnosed with pancreatic cancer. The analytical methods used to complete the 
aims and objectives of my PhD are explained in detail in each of the publications (Chapters 4 to 7 
and Appendix H). This chapter describes in more detail the data collection, data management, 
quality control and derivation of the variables used in the analyses.  My contribution to these 
processes is also explained. 
My research is nested within the pancreatic cancer patterns-of-care study with Associate Professor 
Rachel Neale as the principal investigator. The patterns-of-care study received NHMRC funding in 
2010 (NHMRC grant number 613654). I also conducted a sub-study to develop clinical quality 
indicators and a quality-of-care score to complement the data collected in the patterns-of-care 
study. 
3.1. PATTERNS-OF-CARE STUDY  
The patterns-of-care study was a population-based retrospective medical record review of all 
patients diagnosed with pancreatic cancer in QLD and NSW between July 2009 and December 
2010 (NSW) or June 2011 (QLD). Data collection for the patterns-of-care study began in April 
2010 and was completed in March 2013. 
The data from the patterns-of-care study were used to describe management patterns and survival 
outcomes and to quantify the quality of care for patients with pancreatic cancer. 
3.1.1. Patterns-of-Care Study Participants 
Patients were identified by the cancer registries in NSW and QLD. Eligibility criteria for the study 
included all patients (including death certificate only) who were: 
 aged 18 years or older, 
 diagnosed between 1st July 2009 and 30th June 2011 and notified to the QLD Cancer 
Registry or between 1st July 2009 and 31st December 2010 and notified to the NSW Cancer 
Registry (Cancer Institute NSW)  
 diagnosed with pancreatic cancer (ICD-10 code C25).  
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3.1.2. Cancer Registry Data 
Cancer notification is mandatory in Australia with data sourced from hospital records, pathology 
reports, death certificates and general practice. Data collected are of sufficiently high quality to 
comply with the International Association of Cancer Registries external conventions and be 
included in the Cancer Incidence in Five Continents reports.241 
Data quality is maintained by validating data entry, auditing coding accuracy, monitoring 
notifications, reconciling information from multiple sources, examining multiple registrations, 
collaboration between other registries and medical experts and verifying cases using the electoral 
rolls. 
Discrepancies found between patients identified for the patterns-of-care study by the cancer 
registries and following medical record review were discussed by the registry and study personnel, 
and changes made to either dataset as necessary.  
3.1.3. Data Collection Process 
We obtained information from the cancer registries about the patients’ sex, age at diagnosis, date of 
initial diagnosis, name and address of the treating clinician at the time of the initial diagnosis, the 
hospital where the diagnosis was made (if applicable) and, where available, the date of death. The 
cancer registries also provided the statistical local area (SLA) in QLD or local government area 
(LGA) in NSW for the patients’ residential locations.  
Following cancer registry notification, the research nurses accessed medical records for each 
patient, commencing with the record from the facility where the diagnosis was made if possible. 
They abstracted detailed information about patient management from the medical record onto a 
standardised case report form (CRF) (Appendix D). Discharge summaries and correspondence were 
checked for evidence of referral to other centres for further management, and medical records at 
these centres were also reviewed. If limited details were available we sought information from the 
patient’s local general practitioner to enable completion of the CRF, but we did not routinely 
ascertain details from general practice.  Depending upon the number of centres visited by the 
patient and their treatment patterns, the time taken to complete a CRF varied from approximately 2 
to 6 hours.  
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3.1.4. Data collected 
Information collected on the case report form included details of: 
(1) Initial presentation: 
 symptoms  
 investigations  
 comorbidities  
 resectability / clinical stage of disease.  
(2) Treatment: 
 whether or not surgery occurred, and if not, the reason why not 
 if surgery occurred, the place of surgery and the surgeon (both coded for anonymity), 
surgical procedure performed (pancreaticoduodenectomy, total or distal pancreatectomy), 
surgical margins achieved and complications experienced  
 chemotherapy and radiotherapy including planned regimens, dates and doses of 
drugs/radiation administered, complications and responses 
 details about insertion of biliary stents or surgical bypass for obstructed bile duct 
 symptom management, including prescription of replacement pancreatic enzymes, coeliac 
plexus blocks or use of opioids for pain management and treatment of nausea 
(3) Referrals to:  
 multidisciplinary team (including dates presented) 
 social workers 
 physiotherapists  
 psychologists  
 palliative care services  
 dieticians  
 nursing care coordinators  
(4) Admissions occurring up until death or to 12 months after the index admission including: 
 dates of admission and discharge,  
 the types of health professionals involved in each episode of care  
 all investigations and treatment. 
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(5) Patient’s disease status at six and twelve months post diagnosis:  
 if alive, place of residence  
 if deceased, date and cause of death. 
Cancer registries provided up-to-date survival status in February 2014. 
3.1.5. Quality assurance 
The research nurses who conducted the medical record reviews underwent an initial two-day 
training workshop with clinicians in attendance. This was repeated midway through the data 
collection period (after approximately 18 months). At these workshops, all nurses reviewed the 
same series of charts and completed CRFs. Completed CRFs were compared, with discrepancies 
discussed, and differences in interpretation resolved.  
I (a registered nurse) commenced data collection following the training workshop and completed 
the training individually. My training involved completing a training CRF with reference to a 
working data collection manual. To ensure data quality I then completed CRFs for patient charts 
previously reviewed and the CRFs were audited. After completion of three chart reviews, 
discrepancies between reviews were less than 1%, and this was confirmed following a further two 
review audits. 
3.1.6. Data management 
Professional data entry staff entered information from the CRFs into a Microsoft Access database. 
We undertook a comprehensive series of range and logic checks to ensure the accuracy of the data. 
Data entry errors were corrected with reference to the original CRFs. Logic errors were corrected 
through consensus review by me, A/Prof Neale and the nurses who collected the data where 
possible. Notes that were taken during the review assisted with this process.  
3.1.7. Candidate contribution to data collection  
I joined the patterns-of-care pancreatic cancer group and commenced data collection in September 
2012; I completed the final chart review in June 2013. During this time I reviewed approximately 
350 charts for about 120 patients from 44 medical facilities throughout QLD, drove over 5000km 
and spent 17 nights away from home (Table 3-1). With the aid of a research assistant I completed 
the comprehensive data cleaning. I wrote the data checks and together we tested the quality of the 
data, amending the data as required. 
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Table 3-1 : Contribution of candidate EAB to data collection in Queensland 
 NSW QLD EAB in QLD 
Number of patient reviews 1052 811 ±a 120 (15%) 
Medical facilities visited 119 141 44 (31%) 
Chart reviews  ±a 2100 ± 350a (17%) 
Note: a Unable to calculate precise numbers as numerous charts may have been examined by different 
research nurses for each patient. Study registers only recorded the research nurse who began the 
initial chart review and the nurse who completed the final chart review. 
 
3.1.8. Patterns-of-care study enrolment 
NSW and QLD cancer registries notified the study team of 2090 potentially eligible patients for the 
patterns-of-care study (Figure 3-1). We accessed the records for 2003 (96%) of these and found 140 
(7%) to be ineligible. Reasons for ineligibility are listed in Table 3-2. Of the 1863 eligible patients, 
we completed chart reviews for 1695 and 168 were partially completed.   
Table 3-2: Reasons for patterns-of-care study ineligibility 
Reason Number (%) 
Tumour did not originate in the pancreas 94 (67) 
Tumour was not adenocarcinoma 23 (16) 
Patient was not resident of NSW or QLD 18 (13) 
Diagnosed outside study dates 5 (4) 
Total 140 
 
Reviews were not commenced for 87 patients due to difficulty accessing records or because the 
cancer registries were only notified when the patient died and no hospital information was 
available.  
  
 74 
 
 
 
 
 
 
 
 
 
 
 
 
3.2. DEVELOPMENT OF THE QUALITY-OF-CARE SCORE  
I designed and implemented an electronic Delphi process to develop a set of quality-of-care 
indicators. Patient care was then benchmarked against these to calculate an overall quality-of-care 
score for each patient.  
I aimed to recruit a diverse range of clinicians involved in the care of patients with pancreatic 
cancer, including surgeons, gastroenterologists, oncologists, palliative care physicians, allied health 
professionals, interventional radiologists, general practitioners and nurses. I identified potential 
Delphi participants through searching the literature, personal contacts and professional groups 
involved in the care of pancreatic cancer patients across Australia. I also asked participants to 
nominate other relevant clinicians at the time they completed the survey. In total I identified 250 
clinicians. 
The Delphi survey was administered using a security-enhanced version of an electronic survey 
application (SurveyMonkey Inc.).242 I emailed clinicians an invitation to participate, including the 
aims of the research and a link to the survey, which asked the clinicians to “list all/any factors you 
consider important in the care of patients with suspected or confirmed pancreatic cancer”. This 
initial survey also included questions about specialty, number of years of experience in their 
specialty, the number of years caring for patients with pancreatic cancer, and age-group. 
Completion of the questionnaire was considered as consent to participate.  
Patterns-of-care 
study eligible 
n = 1863 
Completed reviews 
n = 1695  
Patterns-of-care 
ineligible 
n = 140 (7%) 
Partially completed 
reviews 
n = 168  
No review 
 
n = 87 (4%) 
Cancer registry 
eligible 
N = 2090 
Figure 3-1: Patterns-of-care cancer registry notifications, eligibility and chart reviews 
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A/Prof Neale and I thematically analysed the list of 380 responses (from 78 participants) to the 
open-ended question to generate a list of 55 indicators. The statements were grouped into four 
sections which encompassed themes of presentation/staging, surgery and biliary obstruction, 
multidisciplinary team details and oncology. I then invited all 250 clinicians, irrespective of 
whether or not they had responded to the first survey, to complete an electronic survey in which 
they were asked to score each statement (indicator) on a scale from 1 (not at all important / strongly 
disagree) to 10 (extremely important / strongly agree). I also invited respondents to suggest 
amendments to the statements to improve content validity. Non-responders were re-sent the 
electronic survey in an attempt to increase participation. A total of 65 participants completed the 
first scoring round. 
I calculated the mean score for each indicator and made amendments to the statements where 
feasible. I then sent the survey to all clinicians who had responded to either the open-ended 
question or the first survey, with the mean score for each of the original responses included. 
Participants were asked to re-score each item, after consideration of the group mean.  
Overall 63 (66% of those sent the final questionnaire; 25% of those initially invited) health 
professionals from 9 disciplines completed the final scoring of the 55 statements. Mean scores 
ranged from 3.7 to 9.7 with the highest scores related to communication and patient assessment. 
There was substantial intra- and inter-disciplinary variation in views about multidisciplinary team 
membership and roles. 
3.2.1. Calculating a quality-of-care score 
A quality-of-care score for participants in the patterns-of-care study based on the indicators 
identified through the Delphi process was calculated. Only those indicators for which data had been 
collected from the medical records could be included, resulting in 18 indicators. 
For each patient I identified a set of indicators specific to their clinical situation. For example, 
indicators related to surgical volume were only included in the indicator set for patients who 
underwent an attempted resection. The mean scores from the Delphi process for the relevant 
indicators were summed to create a total potential score for each participant. To create a total actual 
score I summed the scores for the relevant items where there was evidence in the medical record 
that the care had been delivered. This was divided by the potential score to create a proportional 
care score.  
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The formula was:   
𝑆𝑖 =  
∑ 𝑤𝑗 ∗ 𝑥𝑖𝑗 ∗ 𝑦𝑖𝑗18𝑗=1
∑ 𝑤𝑗 ∗ 𝑥𝑖𝑗18𝑗=1
 
 
Where Si is the score for patient i (i = 1,…,n): 
wj is the weight (the mean score from the Delphi process) for item j 
For patient i: 
xij indicates whether or not item j is applicable to patient i (xij = 1 or 0) 
yij indicates whether item j was met for patient i (yij = 1 or 0) 
The advantage of this approach for calculating the score is that it applied a relative weight 
depending on the importance that the expert panel attributed to each item. This is preferable to 
applying the same weight to all items which is an approach that has been used previously.119, 168, 243 
The distribution of the score for all patients, patients who underwent surgical resection of their 
tumour and patients with no surgical resection was examined and found to be normal in all groups. 
3.3. ANALYSES 
Analyses are described in detail in each results chapter; the approaches used are summarised briefly 
in this chapter. I used Stata13/14 (Statacorp, Texas) for all analyses.  
Table 3-3 shows the definition and derivation of explanatory and outcome variables used in the 
analyses. 
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Table 3-3: Derivation of analysis variables and corresponding codes 
Variable Description 
Patient characteristics 
Date of diagnosis Earliest date from histological or imaging diagnosis. 
Age at diagnosis Age at diagnosis (as above) in years 
Sex As recorded by the cancer registries at diagnosis. 
Performance 
status  
Eastern Cooperative Oncology Group (ECOG) ranking at diagnosis. If not recorded in 
the medical record, derived from admission notes where possible. 
Charlson 
comorbidity 
index.244 
Comorbidities such as cardiovascular disease, respiratory disease, renal impairment, 
diabetes and other cancers were recorded as noted in patient medical records. These 
were then coded and the Charlson comorbidity index calculated by summing the 
number of comorbidities according to the Charlson scoring methods.244 Total index 
scores were categorised into three groups: score equal to zero, score equal to one and 
score equal to two or more. 
Socio-economic 
Index For Areas 
(SEIFA)2 
Using the statistical local area for Queensland and the local government area for New 
South Wales, each patient was allocated an Index of Relative Socio-economic 
Disadvantage (IRSD) (SEIFA 2011)245 score and ARIA246  category according to their 
place of residence at diagnosis.  
The SEIFA scores were used to rank the patients’ area of residence into quintiles of 
disadvantage by using the quintile cut-points for the state-specific population 
distributions. Place of residence (ARIA) categories were collapsed into three groups: 
major city; inner regional; and outer regional/remote/very remote. 
Accessibility/ 
Remoteness 
Index of Australia 
(ARIA)246 
Tumour characteristics 
Site of tumour 
within the 
pancreas 
The site of the tumour within the pancreas was categorised into four groups: (1) 
head/neck/uncinate process; (2) body; (3) tail; or (4) multiple/unstated. Obtained 
from clinical notes in the medical records, including radiological investigation reports. 
Stage of tumour Stage of the tumour was extracted from medical records, (multidisciplinary meeting 
notes, medical specialist notes, autopsy reports) radiology or pathology reports. 
Surgical specimen reports, where available, took precedence over biopsy reports. 
Where there was inadequate staging information in the notes, collaborating medical 
specialists reviewed investigations to clarify staging information, where possible. 
Two approaches to staging were recorded:  
(1) The final stage of the tumour, which incorporated findings at surgery, was 
classified using the TNM UICC staging system81 and classified as stage I – IV disease. 
(2) Classified according to resectability of the tumour, as confined to the pancreas, 
locally advanced disease or metastatic disease and based on all staging investigations.  
Resectable 
 
The classification of the disease as resectable or not was obtained from clinical notes 
in the medical records.  
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Variable Description 
Health Service Characteristics 
Type of specialist 
first seen 
The specialty of the first specialist seen by a patient on diagnosis, either following 
referral by the general practitioner or at a hospital. 
Hepatobiliary 
surgeon 
Defined as a surgeon with recognised specialised hepatobiliary surgical training and/or 
is recognised by their peers as an experienced hepatobiliary surgeon. Surgeons were 
coded for anonymity and each code was allocated to either a general or hepatobiliary 
surgeon. For surgeons where data collectors were uncertain of their specialty 
classification, details were forwarded to the hepatobiliary surgeon on the study 
management team to be classified. 
Review by a 
multidisciplinary 
team (MDT) 
If there were notes from any formal MDT meeting in the medical record the patient 
was recorded as having been presented to an MDT. They were otherwise classified as 
having no evidence of MDT review. There were no details of what constituted an MDT 
and in some smaller centres this was subjective. If there was evidence of a 
collaborative review by multiple clinicians in a formal or informal context this was 
classified as an MDT. For example, if a surgeon, palliative care specialist and oncologist 
or social worker had met to discuss the patient care plan this was classified as an MDT. 
First facility of 
presentation 
The first facility to which the patient was admitted. If not admitted then the facility to 
which they initially presented. 
Volume of  first 
facility 
We used information from patients whose medical records were reviewed to code the 
volume of the first facility attended using two methods: 
(1) The number of pancreatic cancer resections performed each year by the facility. 
Initial categories were based on the literature but following sensitivity analyses and 
clinical judgement category cut-points of ≤ 4, 5 and ≥ 6 resections per year were used. 
This coding was used for surgical outcome analyses but was not suitable for whole 
cohort analyses as many patients did not undergo resection of their tumour. 
(2) The number of patients first admitted to a facility each year. Facilities categorised 
into three groups: < 10, 10 - 29 and ≥ 30 patients. 
Volume of 
surgeon 
This variable was used for the surgical outcome analyses only (Appendix H). The 
number of resections performed each year by a surgeon on eligible patterns-of-care 
study cases with medical records reviewed, with ≤ 4 resections per year classified as 
low volume, 5 medium and ≥ 6 as high volume.  
Chemotherapy Coded as received if a patient received any chemotherapy. 
Surgery Surgery was recorded as attempted if a laparotomy occurred and a pancreatic 
resection was planned but was unable to be completed for reasons such as vascular 
invasion or the presence of metastases.  
A surgical resection was recorded as complete if the pancreatic tumour was surgically 
removed, irrespective of the margin status. 
Investigations The date of each investigation performed was recorded. Investigations included: 
computerised tomography (CT) (+/- pancreas protocol), endoscopic ultrasound (EUS), 
endoscopic retrograde cholangio-pancreatography (ERCP), magnetic resonance 
imaging (MRI) or cholangiopancreatography (MRCP), and laparoscopy or laparotomy. 
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Descriptive statistics including frequencies and percentages were used to describe the cohort 
according to variables listed in Table 3-3.  The proportions of patients for whom surgery was 
attempted or completed, and who received chemotherapy were estimated and expressed as 
percentages, and were included as outcomes or independent variables in the analyses. 
3.3.1. Missing data  
Cases with missing data were omitted from the denominators for the descriptive percentages. 
Complete-case analyses (only including cases with non-missing data) were performed, when 
missing data was found in the exposure or outcome variables. Only performance status (ECOG) at 
diagnosis had significant missing data (n=263, 14%). Results from complete-case analyses (only 
including cases with non-missing ECOG) were compared with those from all-case analyses (with 
the missing values coded as a separate category) and if a difference was noted with the inclusion of 
the missing category, missing values were included in multivariable analyses. 
3.3.2. Survival  
Survival time was calculated as the number of days between the date of diagnosis and death from 
any cause or, if no record of death was located, 25 February 2014 (date of final death status 
review). Survival curves and median survival were estimated using Kaplan-Meier methods. The 
median time of follow-up was estimated using reverse Kaplan-Meier methods.247  
3.3.3. Statistical models 
The associations between all patient, tumour and health-care factors and outcomes were tested 
using Chi-squared tests and logistic regression for binary outcomes (including mortality, attempted 
surgery, and classification as resectable disease), linear regression for continuous outcomes 
(quality-of-care score) or Cox proportional hazards models for survival. All model assumptions 
were checked prior to use. When the outcome of interest is a common event (occurring in >20% of 
patients in any group), it was recognised that odds ratios cannot be interpreted as a relative risk.  
For multivariable causal models I used directed acyclic graphs to guide the selection of potential 
confounding variables to maximise control of confounding and avoid introducing bias.248 
Hierarchical mixed effects models, with hospital as a random intercept, were used to adjust for the 
effects of clustering within hospitals when assessing associations between the outcomes of interest 
and hospital volume.  
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3.4. ETHICAL APPROVAL 
For the patterns-of-care study, we accessed medical records without patient consent; approval for 
this access was obtained under the Queensland Public Health Act and under the guidelines of the 
New South Wales Privacy Act. Ethics approvals were obtained from the Human Research Ethics 
Committees at the QIMR Berghofer Medical Research Institute (P1292), the Royal Brisbane and 
Women’s Hospital (on behalf of all public hospitals in Queensland) (HREC/10/QRBW/16) and by 
the New South Wales Population and Health Services Research Ethics Committee 
(HREC/10/CIPHS/45). Approximately 250 additional ethics approvals and/or individual site-
specific approvals were obtained for each public hospital and private hospital as required. 
Ethical approval from the QIMR Berghofer Medical Research Institute for the sub-study to develop 
the quality-of-care score was obtained, as an amendment to the patterns-of-care study.  
The University of Queensland approved the research contained in this thesis: Ethics Approval 
EB020713. 
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4.1. INTRODUCTION 
The objective of the publication presented in this chapter was to establish components of care 
which Australian health professionals believed important in providing optimal care and 
management of patients with pancreatic cancer. 
4.2. CONTRIBUTION OF CANDIDATE 
All authors contributed to the conceptualisation of this publication, in particular Assoc. Prof. 
Rachel Neale. I contacted all Delphi participants (100%), designed the surveys (100%) collected 
and analysed all data (90%) with the aid of REN who completed an independent thematic analysis 
of the initial statements for quality and consistency purposes.  I was responsible for writing (75%), 
editing (36%) and submitting (90%) the manuscript taking into account the comments and 
suggestions of REN and the study team.  
4.3. MANUSCRIPT 
The following work was published in the Asia Pacific Journal of Clinical Oncology: 
Asia Pac J Clin Oncol 2016; 12 (2): 105-14. 
Using a Delphi process to determine optimal care for patients with pancreatic 
cancer 
Elizabeth A. Burmeister, Susan J. Jordan, Dianne L. O’Connell, Vanessa L. Beesley, David 
Goldstein, Helen M. Gooden, Monika Janda, Neil D. Merrett, David Wyld, Rachel E. Neale for The 
Pancreatic Cancer Clinical Working Group.  
Authors have provided permission to include this publication in this thesis (Appendix I). 
Abstract  
Aim 
Overall 5-year survival for pancreatic cancer is ~5%. Optimising the care that pancreatic cancer 
patients receive may be one way of improving outcomes. The objective of this study was to 
establish components of care which Australian health professionals believe important to optimally 
manage patients with pancreatic cancer.  
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Methods 
Using a Delphi process, a multidisciplinary panel of 250 health professionals were invited to 
provide a list of factors they considered important for optimal care of pancreatic cancer patients. 
They were then asked to score and then rescore (from one (no importance/disagree) to 10 (very 
important/agree) the factors. The mean and coefficient of variation scores were calculated and 
categorised into three levels of importance. 
Results  
Overall 63 (66% of those sent the final questionnaire; 25% of those initially invited) health 
professionals from 9 disciplines completed the final scoring of 55 statements/factors encompassing 
themes of presentation/staging, surgery and biliary obstruction, multidisciplinary team details and 
oncology. Mean scores ranged from 3.7 to 9.7 with the highest related to communication and 
patient assessment. There was substantial intra- and inter- disciplinary variation in views about 
MDT membership and roles. 
Conclusion 
Overall the opinions of Australian health professionals reflect international guideline recommended 
care; however they identified a number of additional factors focusing on where patients should be 
treated, the importance of clear communication and the need for multidisciplinary care which were 
not included in current clinical practice guidelines. Differences in priorities between specialty 
groups were also identified.    
Introduction   
Pancreatic cancer is the 10th most commonly diagnosed cancer in more developed regions of the 
world. In Australia it is the 6th most common cancer diagnosis and the 4th leading cause of cancer 
related death.249  People diagnosed with pancreatic cancer have the poorest prognosis of any cancer. 
One-year survival is currently 15% and five-year all-stage survival for pancreatic cancer in 
Australia is 5.2%, which mirrors other western countries.36, 37  Current projections suggest that it 
will be the second leading cause of cancer death within 10 years as survival from other cancers 
improves.40, 250  
Provision of optimal care increases the likelihood of desired health outcomes.251, 252 To facilitate 
this clinical practice guidelines/recommendations for pancreatic cancer have been published in 
Europe4, 5, 105, 188 and the United States.6 However, the extent to which health professionals in the 
field agree with the guidelines, and if they consider all elements of the guidelines equally important 
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is not known. In addition, guidelines may not cover some clinical situations or aspects of care that 
health professionals believe to be necessary for optimal management.253 Assessing the elements of 
care that specialist clinicians consider to be important for patients with pancreatic cancer and 
assessing whether these elements are evidence-based could assist in the modification of guidelines 
and/or identify areas where system changes or clinician education could help to improve patient 
outcomes.  
One way of harnessing the opinions of a group of specialists is to use a Delphi process.  This 
method has been used facilitate clinical consensus in a variety of medical situations.232, 254, 255 It 
begins with open-ended questions soliciting information from a panel of experts in the field.256 This 
is followed by ranking or scoring of the derived statements by the panel according to set criteria. 
The combined resultant scores/rankings are fed back to the panel members who are then invited to 
re-score the statements. The process is conducted anonymously, preventing domination of 
individuals and iterations of the scoring and feedback process repeated until consensus is reached 
or negligible change in scores is noted. 
The aim of this study was to use a Delphi process to establish components of care which Australian 
health professionals believe are important to optimally manage patients diagnosed with pancreatic 
cancer. 
Methods 
The Delphi process 
We used the literature, personal contacts and professional groups, including the Australian 
Pancreatic Cancer Genome Initiative257 and Cancer Council Australia, to identify health 
professionals involved in the care of pancreatic cancer patients from across Australia. We emailed 
these clinicians inviting them to participate and also asked them to nominate other clinicians who 
may be interested in participating. The panel consisted of surgeons, medical oncologists, radiation 
oncologists, gastroenterologists, palliative care specialists, nurses, allied health professionals, 
interventional radiologists and general practitioners. These experts were initially asked (online) to 
“...list all/any factors you consider important in the care of patients with suspected or confirmed 
pancreatic cancer.” They were also asked about their specialty and years in practice. 
The responses to the open-ended question were used to develop the quantitative questionnaire. 
Each response was grouped with those of similar themes and we eliminated duplicate statements. 
This process was done independently by two authors (EB and RN) and a structured list of 
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statements was developed. Where possible, statements were used as written by participants. Some 
statements with similar inferences required merging to avoid duplication; these were discussed 
within the study team to avoid corrupting their original meanings. 
Via email, we invited panel members to complete the quantitative questionnaire. They were asked 
to rate the importance of, or their level of agreement with, each statement on a scale of one (no 
importance/disagree) to 10 (very important/agree). Panel members could record ‘no opinion’ for 
statements they felt were beyond their scope of expertise. We provided the mean and median scores 
for each statement from the initial questionnaire to those who had responded to either the open-
ended question or the first quantitative questionnaire and asked them to re-score the statements in 
light of this information. 
Analyses 
The mean and coefficient of variation (CV) were calculated for each statement using the scores for 
all participants and also stratified according to specialty. The CV is the ratio of the standard 
deviation (SD) to the mean and gives the relative magnitude of the SD; it was multiplied by 10 for 
ease of reporting.  
Using a priori criteria each statement was categorized based on the mean score and CV as follows: 
Mean 9 - 10; CV < 4: very important  
Mean 6 – 8.9; CV < 4: moderately important  
Mean 1- 5.9; CV < 4: unimportant   
Any mean; CV ≥ 4: unable to agree. 
We used analyses of variance (ANOVA) to assess differences between the specialty groups. 
Ethics   
The Human Research Ethics Committees of the QIMR Berghofer Medical Research Institute and 
the University of Queensland approved this study.  Completion of questionnaires was considered to 
imply consent. 
Results  
In June 2013, 250 health professionals involved in the care of pancreatic cancer patients were 
invited by email to complete the initial open-ended question (Figure 4-1). Of these, 78 (31%) 
replied and suggested a total of 380 overlapping items that they considered important in the care of 
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pancreatic cancer patients. These were reduced to 55 items that encompassed the following themes: 
presentation and staging; surgery and biliary obstruction; the management team (including 
multidisciplinary team (MDT) details); oncology; and other (such as enrolling patients in clinical 
trials and establishing a national pancreatic cancer prospective database). The list of 55 items was 
then sent to the original 250 health professionals, irrespective of whether or not they responded to 
the first open-ended question.  Following scoring of the initial items, the statements were resent to 
the 96 health professionals who had responded during round 1 or round 2. Of these, 63 (66% of 
those sent the final questionnaire; 25% of those initially invited) rescored the items.  
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Figure 4-1: Consort diagram for the number of health professionals participating in the 
modified Delphi process 
Specialties of the participants invited included surgery (n = 56; 22%), medical oncology (n = 43; 
17%), allied health and nursing (n = 40; 16%), gastroenterology (n = 29; 12%), palliative care (n = 
28; 11%), radiation oncology (n = 13; 5%), and others (n = 41; 16%) which included interventional 
radiology, general practice, gerontology and medicine (Figure 4-2).  The response proportion to the 
final questionnaire ranged from 10% (other) to 54% (radiation oncology).  The specialties of the 
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Open-ended question “What are the important aspects of care for patients with pancreatic cancer?” 
55 quality-of-care statements to score        1 (no importance/disagree) to 10 (very important/ agree) 
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final questionnaire respondents were: 22% - medical oncology, 18% - surgery, 19% - palliative 
care, 18% - allied health and nursing, 11% - radiation oncology and 6% from each of 
gastroenterology and others. Seventy-six respondents to the initial open-ended questionnaire (97%) 
described their clinical experience. Of these 12, (16%) reported more than 20 years treating patients 
with pancreatic cancer and treating more than ten patients each year.  The majority of respondents 
treated more than 10 patients each year ( n = 43, 57%) and years of experience were reported as 
less than 10 years, 10 to 20 years and more than 20 years by 30 (39%), 25 (33%) and 21 (28%) 
clinicians respectively. 
 
Figure 4-2: Numbers of invited and final responders by specialty 
Based on the initial scores, 8 of the 55 statements (15%) were classified as very important and 33 
(60%) as moderately important. The CV was greater than 4 for 14 (25%) statements, including 8 
that were considered unimportant. No items where the CV was less than 4 were classified as 
unimportant. Only two statements “All patients should have a full physical examination, geriatric 
assessment if elderly, assessment of comorbidities and performance status prior to any treatment” 
and “Patients should be fully aware of the risks and benefit of interventions prior to any treatment” 
were given a moderately-high or higher score by all participants. 
The mean scores for almost half the statements (n = 24; 44%) increased between surveys but were 
unchanged for 17 statements (31%), and decreased for 14 (25%) statements. The majority (n = 30; 
55%) of CVs remained the same between surveys; 11% (n = 6) increased and 35% (n = 19) 
decreased between surveys. 
Statements scores according to clinician specialty are displayed below within thematic categories 
and by score of importance (Table 4-1). 
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Table 4-1: Final scores for all statements by specialty 
 
 
Surgery 
Gastro-
enterology 
Medical 
Oncology 
Radiation 
Oncology 
Allied  
Health & 
Nursing 
Palliative 
Care 
Other Total 
 n† Mean (Coefficient of Variation) 
Presentation and Staging (n = 13 statements)          
aAll patients should have a full physical examination, geriatric 
assessment if elderly, assessment of comorbidities and performance 
status prior to any treatment 
59 8.9 (2) 10.0 (0) 9.2 (1) 9.1 (1) 9.0 (2) 9.3 (2) 8.8 (2) 9.2 (2) 
aStandard guidelines for staging should be developed 60 8.5 (3) 10.0 (0) 9.4 (1) 9.1 (1) 9.3 (1) 8.6 (2) 8.8 (2) 9.1 (2) 
bAll patients should have a triple phase/ pancreas protocol CT scan for 
staging 
55 9.5 (1) 10.0 (0) 8.9 (1) 9.0 (1) 9.3 (1) 7.6 (4) 8.5 (2) 8.9 (2) 
bAll patients should have an initial TNM stage recorded 59 7.9 (3) 10.0 (0) 9.1 (1) 8.6 (2) 9.1 (1) 8.4 (2) 8.3 (2) 8.7 (2) 
bStandard guidelines should be developed to determine which 
patients would benefit from transfer to a tertiary centre 
61 8.2(2) 10.0 (0) 7.7 (3) 9.0 (1) 8.5 (2) 8.7 (2) 6.5 (2)    8.3 (2)* 
bTissue diagnosis should be obtained where possible 59 7.2 (3) 6.2 (8) 8.9 (2) 9.1 (1) 8.9 (2) 8.3 (2) 8.3 (2) 8.3 (3) 
bAll patients should have access to ERCP and EUS facilities 57 7.4 (3) 10.0 (0) 8.2 (2) 7.9 (2) 9.2 (1) 7.8 (3) 7.8 (3) 8.2 (2) 
bA laparoscopy should be performed if resectability is uncertain 52 7.1 (4) 9.5 (1) 8.0 (3) 8.7 (1) 8.0 (1) 7.9 (2) 6.8 (2) 7.9 (2) 
bAll patients presenting with ongoing epigastric/back pain should 
have a CT as part of the initial investigations 
58 8.0 (3) 8.0 (4) 7.6 (3) 7.7 (1) 8.2 (2) 8.5 (1) 6.0 (2) 7.8 (2) 
bGeneral practitioners should coordinate the initial workup 59 7.3 (2) 7.0 (3) 6.4 (3) 5.9 (4) 7.1 (4) 7.2 (3) 7.3 (2) 6.8 (3) 
cIf disease appears to be localised a PET scan should be performed 56 5.1 (4) 8.4 (3) 6.1 (5) 7.7 (2) 7.4 (3) 8.4 (2) 6.8 (3)   6.9 (4)* 
cAll patients should have an EUS 56 6.2 (5) 6.6 (6) 6.4 (3) 5.4 (4) 7.2 (3) 5.5 (4) 5.0 (6) 6.1 (4) 
cAll patients presenting with ongoing epigastric or back pain should 
have a CA19.9 blood test 
56 5.9 (6) 4.0 (8) 4.6 (7) 4.3 (6) 5.3 (2) 5.3 (4) 4.5 (1) 4.9 (6) 
Surgery and biliary obstruction (n = 9 statements)          
aAll patients with a small lesion and technically resectable disease 
plus adequate performance status should be offered a resection 
57 9.2 (1) 10.0 (0) 9.1 (1) 9.3 (1) 10.0 (0) 8.8 (1) 8.7 (2) 9.2 (1) 
aResectability should be assessed and surgery performed by surgeons 
who perform more than 5 pancreatic surgeries per year 
53 8.7 (2) 10.0 (0) 8.7 (2) 9.3 (1) 9.2 (2) 8.8 (1) 8.5 (2) 9.0 (2) 
bSurgery should take place in tertiary institutions where > 15 
resections are performed annually 
57 7.5 (4) 10.0 (0) 8.4 (2) 9.0 (1) 9.4 (2) 8.5 (2) 8.5 (2) 8.6 (2) 
bBiliary obstruction should routinely be managed endoscopically in 
non-resectable patients 
50 8.2 (3) 9.0 (2) 8.6 (1) 8.4 (1) 8.3 (1) 7.5 (2) 8.0 (2) 8.2 (2) 
cPatients with resectable disease should not be stented prior to 
surgery unless surgery is delayed 
42 5.7 (5) 9.6 (1) 5.6 (5) 7.5 (2) 9.0 (0) 7.1 (3) 7.0 (0) 6.8 (4) 
  
 
 
Surgery 
Gastro-
enterology 
Medical 
Oncology 
Radiation 
Oncology 
Allied  
Health & 
Nursing 
Palliative 
Care 
Other Total 
 n† Mean (Coefficient of Variation) 
cA self-expandable metallic stent (SEMS) should be used instead of a 
plastic stent if biliary drainage is indicated prior to surgery 
36 5.7 (6) 7.2 (5) 6.9 (3) 6.5 (2) 9.0(-) 6.8 (3) 5.5 (1) 6.6 (4) 
cPotential for coeliac plexus block should be discussed before any 
surgical procedure 
41 3.3 (6) 6.6 (5) 5.9 (4) 5.5 (6) 9.0 (-) 7.2 (2) 7.0 (-)    5.8 (5)* 
cBiliary obstruction should be managed surgically if performance 
status and prognosis are satisfactory in non-resectable patients 
48 5.2 (4) 2.2 (8) 4.5 (3) 4.8 (3) 5.5 (1) 5.7 (4) 6.0 (5) 4.8 (4) 
cPotentially resectable patients should not have a tissue biopsy prior 
to surgery 
46 5.3 (5) 3.6 (11) 4.5 (5) 3.4 (4) 4.5 (2) 5.3 (4) 6.0 (5) 4.7 (5) 
Oncology and Other (n = 14 statements)          
aPatients should be fully aware of the risks and benefit of 
interventions prior to any treatment 
63 9.6 (1) 10.0 (0) 9.7 (1) 9.0 (2) 10.0(0) 9.7 (1) 9.3 (1) 9.7 (1) 
aPatients should be advised of the limitations of chemotherapy 61 9.5 (1) 10.0 (0) 9.5 (1) 9.1 (1) 9.9 (0) 9.6 (1) 9.0 (2) 9.5 (1) 
aCareful attention to pain control is important, using nerve blocks if 
required 
58 8.3 (2) 10.0 (0) 9.1 (1) 9.1 (1) 9.9 (0) 9.6 (1) 9.3 (1)    9.3 (1)* 
bAll patients should have a collaborative generalist/ specialist care 
model 
61 7.4 (4) 9.0 (2) 8.7 (1) 9.0 (1) 9.9 (0) 9.3 (1) 8.8 (1)    8.8 (2)* 
bEntry into a clinical trial should be considered for all patients 57 7.7 (3) 8.8 (2) 9.4 (1) 9.1 (1) 9.5 (1) 8.3 (3) 8.3 (2) 8.8 (2) 
bApart from surgery, all treatment should occur as close to the 
patient's home as possible 
62 9.3 (1) 9.8 (0) 8.7 (2) 7.1 (3) 9.7 (1) 8.7 (3) 7.3 (4)    8.8 (2)* 
bAll pancreatic cancer patients' details should be entered into a 
prospective database 
60 9.1 (2) 9.8 (0) 8.4 (2) 8.7 (1) 8.7 (2) 8.3 (2) 8.0 (2) 8.7 (2) 
bTissue should be routinely banked 51 9.2 (1) 9.2 (1) 8.9 (1) 6.8 (5) 9.8 (1) 7.1 (4) 9.0 (1)    8.5 (2)* 
bAll patients should be offered adjuvant therapy post operatively, 
assuming performance status is adequate 
52 7.7 (4) 8.0 (3) 9.0 (1) 7.9 (2) 9.3 (1) 7.5 (2) 7.5 (1) 8.1 (2) 
bCreon prescription should be considered for all patients 51 9.0 (1) 6.2 (5) 8.0 (2) 6.8 (4) 8.8 (1) 7.9 (2) 6.5 (3) 7.9 (3) 
bAll patients should have access to new drugs 59 7.2 (3) 8.2 (2) 7.9 (2) 7.7 (3) 8.9 (2) 7.2 (3) 7.5 (2) 7.7 (3) 
bBorderline resectable cases should be considered for neo-adjuvant 
therapy 
51 6.8 (4) 8.8 (1) 6.9 (3) 8.0 (2) 9.0 (1) 7.3 (2) 8.0 (0) 7.5 (3) 
bBiomarkers should be used as prognosis and management tools 51 7.7 (3) 7.8 (4) 7.4 (3) 7.2 (3) 8.7 (1) 6.6 (3) 8.5 (2) 7.4 (3) 
bAll patients should have access to conformal radiotherapy 52 6.2 (3) 8.3 (3) 6.6 (4) 8.9 (1) 7.5 (3) 7.5 (2) 7.0 (0) 7.2 (3) 
  
 
 
Surgery 
Gastro-
enterology 
Medical 
Oncology 
Radiation 
Oncology 
Allied  
Health & 
Nursing 
Palliative 
Care 
Other Total 
 n† Mean (Coefficient of Variation) 
MDT  and Referrals (n = 19 statements )          
aAll patients with potentially resectable disease should be referred to 
an hepato-biliary surgeon 
59 9.9 (0) 8.2 (5) 9.6 (1) 9.7 (1) 10.0 (0) 8.7 (2) 7.8 (3) 9.3 (2) 
aTumour resectability should be assessed by a MDT at a tertiary 
hospital 
60 8.4 (2) 10.0 (0) 9.3 (1) 9.1 (1) 9.6 (1) 8.4 (1) 7.7 (3)    9.0 (1)* 
bMDT meetings should include palliative care specialists 63 8.5 (2) 7.2 (4) 8.2 (2) 8.9 (1) 9.6 (1) 9.3 (2) 9.0 (1) 8.7 (2) 
bSymptom management should be discussed at MDT meetings 63 6.8 (4) 9.0 (2) 7.7 (3) 8.9 (1) 9.5 (1) 9.2 (1) 8.8 (1)   8.5 (2)* 
bEach patient should have a care-coordinator assigned with an 
individualised treatment/ clinical plan 
62 7.8 (2) 9.6 (1) 8.2 (2) 8.7 (1) 9.5 (1) 8.3 (1) 8.0 (3) 8.5 (2) 
bTertiary hospital MDTs should be involved in the care of patients 
from smaller centres (via video-conferencing etc if necessary) 
62 8.9 (1) 10.0 (0) 7.8 (2) 8.9 (1) 9.4 (1) 8.1(2) 7.3 (2)   8.5 (2)* 
bMDT meetings should include allied health professionals 61 7.4 (4) 9.0 (1) 7.8 (3) 8.7 (1) 9.1 (2) 8.8 (1) 9.0 (1) 8.4 (2) 
bAll patients should be presented to a MDT 63 7.1 (5) 10.0 (0) 8.1 (2) 8.9 (1) 9.7 (1) 7.3 (4) 7.3 (1)   8.3 (3)* 
bPatients requiring diabetes management should be seen by a 
diabetic educator 
63 7.8 (3) 9.4 (1) 8.8 (1) 7.6 (2) 9.1 (1) 7.3 (3) 8.3 (2)   8.3 (2)* 
aAll patients should be offered psychosocial support 62 6.7 (3) 9.4 (1) 8.0 (3) 6.7 (3) 8.8 (3) 8.6 (2) 7.8 (3) 8.0 (3) 
bAll patients should see a medical oncologist 58 8.2 (3) 7.6 (4) 8.1 (2) 8.0 (2) 8.3 (4) 7.2 (4) 7.8 (3) 7.9 (3) 
bA specialist HPB surgeon should be the initial/primary specialist 
unless the patient has obvious metastases 
57 7.7 (3) 7.6 (3) 7.6 (2) 6.6 (4) 8.1 (3) 6.4 (3) 7.3 (3) 7.3 (3) 
bAll patients should be referred to a dietitian soon after diagnosis 61 6.5 (3) 8.2 (4) 7.9 (2) 7.1 (1) 7.8 (4) 7.0 (2) 6.3 (2) 7.3 (3) 
cAll patients should be referred to a social worker 60 5.9 (4) 7.0 (4) 6.4 (4) 5.0 (3) 6.9 (5) 6.6 (2) 7.3 (3) 6.4 (4) 
cAll patients should be referred to a physiotherapist 60 4.9 (6) 4.3 (5) 5.1 (4) 3.8 (3) 5.1 (4) 4.9 (5) 5.0 (3) 4.8 (4) 
cAll patients should be referred to an occupational therapist 59 4.3 (7) 5.8 (7) 4.8 (5) 4.7 (4) 4.1 (5) 5.3 (4) 4.8 (2) 4.7 (5) 
cPatients should only be referred to palliative care when they have 
confirmed metastatic disease 
59 6.7 (3) 4.2 (8) 5.4 (4) 6.5 (2) 7.1 (4) 5.5 (5) 7.0 (3) 6.0 (4) 
cOnly patients who are potentially suitable for resection should be 
presented to a MDT 
61 5.1 (7) 1.2 (4) 4.3 (6) 2.0 (5) 1.8 (7) 4.3 (5) 4.8 (4)   3.6 (7)* 
cOn diagnosis all patients should be referred to palliative care 61 2.7 (10) 2.8 (8) 3.6 (5) 3.1 (5) 4.6 (6) 6.1 (5) 4.3 (7)   4.0 (6)* 
CV = coefficient of variation     PET = Positron emission tomography; EUS = Endoscopic Ultrasound; MDT = Multidisciplinary team; “Other” specialty group 
includes interventional radiologists, general practitioners and physicians. 
a all agree important (9 +); b all agree moderately important (6 - 8.9); c unable to agree (CV ≥4); † Number of observations/respondents with an opinion;  
* statistically significant (p-value less than 0.05) difference between groups. 
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Presentation and Staging:  
Almost 25% of the statements derived from the initial open-ended question related to presentation 
and staging (n = 13; 24%).  The need to conduct a full physical assessment prior to treatment and to 
develop standard staging guidelines were both rated as very important.  The panel did not reach 
consensus about the value of positron electron tomography (PET) scans, endoscopic ultrasounds 
(EUS) or carbohydrate antigen 19.9 (CA19.9) as staging tools, with evidence of variability in the 
rated importance of these statements both between and within specialty groups. Palliative care 
specialists rated the value of PET scans more highly than surgeons (mean scores 8.4 and 5.1 
respectively, p = 0.03) and had a lower CV (2 versus 4). 
Surgery and biliary obstruction:  
The 9 statements related to surgery and biliary obstruction had the fewest responses with some high 
proportions (9 – 91%) of the allied health, nursing and “other” groups indicating no opinion due to 
lack of expertise in the area.  Amongst those who did respond, the statements "all patients with a 
small lesion and technically resectable disease plus adequate performance status should be offered a 
resection" and "Resectability should be assessed and surgery performed by surgeons who perform 
more than 5 pancreatic surgeries per year", were classified as very important. Consensus was not 
reached for 5 statements. Allied health /nursing and palliative care specialists rated the statement 
“Potential for coeliac plexus block should be discussed before any surgical procedure” much higher 
than the surgical specialists (scores 9.0, 7.2 and 3.3 respectively, p = 0.02).  
Referrals and Multidisciplinary team (MDT):  
Over a third of the survey statements (n = 19; 35%) referred to when and where treatment should 
occur, and which specialists should be involved. The statements "all patients with potentially 
resectable disease should be referred to a hepato-biliary surgeon" and "tumour resectability should be 
assessed by a MDT at a tertiary hospital" were thought very important with overall mean scores of 
9.3 and 9.0 respectively. 
No overall or within-specialty consensus was reached for the statement “On diagnosis all patients 
should be referred to palliative care” (CV = 6). There was a significant difference in the scores 
between palliative care and surgical specialists with mean scores of 6.1 and 2.7 respectively, (p = 
0.03). Similarly, the panel did not agree on which patients should be presented at MDT meetings, 
with high inter- and intra-specialty variability.  
Although surgeons and gastroenterologists had significant variation within their specialty groups (p 
< 0.001) they thought it less important that “MDT meetings should include palliative care 
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specialists” and that “symptom management should be discussed at an MDT” than allied health, 
nursing and palliative care specialists (p = 0.02). 
Oncology and Others:  
All the 14 oncology and "other" statements were classified as moderately or very important with 
participants able to reach consensus and ranking none as unimportant. 
The statements that “patients should be fully aware of risks and benefits of interventions prior to any 
treatment” and “patients should be advised of the limitations of chemotherapy” were the highest 
scoring statements with total mean scores of 9.7 and 9.5 respectively and little variability across 
specialty.  
Radiation oncologists regarded access to conformal radiotherapy as more important than other health 
professionals. Surgeons scored the statement "all patients should have a collaborative 
generalist/specialist care model" lower than all other health professional groups. This difference 
between surgical and allied health/nursing specialists was statistically significant (p = 0.03). 
Gastroenterology, palliative care and allied health and nursing specialists rated the statement “careful 
attention to pain control is important, using nerve blocks if required” more highly than surgeons (p = 
0.03). 
Discussion 
We used a Delphi process to identify factors that health professionals from a range of disciplines 
consider important in the care of patients with pancreatic cancer. As expected, many of the items 
rated as important are consistent with existing evidence-based clinical guidelines, but there were also 
items rated as important by health professionals that are not considered by guidelines. Furthermore, 
for some consensus-based or expert opinion-based items included in guidelines agreement on the 
importance of these between the health professionals we surveyed was not reached. We also found 
that the rating of particular issues varied substantially by clinical discipline. 
Clinical guidelines have been developed by peak bodies in Europe and the United States, most 
notably the National Comprehensive Cancer Network (NCCN)6 and the European Society for 
Medical Oncology (ESMO),105, 188 which describe clinical pathways from diagnosis to treatment for 
patients with pancreatic cancer. In Australia no national clinical practice guidelines have been 
developed that are specific to the care of patients with pancreatic cancer.  
Comparing current guidelines with the opinions of clinicians working in the field identified some 
areas requiring further clarification, in particular the diagnosis and staging of pancreatic cancer. 
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Respondents in this study rated highly the need for development of standard guidelines for staging. 
This was underscored by the very high variability in responses about the value of PET, CA19.9 and 
EUS. Lack of clarity about PET is also apparent in the guidelines, with NCCN stating that it is 
unclear if PET is useful and ESMO guidelines recommending PET not be used. Both organisations 
recommend that CA19.9 should only be used in treatment monitoring and that EUS be used as an 
adjunct to a pancreatic protocol computerised tomography (CT) or magnetic resonance imaging 
(MRI) only in those without biopsy-proven metastases. The high variation in scores for EUS 
amongst our participants may result from the inclusion of the words “all patients” in the statement as 
those with confirmed metastases would not benefit from the procedure.    
It is notable that of the 55 items derived from panel members’ responses, approximately half related 
in some way to access to treatment, where treatment should occur or who should be involved in 
different treatment aspects. This may be a recognition that pancreatic cancer patients require highly 
specialised care and the provision of treatment at specialist centres might improve outcomes. This 
could also reflect the substantial geographical dispersion of the Australian population and the finding 
of a trend towards poorer survival in rural and remote areas.258 The study participants agreed that 
patients should be managed as close to home as possible, but that standard guidelines should be 
developed to determine who would benefit from transfer to a tertiary centre. Improved access 
through video-link to tertiary centres was also considered important. Telehealth aims to remove 
barriers to accessing medical services for residents of rural and remote Australia,259 and there are 
International and Australian recommendations around its use.260 The Queensland state Department of 
Health estimates that use of Telehealth would reduce health costs by 30% 261 and is currently under-
used throughout QLD.262 
Access to specialist surgical management was particularly highlighted. There was high agreement 
that all patients with potentially resectable disease should be assessed by a hepatobiliary surgeon, 
ideally as part of a multidisciplinary team. The need for multidisciplinary assessment of resectability 
is specifically stated in guidelines6 and has been shown to improve surgical mortality rates140 but it is 
unclear to what extent this currently occurs. Respondents also agreed that pancreatic cancer 
resections should occur in high-volume centres, reflecting guideline recommendations although 
definitions of high-volume vary across guidelines. The cut-off recommended by our panellists was 
consistent with the NCCN guidelines (15 surgeries/year). However, the National Cancer Institute 
(NCI) guidelines classify hospitals carrying out > 5 resections/year as high-volume and the British 
Society of Gastroenterology (BSG) guidelines137 do not give a value, but rather recommend that 
surgery be carried out in ‘specialist centres’. The evidence available suggests different values (range 
5 - 19) for high-volume classification.120, 128 Few data support a role for surgeon volume independent 
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of hospital volume,128, 135 probably because these are highly correlated, but our participants 
nevertheless felt pancreatic resections should be undertaken by surgeons performing more than 5 per 
year. These data clearly show that clinicians feel that centralisation of surgical care for pancreatic 
cancer is important. In the United States, hospital volume for pancreatectomies more than tripled 
between 2000 and 2008 with the median volume increasing from 5 to 16120 whereas in Australia 
volume is increasing but resections are still performed in low-volume hospitals.100, 141 
Multidisciplinary care has become the accepted standard for cancer patients and has been shown to 
improve treatment access and timeliness.252 263 However, systematic review evidence suggests there 
is substantial variability in the way MDT meetings are incorporated into patient care170 and this is 
reflected in our data, which show that clinicians value multidisciplinary care but vary in their views 
about the function of MDTs in the management of patients with pancreatic cancer. For example, in 
contrast to other specialties, surgeons were less likely to agree that all patients should be presented to 
MDTs and more likely to indicate that only potentially resectable patients should be presented to 
MDTs. The NCCN guideline also suggests that only patients without metastatic disease be presented 
at MDT meetings. However, The European Partnership for Action Against Cancer (EPAAC) 
recommend in their MDT policy document94 that MDTs co-ordinate cancer care at all stages.  While 
there was strong consensus among our panellists across all specialties that palliative care specialists 
should be present at MDT meetings, the presence of allied health professionals was not consistently 
rated as important by surgeons. This may reflect the fact that surgeons lead most MDT meetings and 
may prioritise surgical and medical issues over psychosocial concerns.185 EPAAC guidelines 
emphasise the need for MDTs to address the supportive care and psychosocial needs of their patients. 
They also emphasise the need for coordination across different disciplines to achieve continuity of 
care. While our Delphi process identified the importance of care coordination, the reality is that in 
Australia there is considerable variability in the way that the coordination role is implemented.264 
Adopting system-wide policies regarding MDTs and care coordination may be one way of improving 
the management of patients with pancreatic cancer. 
The two top-scoring items in our study related to patient communication. Both items emphasised the 
importance of ensuring that patients are aware of the risks, benefits and limitations of treatment.   
While this should be standard in all clinical situations, it is particularly important for patients with 
pancreatic cancer where surgery can result in significant morbidity and, even with successful 
resection, median survival is poor at ~20 months.265 In addition, current chemotherapy regimens 
have limited survival benefit and a United States national cohort study showed that about three 
quarters (69 - 81%) of patients with advanced cancer did not understand that the chemotherapy they 
were receiving was unlikely to result in cure.266   
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Up to 75% of patients with advanced pancreatic cancer report pain and it is one of the major factors 
adversely affecting quality of life.207, 267, 268 The need to manage pain was one of the highest-scoring 
items on the survey, but there was a lack of consensus about whether coeliac plexus neurolysis 
(CPN) should be discussed before embarking on any surgical procedure. CPN can prevent pain 
development for up to 6 months post-operatively269 and, while some studies suggest that CPN may 
not offer greater pain relief over opioid analgesia, it has fewer side effects.268 The NCCN guidelines 
do suggest that CPN should be considered at the time of palliative surgery.   
A major strength of this study was the robust method we used to elicit opinions from experts in 
pancreatic cancer management.237, 270 Key features of the Delphi process we used included: (1) the 
multidisciplinary panel drawn from a wide range of medical and allied health fields; (2) each health 
professional rated the quality-of-care statements anonymously, limiting the potential for a single 
individual to dominate the proceedings; (3) we provided structured feedback, where following the 
first round of ratings the panel received the ratings from the entire group; (4) it was  iterative, with 
two rating rounds allowing panel members to change their minds after deliberation;255 (5) it was 
internet-based and therefore less costly than other methods such as focus groups. 
The study has two key limitations. Firstly, although a broad range of specialist clinicians 
participated, response rates were highly variable and some specialties (notably gastroenterology) 
were under-represented. For ethical reasons we were unable to capture detailed information about the 
non-responders so it is difficult to determine the representativeness of the final sample in terms of 
factors such as location of practice and years of experience. Secondly, some statements did not fully 
portray the clinical variability that underlies decisions about care. This particularly applies to those 
statements which commenced with the words "All patients".  While the statements had been 
transcribed verbatim following responses to the open-ended questionnaire and to amend them would 
have resulted in a deviation from the Delphi method, some items may have scored more consistently 
had they been worded differently.  
This work shows that, for the most part, clinicians’ opinions reflect clinical guideline-recommended 
care, albeit with some exceptions. However, clinicians identified a number of additional factors that 
are not incorporated in pancreatic-cancer specific guidelines, with a particular focus on where 
patients should be treated, the importance of clear communication and the need for multidisciplinary 
care. The lack of agreement about which patients and clinicians should be included in MDT meetings 
reinforces the notion that further in-depth investigations are required to identify the optimal 
composition and schedule of MDT meetings to improve and standardise practice in this area. 
Similarly, clinicians support the need to develop policies about transfer to tertiary centres and 
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implementation of Telehealth to ensure that all patients with pancreatic cancer receive optimal 
multidisciplinary coordinated care.  
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5.1. INTRODUCTION 
This chapter includes a paper published in 2015. The aims of this publication were to describe the 
cohort included in the pancreatic cancer patterns-of-care study, to provide a broad overview of initial 
treatment patterns and to document overall survival. 
5.2. CONTRIBUTION OF CANDIDATE 
All authors contributed to the conceptualisation of the study. My contribution to this publication 
included data collection (20%).  I completed the majority of the data cleaning (80%) with the help of 
MP and REN and all statistical analyses (100%). I was responsible for the interpretation of the 
results (32%) in consultation with the study team, in particular REN. I was also responsible for 
writing (70%), editing (35%) and submitting the manuscript (100%) taking into account the 
comments and suggestions of REN and the study team. 
5.3. MANUSCRIPT 
The following manuscript was published in the journal Pancreas:  
Pancreas 2015; 44 (8):1259-65. 
Describing Patterns of Care in Pancreatic Cancer – a population-based study 
Burmeister EA, O’Connell DL, Beesley VL, Goldstein D, Gooden HM, Janda M, Jordan SJ, 
Merrett ND, Payne ME, Wyld D, Neale RE.     
Authors have provided permission to include this publication in this thesis (Appendix I). 
Abstract 
Objectives: Despite pancreatic cancer being the 5th highest cause of cancer death in developed 
regions there is a paucity of population-based management details for patients with pancreatic 
cancer. The objective of this study was to reflect on current practice and outcomes to facilitate future 
improvement. 
Methods:  A comprehensive population-based patterns-of-care study in two Australian states was 
conducted. Patients diagnosed with pancreatic adenocarcinoma between July 2009 and June 2011 
were identified by cancer registries, and detailed clinical data were collected from medical records. 
Results: Data were collected for 1863 patients, 96% of those eligible. The majority resided in major 
cities, their median age was 72 years and 54% were men.  Over half the cases (58%) had metastatic 
disease at diagnosis. Resection was attempted for 20% of patients but only completed in 15%. The 
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uptake of adjuvant chemotherapy (76%) and the proportion alive at one-year (22%) were higher than 
reported in previous population-based reports. Of those with no complete surgical resection, 43% 
received palliative chemotherapy. 
Conclusion: This population-based overview of the management of patients with pancreatic cancer 
suggests that, despite evidence that the proportion surviving and the use of adjuvant chemotherapy 
has increased, there may still be under-utilisation of cancer-directed therapies.   
Introduction 
Pancreatic cancer is the 14th most common type of cancer diagnosed in the developed world.1 It has a 
median survival of 6 months and an overall five-year survival of less than 5%. Consequently it is the 
5th most common cause of cancer death in developed regions,1 and current projections suggest that it 
will be the second leading cause of cancer death within 10 years.40, 250  
Surgery offers the only possibility for cure, but the majority of patients present with metastatic or 
locally advanced disease which precludes curative resection. Co-morbidities and performance status 
in an older patient cohort may also influence the decision to withhold a radical surgical resection. 
Those patients who undergo an oncologically complete resection have five-year survival of 
approximately 15 to 20% compared with less than 5% for the 80% of patients who are inoperable.271 
Chemotherapy and radiotherapy are treatment options in neo-adjuvant, adjuvant or palliative 
settings, but these modalities offer minimal benefit in terms of survival.99, 103, 272  
Best practice recommendations for  management of pancreatic cancer were compiled by a group of 
experts at the World Congress on Gastrointestinal Cancer in 2006 (Barcelona 2006),4 with additional 
recommendations for management of metastatic cancer made in 2012.5 The United States National 
Comprehensive Cancer Network (NCCN) has also published clinical practice guidelines for 
pancreatic cancer.6 Despite these publications it is apparent that there is considerable variation in the 
quality of management and care of patients with pancreatic cancer.7-9  
There have been few attempts to describe management of pancreatic cancer at a population level, but 
evidence from the limited population-based studies that have been conducted in Australia (2011), 
Europe (2009) and the United States (2007) suggest that multimodality therapies are underutilised 
and that this may be related to patient and/or health-service characteristics.12,13,15  
Data reflecting the current status of the variability in the management of patients with pancreatic 
cancer and the factors associated with the choice of different treatments is required. This will support 
changes in clinical practice and policy needed to optimise the care of all patients with this disease. 
We have therefore carried out a population-based study in two Australian states where over 50% of 
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Australians reside. In this report we describe the methods and patient cohort and provide a broad 
overview of care.  
Materials and Methods 
Patient identification and data from Cancer Registries 
Eligible patients were those who were aged 18 years or older, notified to the Queensland (QLD) 
Cancer Registry between 1 July 2009 and 30 June 2011 or to the New South Wales (NSW) Cancer 
Registry (Cancer Institute NSW) between 1 July 2009 and 31st December 2010 with a diagnosis of 
pancreatic ductal adenocarcinoma (ICD-10 code C25).  
From the cancer registries we obtained the patients’ sex, age at diagnosis, date of initial diagnosis, 
name and address of the treating clinician at the time of the initial diagnosis, and the hospital where 
the diagnosis was made (if applicable). Where available we also obtained the date of death. The 
cancer registries also provided the statistical local area (SLA (QLD)) or local government area (LGA 
(NSW)) for the patients’ residential locations. We used these to allocate patients to a level of 
socioeconomic status using the Socio-Economic Indexes for Areas (SEIFA) 2011245  and 
geographical location based on the Accessibility/Remoteness Index of Australia (ARIA+) 2011.246 
The Index of Relative Socio-economic Disadvantage (IRSD) (SEIFA 2011) is a general index of 
disadvantage which uses data including income, home-ownership and occupation, captured in the 
five-yearly census, to rank areas in Australia according to relative socioeconomic advantage and 
disadvantage. We categorised patients according to their IRSD score by using the quintile cut-points 
for the state-specific population distributions. ARIA+ is derived from measures of road distances 
between populated localities and service centres. Areas are categorised as major cities, inner 
regional, outer regional, remote or very remote. Due to the small population in remote and very 
remote areas these were grouped with outer regional areas. 
Ethical review: 
We obtained approval to access medical records without patient consent under the QLD Public 
Health Act and under the guidelines of the NSW Privacy Act. Ethics approval was obtained from the 
QIMR Berghofer Medical Research Institute, the Royal Brisbane and Women’s Hospital (on behalf 
of all public hospitals in QLD) and by the NSW Population and Health Services Research Ethics 
Committee. Additional ethics approvals and individual site-specific approvals were obtained for each 
public hospital and private hospital as required. All data collected for review was de-identified at 
source.  
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Clinical Data Collection:  
Research nurses accessed medical records for each patient, commencing with the record from the 
facility where the diagnosis was made if possible. The nurses used a standardised case report form 
(CRF) to abstract very detailed data about patient management from the medical record. Discharge 
summaries and correspondence were checked for evidence of referral to other centres for further 
management, and medical records at these centres were also reviewed. 
Information about initial presentation and investigations: 
We captured information about initial symptoms, investigations and disease stage according to the 
International Union Against Cancer (UICC 6th Edition) tumour node metastasis classification 
system.81 The tumour (T), node (N) and metastatic (M) status used to stage the disease was obtained 
from pathology reports on resection or, for those with no resection or missing TNM data, from initial 
investigations including imaging. We also classified patients according to the treating clinician’s 
assessment of whether the tumour was resectable or not. 
Initial Eastern Cooperative Oncology Group (ECOG) performance status and co-morbidities, such as 
cardiovascular disease, respiratory disease, renal impairment, diabetes and other cancers were noted 
and coded.  Co-morbidity scores were then calculated using the Charlson index244 and patients 
categorised into three groups according to their score: low (score equal to zero), medium (score equal 
to one) and high (score equal to two or more). 
Information about treatment: 
If patients underwent an attempted resection we recorded the place of surgery and the surgeon (both 
coded for anonymity), the surgical procedure performed (Whipple, total or distal pancreatectomy), 
surgical margins achieved and complications experienced. The reasons for not completing or 
attempting a resection were noted.  
Information about other procedures such as insertion of biliary stents and bypass surgery was 
included along with any complications that arose as a result of these procedures. Nurses also 
extracted details for chemotherapy and radiotherapy including planned regimens, dates and doses of 
drugs/radiation administered, complications and responses. Symptom management was recorded, 
including prescription of replacement pancreatic enzymes, coeliac plexus blocks or use of opioids for 
pain management and treatment of nausea. 
Dates of presentation at multidisciplinary team (MDT) meetings were noted as were referrals to 
social workers, physiotherapists, psychologists, palliative care services and dieticians. If the patient 
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had access to nursing care co-ordinators or had a documented care plan, these details were included 
on the CRF.  
Information about admissions occurring until death or up to 12 months after the index admission 
were documented, including dates of admission and discharge, the types of health professionals 
involved in each episode of care, and all investigations and treatment. 
At six and twelve months post diagnosis the patient’s disease status and, if alive, place of residence 
was recorded.  Date and cause of death was captured from the medical record if the patient died 
within 12 months of diagnosis. To update survival information we reviewed death information held 
by the Cancer Registries in February 2014. 
Quality assurance: 
The research nurses who conducted the medical record reviews underwent an initial two-day training 
workshop with clinicians in attendance. This was repeated midway through the data collection period 
(after approximately 18 months). At these workshops all nurses reviewed the same series of charts 
and completed CRFs were compared. Discrepancies were discussed, and differences in interpretation 
resolved.   
Statistical analysis 
Descriptive statistics including frequencies and proportions were used to describe the cohort 
according to age, socio-economic status, place of residence, stage at diagnosis and patients’ co-
morbidities. Here we describe the overall treatment modalities as simple proportions, with cases with 
missing data omitted from denominators. Survival curves according to stage were generated applying 
Kaplan-Meier methods using the date of diagnosis until death of any cause, or February 20, 2014. 
Date of diagnosis was taken as the date of histological diagnosis or, for those with no histological 
diagnosis, the date of diagnosis via imaging.  
Results 
The NSW and QLD cancer registries identified 2090 patients as potentially eligible for inclusion in 
the cohort. Of these 140 (7%) were found to be ineligible after medical record review, most often 
because their cancer did not originate in the pancreas (n = 94, 67%). Charts were available for review 
for 1863 patients (96%); 87 reviews were not commenced due to difficulty accessing records or 
because the cancer registries were only notified when the patient died and no hospital information 
could be located. These have been excluded from all analyses (Figure 5-1). 
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*Pancreatic cancer patterns-of-care study 
Notes: Other cancers included ampullary, cholangiocarcinoma, duodenal, gastric and other metastatic cancer; 
Interstate resident describes people diagnosed in QLD or NSW but who did not reside in these states; Other 
ineligibility includes diagnosed outside of study dates. 
Figure 5-1: Flow chart of patient accrual and eligibility in QLD and NSW flow chart of patient 
accrual and eligibility in Queensland and New South Wales 
Cohort and disease characteristics 
The median age of those included in the cohort was 71 years (range 29 – 99) and 54% were men 
(Table 5-1). The sex distribution differed with age; 66% of patients 60 years or younger were male 
compared with 44% of those over 80 years.  A SEIFA IRSD median score of 991 for the cohort 
showed that patients lived in slightly more disadvantaged areas than the Australian population 
(median 1000).  The majority of patients (68%) lived in a major city at the time of diagnosis. Over 
half of the patients for whom we had information about co-morbidities (98% of all patients) had a 
Charlson co-morbidity index score of at least one.  
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Table 5-1: Sociodemographic and disease characteristics of pancreatic cancer patients in QLD 
and NSW (n=1863) 
 
Notes: 1: Undetermined or missing data are not included in the denominator for calculation of percentages.    
           2: Quintile cut-points are based on census data state population distributions. 
       n (%)1 
Sex   Men 1015 (54) 
Age at diagnosis, years 
  
 ≤44       
45 - 54  
55 – 64 
65 - 74  
75 - 84 
≥ 85 
 39 (2) 
     137 (7) 
335 (18) 
552 (30) 
551 (30) 
249 (13) 
Place of residence   
 
Major cities 
Inner regional 
Outer regional/remote /very remote Unknown 
residence 
  1257 (68)    
    397 (22) 
193 (10)  
16 (1) 
Socio-economic status 
– quintiles 2 
       
 
Most disadvantaged 
Second 
Third 
Fourth 
Least disadvantaged 
Unknown status 
372 (20) 
399 (22) 
383 (21) 
390 (21) 
    303 (16) 
16 (1) 
T Stage 
  
T 0/1 
T 2 
T 3 
T 4 
Tumour cannot be evaluated (Tx)    
44 (3) 
306 (20) 
876 (57) 
302 (20) 
335 (18) 
N Stage 
      
 
N0 
N1  
Regional lymph nodes cannot be evaluated (Nx) 
338 (29) 
827 (71) 
698 (37) 
M Stage 
 
M0 
M1  
Distant metastases cannot be evaluated (Mx) 
782 (43) 
  1037 (57) 
44 (2) 
TNM Stage 
 
Stage I 
Stage II 
Stage III 
Stage IV 
Undetermined stage 
85 (5) 
507 (28) 
     148 (8) 
  1036 (58) 
  87 (5) 
Confirmed tissue diagnosis 1368 (73) 
Site 
      
 
Head/neck/uncinate process 
Body 
Tail 
Multiple/other 
Not stated 
  1184 (72) 
    156 (9) 
177 (11) 
133 (8) 
213 (11) 
Potentially Resectable 
Disease 
  
Yes 
No 
Unknown 
537 (30) 
  1283 (70) 
  43 (2) 
Charlson Comorbidity 
Index (score) 
 
 
Low (0) 
Medium (1) 
High (≥2) 
Not stated 
779 (43) 
608 (33) 
446 (24) 
30 (2) 
Performance Status 
 
Fully active 
Limited activity 
In bed < 50% day 
In bed > 50% day 
Bed bound 
Not stated 
447 (28) 
583 (36) 
323 (20) 
218 (14) 
29 (2) 
263 (14) 
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Histological or cytological confirmation of disease was obtained in 73% of patients. The head, neck 
or uncinate process of the pancreas was affected in 72% of the cohort, and the body, tail or multiple 
sites were affected approximately equally for the remainder of those with known site. Almost a fifth 
of patients were missing tumour size (n = 335), and more than a third were missing nodal status (n = 
698, 37%). However, because a large proportion of patients without this information had metastatic 
disease, the overall UICC stage was able to be derived for 95% of patients, 58% of whom were stage 
IV.  Following investigations and staging 537 (30%) patients were thought to have potentially 
resectable disease but this varied according to the site of the tumour. Approximately 40% (449) of 
cancers in the head, neck or uncinate process were judged to be resectable compared with 12% (19), 
21% (37), and 12% (16) in the body, tail or multiple sites respectively. 
The median survival of the cohort was 4.5 months (95% confidence interval (CI) 1.7 to 10.8) with 
22% alive one year after diagnosis (Figure 5-2). 
 
Figure 5-2: Survival for pancreatic cancer by stage at diagnosis in QLD and NSW 
 
Median survival was 10.4 months (95% CI, 4.5 to 22.2) for patients diagnosed with stage I / II 
disease and 8.7 months (95% CI, 4.2 to 14.1) and 2.5 months (95% CI, 1.2 to 5.5) for those with 
stage III and stage IV disease, respectively. 
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Treatment 
Figure 5-3 shows an overview of the management of this cohort. Resection was attempted for 369 
patients (69% of those with potentially resectable disease, 20% of the total). Many patients (168, 
31%) with potentially resectable disease did not undergo attempted curative surgery. The presence of 
co-morbidities accounted for the majority of these (n = 97; 58%). Advanced age was recorded as the 
primary reason for 31 patients (18%) and 34 (20%) declined surgery. The reason was unknown for 6 
patients (4%). To enable comparison with other series, we also report the data for the 85 stage I 
patients. Fifty-eight percent (n = 49) did not undergo an attempted resection. For 30 patients (61%) 
the reason was old age and/or co-morbidities. Twelve patients (24%) declined surgery, and 4 (8%) 
had poor performance status. There were only 3 patients (6%) where no reason was recorded.  
In approximately one quarter of patients who underwent an attempted resection it was not completed 
due to locally advanced disease (n = 50, 56%), the detection of metastases (n = 25, 28%), both local 
spread and metastases (n = 10, 11%) or unknown and other causes (n = 5, 6%). Only one stage I 
patient did not undergo a completed resection – this was due to the presence of liver cirrhosis. 
Ultimately 279 patients in this cohort (15%) had a completed curative surgical procedure. 
Adjuvant chemotherapy was received by 187 (76%) of the 279 patients with completed surgical 
resections for whom we could find chemotherapy information (32 had missing data). Information 
about chemotherapy was missing for 163 (10%) of the 1584 patients who had an incomplete 
resection or no attempted resection. Where the information was recorded, palliative chemotherapy 
was given to 67% (n = 56) of those who had an attempted surgical resection, and 41% (n = 555) of 
those in whom surgery was not attempted (Figure 5-3). 
Half of the patients (n = 139) who underwent a completed resection had recurrent disease within 12 
months of diagnosis and 32% of these received palliative chemotherapy.  
Radiotherapy was used infrequently. Only 151 patients (8%) underwent radiotherapy; 48 in an 
adjuvant and 103 in a palliative setting. 
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Notes: 1: Patients with unknown adjuvant chemotherapy information (n = 32) were removed from the denominator; 2: Recurrence within one year of diagnosis; 3: Including patients 
with incomplete resections. 
 
Figure 5-3: Resection, recurrence and chemotherapy patterns of care for pancreatic cancer in QLD and NSW 
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Discussion 
This is one of the most comprehensive studies of management of patients with pancreatic cancer 
conducted to date. We carefully reviewed medical records for a cohort of Australian patients with 
pancreatic cancer diagnosed over a two-year period. This broad overview of patient management 
has shown that, despite improvements in surgery and a relatively high number of people 
undergoing attempted resection, the number of patients having successful resections has only 
increased marginally compared to historical reports.106, 273 Adjuvant treatment use, principally 
chemotherapy, is higher than in previous series,12, 13, 18  which may explain the slightly higher 
survival than has been reported in other population-based cohorts.12, 33  
The demographic characteristics of this cohort are consistent with other Australian and 
international data. The median age of 71 is identical to that reported in the United States SEER 
data274 and the proportion who are male is as expected: 55% of patients included in our cohort 
compared with 53% of pancreatic cancer patients in the Australian cancer registry data in 2010275. 
With respect to geographical location, the distribution of our cohort is almost identical to that of the 
Australian population,276 suggesting that the risk of pancreatic cancer does not differ appreciably 
according to remoteness. A slightly higher proportion of patients lived in more disadvantaged areas 
compared with the population distribution.277  
Comparable to previous international reports,273, 278 approximately 30% of patients were assessed as 
having potentially resectable disease. Of these, 30% did not progress to an attempted resection and, 
for those where resection was attempted, a large proportion was aborted (24%). This high number 
of incomplete resections may indicate incomplete or inadequate staging for patients with higher 
staged disease, or suggest that surgeons are more willing to attempt resections given improvements 
in surgical techniques that have occurred.279 We observed that 58% of patients with stage I disease 
did not undergo attempted resection. This is lower than the 71% found in a series of patients 
diagnosed between 1995 and 2004 in the United States. However the proportion not resected in that 
cohort changed from 79% in 1995 to 64% in 2004 and it is possible that this has reduced further in 
the last decade.  
Ultimately, 15% of all patients had a completed resection. This is marginally higher than previous 
Australian107 European,12 and United States13, 33 reports of around 12%. It is possible that we have 
over-estimated the proportion who had resection due to failure to capture information about all 
patients, but if the 87 patients whose records we could not access were included in the dataset and 
assumed not to have undergone resection, the proportion resected would be 14%. This slightly 
 110 
 
higher proportion may reflect surgical improvements enabling resection of tumours with a greater 
degree of vessel and nerve involvement than was previously possible,265 but this nevertheless 
highlights the dismal prognosis for most patients diagnosed with pancreatic cancer. Identification 
of biomarkers that predict outcomes may lead to improvements in patient selection,280 thereby 
avoiding surgical intervention in those where benefit will be marginal but possibly increasing the 
use of surgery in patients for whom benefit is not currently considered to outweigh risk.  
Three quarters of patients who had a completed resection had adjuvant chemotherapy. In 
comparison, studies from the United States,13 Australia18 and Ireland,12 all of which collected data 
for patients diagnosed over a decade ago, reported that the proportion of patients having adjuvant 
chemotherapy ranged from 39%12 to 47%.18 This may be due to increased use of adjuvant 
chemotherapy following the release of results from the ESPAC-1157 and CONKO-0013 trials and 
may be responsible for the somewhat higher survival than in earlier population-based studies (22% 
surviving to one year in our cohort compared with 15% or less previously).12, 33  
Guidelines suggest that chemotherapy should be considered in the palliative care setting, dependent 
upon a patient’s performance status,5, 6, 190 as it has been shown to improve both survival151 and 
quality of life.281 Recent data identifying novel regimens that for the first time have shown 
incremental improvement over previous standards of care for chemotherapy mandate an 
understanding of contemporary practice in order to judge the impact of these new treatments over 
time.282, 151 We observed that 43% of patients who did not undergo a completed resection received 
palliative chemotherapy. This is higher than some international population studies with rates of 20 
to 30% 12, 62 but similar to previous Australian findings.18  Under assumptions of all those with 
missing information either receiving or not receiving chemotherapy, the proportions would range 
from 32% to 54%, possibly indicating under-use of this treatment modality.  
A major strength of this study is that it is truly population-based. Although we only included 
patients from two of the eight Australian states and territories, approximately 56% of all 
Australians live in these two states. The concordance of age, sex, stage and tumour site with reports 
from cancer registries and previous literature confirms that the cohort is essentially representative 
of the broader pancreatic cancer patient population and, while information for some items was 
difficult to obtain, we captured some data for 96% of all eligible patients diagnosed during the 
study period. The manual extraction from medical records by trained nurses was time- and labour-
intensive, but it has resulted in much more detailed and complete data than would be possible 
through linkage.283, 284 A previous Victorian population-based study collected data using 
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questionnaires sent to treating clinicians,107 potentially leading to differences in the interpretation of 
data items. We carefully trained our staff to ensure reliable capture of information and regularly 
assessed data consistency across collectors.  
In conclusion we have undertaken a comprehensive assessment of the patterns of care for patients 
diagnosed with pancreatic cancer in Australia. In this broad overview we show that there has been a 
small increase in the proportion of patients undergoing surgery and that the use of adjuvant 
chemotherapy in Australia appears to have increased somewhat in the last decade compared to 
previous Australian data from Victoria.18, 107 Nevertheless, there remains under-utilisation of 
cancer-directed therapies which may contribute to the failure to improve outcomes in this difficult 
disease.  
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6.1. INTRODUCTION 
The work in this chapter was published in Pancreatology in 2016. The aim of this publication was 
to estimate the survival of patients with non-metastatic disease and factors associated with survival. 
As surgical resection of the tumour is the only potential strategy for increasing survival, factors 
associated with receipt of resection were also compared. As resection is only attempted in patients 
classified as having resectable disease, factors associated with this classification were also 
examined.  
6.2. CONTRIBUTION OF CANDIDATE 
My contribution to this publication included defining the relevant research question (70%) and data 
collection (20%) with the advice and support from REN and the study team.  I completed the 
majority of the data cleaning (80%) and statistical analyses (80%), with the help of MW and REN, 
and I was responsible for the interpretation of the results (35%) in consultation with the study team, 
in particular REN. With input from REN and the study team I was also responsible for writing 
(70%), editing (32%) and submitting the manuscript (90%). 
6.3. MANUSCRIPT 
The following publication detailing these findings has been published in the journal Pancreatology: 
Pancreatology 2016; 16 (5): 873-881. 
Determinants of survival and attempted resection in patients with non-
metastatic pancreatic cancer: an Australian population-based study.  
EA Burmeister, M Waterhouse, SJ Jordan , DL O’Connell, ND Merrett, D Goldstein, D Wyld, V 
Beesley,  H Gooden, M Janda, RE Neale 
Authors have provided permission to include this publication in this thesis (Appendix I). 
Abstract 
Background 
There are indications that pancreatic cancer survival may differ according to sociodemographic 
factors, such as residential location. This may be due to differential access to curative resection. 
Understanding factors associated with the decision to offer a resection might enable strategies to 
increase the proportion of patients undergoing potentially curative surgery.  
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Methods 
Data were extracted from medical records and cancer registries for patients diagnosed with 
pancreatic cancer between July 2009 and June 2011, living in one of two Australian states. Among 
patients clinically staged with non-metastatic disease we examined factors associated with survival 
using Cox proportional hazards models. To investigate survival differences we examined 
determinants of : 1) attempted surgical resection overall; 2) whether patients with locally advanced 
disease were classified as having resectable disease; and 3) attempted resection among those 
considered resectable.  
Results 
Data were collected for 786 eligible patients. Disease was considered locally advanced for 561 
(71%) patients, 510 (65%) were classified as having potentially resectable disease and 365 (72%) 
of these had an attempted resection. Along with age, comorbidities and tumour stage, increasing 
remoteness of residence was associated with poorer survival. Remoteness of residence and review 
by a hepatobiliary surgeon were factors influencing the decision to offer surgery. 
Conclusions 
This study indicated disparity in survival dependent on patients’ residential location and access to a 
specialist hepatobiliary surgeon. Accurate clinical staging is a critical element in assessing surgical 
resectability and it is therefore crucial that all patients have access to specialised clinical services. 
Introduction 
Pancreatic cancer is the 10th most commonly diagnosed cancer in more developed regions of the 
world. However, it has the worst prognosis of any cancer, with a five-year relative survival of less 
than 5%, so is the 4th most common cause of cancer death.1 Although survival rates have improved 
slightly over the past decade, current projections suggest that it will be the second leading cause of 
cancer death in the United States within 10 years.40 
Worse survival has been observed for patients who live outside metropolitan areas,285 have low 
socioeconomic status and who are elderly.286 While patient factors such as frailty and comorbidities 
may be partially responsible for these survival differences, isolation and access to quality care may 
also play a role. This access to care is becoming increasingly important as vascular reconstruction 
becomes more commonplace in major centres, particularly in combination with neoadjuvent 
therapies for borderline resectable tumours. Multimodality therapy which includes complete 
surgical removal of the tumour currently provides the only potentially curative therapeutic 
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option,265, 287, 288 improving five-year survival to about 20%.113, 289, 290 However, due to the 
proximity of the pancreas to large vessels and organs, assessment of resectability is challenging and 
surgical resection itself is technically challenging.102   National Cancer Comprehensive Network 
(NCCN) guidelines therefore recommend multidisciplinary consultation when determining 
potential resectability,6 with the involvement of a skilled, specialised hepatobiliary surgeon as an 
integral part of the team.291, 292 International data show that resection rates are influenced by 
ethnicity, insurance status, marital status, education level, socioeconomic status and geographical 
distance from large metropolitan areas.10-13 There are indications that this may be related to the 
expertise at the facility where patients are being staged.93  
Understanding factors that influence survival and that are associated with surgical resection may 
enable implementation of strategies to ensure all patients with pancreatic cancer who are suitable 
for surgery are indeed offered such potentially curative surgery as part of their management. Using 
data from an Australian population-based study of patients clinically staged as having non-
metastatic pancreatic cancer, our aim was to investigate survival according to patient, tumour and 
health-service factors and to examine components associated with determination of resectability 
and whether or not resection was attempted.  
Methods 
Study population and data collection 
Data collection and regulatory approvals for the study have been described previously.293 Briefly, 
the study included patients aged ≥18 years who were notified to the Queensland Cancer Registry 
between 1 July 2009 and 30 June 2011 or to the New South Wales Cancer Registry between 1 July 
2009 and 31 December 2010 with a diagnosis of pancreatic ductal adenocarcinoma. We obtained 
demographic and initial diagnosis information from the cancer registries; trained research nurses 
collected detailed clinical data from medical records. Date of death was obtained from medical 
records or cancer registries. As all patients with metastatic disease on initial clinical staging are 
unsuitable for curative resection, analyses were restricted to patients with no evidence of metastatic 
disease on clinical staging. 
Outcomes 
The main outcomes were one- and two-year mortality, defined as death of any cause within one and 
two years of diagnosis respectively, and survival time. Survival time was defined as the number of 
months from diagnosis until death or, for patients still alive, until date of last follow-up (February 
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2014). The date of diagnosis was taken as either the date of first diagnosis on imaging or 
histology/cytology, whichever came first.  
To investigate survival differences, we examined factors associated with: (1) attempted surgical 
resection for all patients with non-metastatic disease; (2) whether patients with locally advanced 
disease were classified as having potentially resectable disease (restricted to this patient group as 
disease confined to the pancreas is automatically classified as resectable); and (3) attempted 
resection for those considered resectable. Whether or not a tumour was considered to be locally 
advanced or resectable was extracted from medical specialist or multidisciplinary team (MDT) 
meeting notes.  
Factors of interest 
Patient characteristics: The patient factors of interest included age at diagnosis, sex, Eastern 
Cooperative Oncology Group (ECOG) performance status and Charlson comorbidity index.244 
Based on area of residence at the time of diagnosis, each person was allocated a socio-economic 
index for areas (SEIFA)245 score and Accessibility/Remoteness Index of Australia (ARIA)246 
category. For analysis we grouped the SEIFA score into quintiles and collapsed the ARIA into 
three groups: major city; inner regional; and outer regional/remote/very remote. 
Tumour characteristics: Tumour factors included the site within the pancreas (head/neck/uncinate 
process, body, tail or multiple/other) and clinical stage of the tumour (confined to the pancreas or 
locally advanced disease). Locally advanced disease was defined as localised (non-metastatic) 
disease spread beyond the pancreas.  
Health service characteristics: Health-service factors included the type of specialist first seen, the 
volume (according to the number of patient presentations in the study) of the facility where the 
patient was first treated as an inpatient, whether the patient was reviewed by a MDT and if they 
were assessed by a hepatobiliary surgeon. A hepatobiliary surgeon was defined as a surgeon who 
had undergone recognised specialised hepatobiliary surgery training and/or was recognised by their 
peers as an experienced hepatobiliary surgeon. Receipt of any chemotherapy was also included in 
the analysis of the mortality and survival outcomes. Associations between investigations performed 
to clinically stage the patient’s tumour including computerised tomography (CT) (+/- pancreas 
protocol), endoscopic ultrasound (EUS), endoscopic retrograde cholangio-pancreatography 
(ERCP), magnetic resonance imaging (MRI) or cholangiopancreatography (MRCP), and 
laparoscopy, and each of resectability and attempted resection were evaluated. 
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Statistical analysis 
Survival curves were generated and median survival was estimated using Kaplan-Meier methods, 
and the median time of follow-up was estimated using reverse Kaplan-Meier methods.247 The 
associations between all patient, tumour and health-care factors and one- and two-year mortality 
were examined using logistic regression and the crude odds ratios (ORs) were estimated. Hazard 
ratios (HRs) for overall survival were estimated using Cox proportional hazards models. All patient 
and tumour factors were then included in multivariable models to estimate adjusted odds ratios 
(AORs) or hazard ratios (AHRs). Models examining health-service factors included all patient and 
tumour factors and the receipt of chemotherapy.  
Associations between patient/tumour/health-service factors and each of (1) attempted resection; (2) 
whether or not the tumour was staged as potentially resectable for patients with locally advanced 
disease; and (3) whether or not a resection was attempted among those who were considered 
resectable were examined using multivariable logistic regression. To understand associations 
between place of residence, age and other patient and health-service factors, Chi-squared tests were 
used. 
Hierarchical mixed effects models, with hospital as a random intercept, were used to adjust for the 
effects of clustering within hospitals when assessing associations between the outcomes of interest 
and hospital volume.  
Statistical analyses were performed in Stata13 (Statacorp, Texas). All p-values are two-sided and 
we considered  p < 0.05 as an indication of statistical significance. 
Results 
Patient characteristics and disease stage 
Overall, 786 patients (44%) were clinically staged as having non-metastatic disease at diagnosis. 
The median age of these participants was 70 years (range 29 - 99) and 54% were men. The majority 
(69%) lived in major cities, 21% resided in inner regional areas and 10% in outer regional or 
remote locations. Disease was considered locally advanced for 561 (71%) patients. About two-
thirds (n = 510; 65%) were classified as having potentially resectable disease after staging (225 
with disease confined to the pancreas and 285 with locally advanced disease) and resection was 
attempted for almost three-quarters (n = 365; 72%) of these.  
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Mortality and survival 
Median survival was 10 months and the proportions of patients who died within one and two years 
of diagnosis were 58% (n = 454) and 80% (n = 626) respectively.  
Increasing age, comorbidities, low performance status, more advanced clinical stage of disease and 
tumours in the body of the pancreas were associated with higher mortality and poorer survival 
outcomes (Table 6-1: Associations between patient, tumour and health-service characteristics and 
1- and 2-year mortality and survival for patients diagnosed with non-metastatic disease (n = 
786)Table 6-1, Figure 6-1).  
  
Table 6-1: Associations between patient, tumour and health-service characteristics and 1- and 2-year mortality and survival for patients 
diagnosed with non-metastatic disease (n = 786) 
  
 
1-year mortalitya 
 
2-year mortalitya 
 
Overall survivalb 
Exposure variable 
Nc 
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI)  
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI)  
Median 
(months) 
Crude HR 
(95% CI) 
Adjusted HRd 
(95% CI) 
Patient / tumour factors             
Age at diagnosis, years             
< 60 141 38.3 1.00 1.00  66.7 1.00 1.00  13.9 1.00 1.00 
60 - 69 218 48.2 1.50 (0.97, 2.30) 1.34 (0.84, 2.15)  76.2 1.60 (1.00, 2.56) 1.45 (0.86, 2.45)  13.0 1.20 (0.95, 1.52) 1.05 (0.83, 1.34) 
70 - 79 223 65.8 2.72 (1.76, 4.20) 2.31 (1.44, 3.73)  79.8 1.98 (1.22, 3.19) 1.69 (0.98, 2.91)  8.4 1.57 (1.24, 1.98) 1.33 (1.04, 1.69) 
≥ 80 204 76.0 5.10 (3.19, 8.13) 3.48 (2.05, 5.91)  92.2 5.88 (3.16, 10.91) 3.99 (1.94, 8.24)  5.0 2.70 (2.14, 3.42) 2.01 (1.56, 2.60) 
Overall p-value, p-trend 
  
<0.001, <0.001 <0.001, <0.001 
  
<0.001, <0.001 0.003, <0.001 
  
<0.001, <0.001 <0.001, <0.001 
Sex 
            Men 422 54.3 1.00 1.00 
 
77.5 1.00 1.00 
 
11.2 1.00 1.00 
Women 364 61.8 1.36 (1.03, 1.81) 1.18 (0.85, 1.63) 
 
82.1 1.34 (0.94, 1.90) 1.22 (0.81, 1.85) 
 
8.8 1.25 (1.07, 1.45) 1.22 (1.04, 1.42) 
Overall p-value 
  
0.03 0.33 
  
0.11 0.34 
  
0.004 0.012 
ECOG performance status             
Fully active 260 37.3 1.00 1.00  65.9 1.00 1.00  15.2 1.00 1.00 
Not fully active 420 68.8 3.71 (2.68, 5.13) 2.53 (1.76, 3.64)  88.1 4.19 (2.84, 6.18) 2.90 (1.87, 4.51)  7.2 2.13 (1.79, 2.53) 1.74 (1.45, 2.08) 
Overall p-value   < 0.0001 < 0.001   < 0.001 < 0.001   < 0.001 < 0.001 
Charlson comorbidity index (score) 
           Low (0) 340 49.1 1.00 1.00 
 
74.1 1.00 1.00 
 
12.4 1.00 1.00 
Medium (1) 243 57.6 1.40 (1.01, 1.96) 1.12 (0.77, 1.63) 
 
80.3 1.42 (0.95, 2.11) 1.10 (0.70, 1.73) 
 
9.9 1.20 (1.00, 1.43) 1.04 (0.86, 1.25) 
High (≥ 2) 199 72.9 2.78 (1.91, 4.06) 2.50 (1.64, 3.81) 
 
88.9 2.81 (1.70, 4.66) 2.22 (1.26, 3.91) 
 
8.0 1.62 (1.34, 1.95) 1.43 (1.18, 1.74) 
Overall p-value, p-trend 
  
<0.001,<0.001 <0.001, <0.001 
  
<0.001,<0.001 0.02, 0.010 
  
<0.001,<0.001 <0.001, 0.001 
Place of residence             
Major city 547 56.5 1.00 1.00  77.9 1.00 1.00  10.4 1.00 1.00 
Inner Regional 163 58.9 1.10 (0.77, 1.58) 1.19 (0.80, 1.79)  81.6 1.26 (0.81, 1.96) 1.54 (0.92, 2.59)  10.1 1.11 (0.93, 1.34) 1.17 (0.97, 1.42) 
Outer regional/remote 76 64.5 1.40 (0.85, 2.31) 1.56 (0.88, 2.77)  88.2 2.11 (1.02, 4.36) 3.10 (1.34, 7.20)  8.4 1.29 (1.00, 1.66) 1.33 (1.03, 1.72) 
Overall p-value, p-trend   0.40, 0.19 0.27, 0.11   0.096, 0.03 0.01, 0.003   0.11, 0.036 0.04, 0.01 
  
  
 
1-year mortalitya 
 
2-year mortalitya 
 
Overall survivalb 
Exposure variable 
Nc 
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI)  
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI)  
Median 
(months) 
Crude HR 
(95% CI) 
Adjusted HRd 
(95% CI) 
Socio-economic Status of area of residence - quintiles 
         Most disadvantaged 156 63.5 1.00 1.00 
 
82.0 1.00 1.00 
 
8.8 1.00 1.00 
Second 171 57.3 0.77 (0.50, 1.21) 0.91 (0.55, 1.50) 
 
77.8 0.77 (0.44, 1.32) 0.91 (0.49, 1.68) 
 
10.1 0.87 (0.69, 1.10) 1.03 (0.81, 1.31) 
Third 158 54.4 0.69 (0.44, 1.08) 0.68 (0.41, 1.14) 
 
78.5 0.80 (0.46, 1.39) 0.81 (0.43, 1.52) 
 
10.8 0.85 (0.67, 1.08) 0.81 (0.63, 1.04) 
Fourth 160 56.9 0.76 (0.48, 1.19) 0.91 (0.54, 1.51) 
 
78.1 0.78 (0.45, 1.36) 0.95 (0.51, 1.78) 
 
10.3 0.90 (0.71, 1.14) 1.05 (0.83, 1.34) 
Least disadvantaged 136 56.6 0.75 (0.47, 1.20) 0.80 (0.47, 1.35) 
 
82.4 1.02 (0.56, 1.86) 1.05 (0.54, 2.05) 
 
10.4 0.93 (0.73, 1.19) 1.01 (0.79, 1.31) 
Overall p-value, p-trend 
  
0.57, 0.26 0.64, 0.46 
  
0.76, 0.97 0.94, 0.86 
  
0.70, 0.71 0.22, 0.86 
Tumour site             
Head/neck/uncinate process 647 58.4 1.00 1.00  81.1 1.00 1.00  10.1 1.00 1.00 
Body 40 67.5 1.48 (0.75, 2.92) 1.71 (0.81, 3.62)  87.5 1.63 (0.62, 4.24) 1.92 (0.68, 5.42)  8.8 1.20 (0.87, 1.67) 1.40 (1.00, 1.96) 
Tail 43 41.9 0.51 (0.27, 0.96) 0.63 (0.32, 1.24)  58.1 0.32 (0.17, 0.61) 0.36 (0.18, 0.72)  18.3 0.53 (0.36, 0.77) 0.60 (0.41, 0.88) 
Multiple/other 33 51.5 0.76 (0.38, 1.52) 0.77 (0.35, 1.68)  81.8 1.05 (0.42, 2.59) 1.13 (0.41, 3.10)  11.7 0.93 (0.63, 1.35) 1.10 (0.75, 1.62) 
Overall p-value   0.091 0.22   0.003 0.02   0.005 0.008 
Clinical Stage             
Confined to pancreas 225 45.8 1.00 1.00  68.0 1.00 1.00  13.4 1.00 1.00 
Locally advanced 561 62.6 1.98 (1.45, 2.71) 2.13 (1.48, 3.06)  84.3 2.53 (1.76, 3.63) 2.55 (1.68, 3.87)  9.3 1.59 (1.34, 1.89) 1.54 (1.29, 1.83) 
Overall p-value   <0.001 <0.001   < 0.001 <0.001   <0.001 < 0.001 
Health Service Factors             
Evidence of MDT review             
No/ Not stated 518 61.8 1.00 1.00e  81.9 1.00 1.00e  9.3 1.00 1.00e 
Yes 268 50.0 0.62 (0.46, 0.83) 0.80 (0.56, 1.14)  75.4 0.68 (0.48, 0.97) 0.77 (0.50, 1.18)  11.9 0.76 (0.65, 0.89) 0.88 (0.74, 1.04) 
Overall P value   0.002 0.22   0.033 0.22   0.001 0.14 
First facility volume (number of patients)          
30 + 411 52.1 1.00 1.00e  76.2 1.00 1.00e  11.4 1.00 1.00e 
10 - 29 232 60.3 1.40 (1.01, 1.94) 1.17 (0.79, 1.72)  81.0 1.34 (0.90, 1.99) 0.93 (0.58, 1.49)  9.3 1.20 (1.01, 1.43) 1.03 (0.86, 1.24) 
< 10 132 74.2 2.65 (1.72, 4.10) 1.84 (1.07, 3.16)  90.2 2.87 (1.55, 5.31) 2.04 (0.91, 4.58)  7.2 1.71 (1.39, 2.09) 1.21 (0.95, 1.53) 
Overall P value, P trend   0.043, <0.001 0.09, 0.04   0.003, 0.001 0.17, 0.23   <0.001, <0.001 0.29, 0.17 
First specialist seen             
Hepatobiliary surgeon 145 50.3 1.00 1.00e  73.1 1.00 1.00e  12.0 1.00 1.00e 
Gastroenterologist 235 54.5 1.18 (0.78, 1.79) 0.83 (0.51, 1.34)  78.7 1.36 (0.84, 2.20) 0.96 (0.55, 1.67)  11.2 1.23 (0.98, 1.55) 1.02 (0.80, 1.29) 
General Surgeon 292 61.0 1.54 (1.03, 2.30) 0.87 (0.54, 1.40)  82.2 1.70 (1.06, 2.73) 1.04 (0.59, 1.82)  9.0 1.40 (1.13, 1.75) 0.99 (0.78, 1.26) 
Other specialty 114 65.8 1.90 (1.14, 3.14) 0.90 (0.49, 1.65)  83.3 1.84 (1.00, 3.40) 0.91 (0.42, 1.94)  2.4 1.56 (1.20, 2.04) 0.92 (0.68, 1.23) 
Overall P value   0.037 0.89   0.11 0.98   0.004 0.87 
  
  
 
1-year mortalitya 
 
2-year mortalitya 
 
Overall survivalb 
Exposure variable 
Nc 
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI)  
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI)  
Median 
(months) 
Crude HR 
(95% CI) 
Adjusted HRd 
(95% CI) 
Seen by hepato-biliary surgeon            
 No / Not stated 395 65.6 1.00 1.00e  87.1 1.00 1.00e  8.0 1.00 1.00e 
 Yes 391 49.9 0.52 (0.39, 0.70) 0.91 (0.64, 1.29)  72.1 0.38 (0.27, 0.55) 0.58 (0.37, 0.90)  12.1 0.61 (0.52, 0.70) .81 (0.69, 0.96) 
Overall P value   < 0.001 0.58   < 0.001 0.015   < 0.001 0.013 
Received chemotherapy             
No / Not stated 387 74.4 1.00 1.00e  88.1 1.00 1.00e  5.5 1.00 1.00e 
Yes 399 41.6 0.24 (0.18, 0.33) 0.34 (0.23, 0.50)  71.4 0.34 (0.23, 0.49) 0.50 (0.31, 0.82)  14.1 0.57 (0.48, 0.66) 0.58 (0.48, 0.70) 
Overall P value   < 0.001 < 0.001   < 0.001 0.005   < 0.001 < 0.001 
Resection             
 No resection attempted 421 74.8 1.00 1.00e  92.4 1.00 1.00e  6.8 1.00 1.00e 
 Resection attempted 365 38.1 0.21 (0.15, 0.28) 0.39 (0.26, 0.57)  64.9 0.15 (0.10, 0.23) 0.30 (0.18, 0.52)  15.1 0.37 (0.32, 0.43) 0.56 (0.46, 0.68) 
Overall P value   < 0.001 < 0.001   < 0.001 < 0.001   < 0.001 < 0.001 
a Crude and adjusted odds ratios (ORs) estimated using logistic regression. P values are from Type 3 tests of  effects using Wald’s chi-square statistic. Overall P 
values are for test of association. 
b Median survival estimated using Kaplan-Meier methods. Crude and adjusted hazards ratios (HRs) estimated using Cox proportional hazards (PH) and stratified 
Cox models, respectively. P values are from Type 3 tests of effects using Wald’s chi-square statistic. Overall P values are for test of association. 
c  Missing data: Socio-economic status, n= 5;  Performance status,  n = 106; comorbidities, n = 4; First facility volume , n = 11. 
d Adjusted for patient (age, performance status (ECOG), place of residence(ARIA), Charlson comorbidity index) and tumour (clinical stage, site of tumour) factors. 
SES not adjusted for place of residence.  
e  Adjusted for patient and tumour factors and receipt of chemotherapy 
Place of residence groups defined by Accessibility/Remoteness Index of Australia; ECOG, Eastern Cooperative Oncology Group; SES Socio-Economic Status 
defined by Socio-Economic Indexes for Areas; First facility volume by number of study participant initial presentations. 
MDT: multidisciplinary team 
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Age, (years) 
< 60 ;                60 - 69 ;                 70 - 79;                  80+ 
 
Place of residence 
Major city ;             Inner regional;                Outer regionala 
 
P value calculated using log-rank tests to test the equality of survivor functions across 
age and place of residence groups. 
a Outer regional includes remote and very remote regions 
 
Figure 6-1: Kaplan-Meier survival curves by age at diagnosis and place of residence using the 
Accessibility/Remoteness Index of Australia (ARIA) for people diagnosed with 
non-metastatic pancreatic cancer (n = 786) 
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Compared with patients from major cities, risk of dying within two years was greater for patients 
from inner regional areas (AOR 1.54; 95% confidence interval [CI]: 0.92 - 2.59) and outer regional/ 
remote areas (AOR 3.10; 95% CI: 1.34 – 7.20). Increasing remoteness was associated with poorer 
survival (p trend = 0.01). Compared with those from major cities, those from outer regional/remote 
areas were 33% more likely to die (AHR 1.33, 95% CI: 1.03 – 1.72). This difference in survival 
remained after adjusting for attempted surgery (p trend = 0.01, AHR 1.31, 95% CI: 1.01 – 1.70). 
There were no associations between socio-economic status and mortality or survival in 
multivariable analyses. After adjusting for patient and tumour factors women had worse overall 
survival than men (AHR 1.22; 95% CI: 1.04 - 1.42), but when also adjusted for attempted surgery 
the difference was reduced and no longer statistically significant (AHR 1.15; 95% CI 0.99 – 1.35, p 
= 0.07). 
Each health-service factor was associated with survival and mortality. Patients reviewed by an 
MDT had lower odds of dying up to one or two years after diagnosis and higher overall survival, 
but after adjustment for patient and tumour characteristics, the estimates were no longer statistically 
significant (Table 6-1). Being seen by a hepatobiliary surgeon was associated with improved 
overall survival (AHR 0.80; 95% CI: 0.69 – 0.96).  Compared with patients who were first admitted 
to a facility that managed at least 30 pancreatic cancer patients annually, those first admitted to a 
hospital that treated fewer than 10 had higher one-year mortality (AOR 1.84; 95% CI: 1.07 – 3.16). 
Estimated survival and mortality rates were more favourable for patients who had an attempted 
resection (AHR 0.56; 95% CI: 0.46 - 0.68). Patients who received chemotherapy were less likely to 
die up to a year after diagnosis compared to those who had no record of chemotherapy treatment 
(AOR 0.34; 95% CI 0.23 – 0.50).  
Determinants of attempted resection in all patients with non-metastatic disease 
Older age, poorer performance status, and/or higher comorbidity scores were each significantly 
inversely associated with the likelihood of having resection attempted (Table 6-1 and 
supplementary Table 9-3). Patients from more remote areas had lower odds of attempted surgery 
compared with those living in major cities (AOR 0.61; 95% CI: 0.33 –1.10), although this was not 
statistically significant. Having tumour only in the tail of the pancreas was associated with a greater 
likelihood of attempted resection compared to having tumour in the head, neck or uncinate process 
(AOR 3.62; 95% CI: 1.58 – 0.33). Presentation at a MDT meeting and low volume of the facility 
where the patient was first admitted were associated with lower odds of having an attempted 
resection (AORs 0.60; 95% CI: 0.42 - 0.86, and 0.57; 95% CI: 0.34 - 0.97) respectively). If the 
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patient was seen by a hepatobiliary surgeon or had a staging laparoscopy they were more likely to 
have surgery (AORs 3.77; 95% CI: 2.63 – 5.39 and 4.84; 95% CI: 2.92 – 8.02 respectively). 
Determinants of classification of cancer as resectable in patients with locally advanced disease  
Factors associated with having a tumour classified as potentially resectable amongst patients with 
locally advanced disease were younger age (< 60 versus ≥ 70 years: 63% versus 44%, p < 0.01), 
better ECOG performance status (fully active versus not fully active: 59% versus 48%, p = 0.02) 
and living in a major city (remote vs major city/ outer regional: 53% versus 36%, p = 0.02) (Table 
6-2). After adjustment for patient factors, the association with place of residence remained 
statistically significant (AOR 0.48; 95% CI: 0.26 –0.89) but further adjustment for health-service 
factors attenuated the association and it was no longer statistically significant (AOR 0.78; 95% CI: 
0.38 – 1.59). Age remained associated with classification of resectability even after controlling for 
patient, tumour and health-service factors. 
Patients presented at a MDT meeting were less likely to be assessed as having a potentially 
resectable tumour than those with no evidence of being reviewed by a MDT (AOR 0.33; 95% CI: 
0.14 - 0.78). If patients were seen by a hepatobiliary surgeon they had almost twice the odds of 
being classified as having resectable disease (AOR 1.95; 95% CI 1.35- 2.82). Patients who 
underwent an EUS compared with those who did not were less likely to be classified as having 
potentially resectable disease (AOR 0.60; 95% CI: 0.41 – 0.86), whereas the opposite was observed 
if they had a laparoscopy (AOR 4.70; 95% CI: 2.77 – 7.98). 
Determinants of attempted surgery in patients classified as having potentially resectable 
disease 
Amongst those patients classified as potentially resectable we found that 28% (n = 145) did not 
proceed to surgery. The recorded reasons were predominantly comorbidities and/or age (88%, n = 
127) with only 12% (n = 18) recorded as other or not stated. There were statistically significant 
associations between age, performance status and co-morbidities and whether surgery was 
attempted (Table 6-2). Patients from more remote areas had lower odds of attempted surgery 
compared with those living in major cities (AOR 0.61; 95% CI: 0.33 –1.10), although this was not 
statistically significant. Having tumour only in the tail of the pancreas was associated with a greater 
likelihood of attempted resection compared to having tumour in the head, neck or uncinate process 
(AOR 3.62; 95% CI: 1.58 – 0.33). Presentation at a MDT meeting and low volume of the facility 
where the patient was first admitted were associated with lower odds of having an attempted 
resection (AORs 0.60; 95% CI: 0.42 - 0.86, and 0.57; 95% CI: 0.34 - 0.97) respectively). If the 
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patient was seen by a hepatobiliary surgeon or had a staging laparoscopy they were more likely to 
have surgery (AORs 3.77; 95% CI: 2.63 – 5.39 and 4.84; 95% CI: 2.92 – 8.02 respectively).  
 
  
 
Table 6-2: Associations between adjusted patient, tumour and health-service factors and (1) attempted resection (n = 786 ) ; (2) classification of 
disease resectability (n = 561); and (3) attempted resection for patients classified as resectable (n=510) 
  (1) All Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectable 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total N (%) Adjusted ORb  (95% CI) 
 
  Total     N (%) Adjusted ORb  (95% CI)  Total   N (%) Adjusted ORb (95% CI) 
PATIENT / TUMOUR FACTORS            
Age at diagnosis, years            
< 60 141 103 (73) 1c  98 62 (63) 1c  105  103 (98) 1c 
60 - 69 218 135 (62) 0.59 (0.37, 0.94)  163 91 (56) 0.71 (0.42, 1.20)  146  135 (92) 0.22 (0.05, 1.04) 
70 - 79 223 107 (48) 0.33 (0.21, 0.53)  161 76 (47) 0.51 (0.30, 0.85)  138  107 (78) 0.06 (0.01, 0.27) 
≥ 80 204 20 (10) 0.04 (0.02, 0.07)  139 56 (40) 0.38 (0.22. 0.66)  121    20 (17) 0.00 (0.00, 0.02) 
  Overall p value, p trend   < 0.001, < 0.001    0.002, < 0.001    < 0.001, < 0.001 
Sex            
Men 422 222 (53) 1d  299 164 (55) 1d  287  222 (77) 1d 
Women 364 143 (39) 0.77 (0.55, 1.08)  262 121 (46) 0.74 (0.52, 1.05)  223  143 (64) 0.89 (0.48, 1.65) 
   Overall p value   0.13    0.09    0.71 
Performance status            
Fully active  260  183 (70) 1e  160 95 (59) 1e  195  183 (94) 1e 
Not fully active  420 134 (32) 0.24 (0.17, 0.35)  325 156 (48) 0.71 (0.47, 1.05)  251  134 (53) 0.06 (0.02, 0.14) 
  Overall p value   < 0.001    0.09    < 0.001 
Charlson comorbidity index (score)           
Low (0) 340 184 (54) 1e  252 126 (50) 1e  214  184 (86) 1e 
Medium (1) 243 105 (43) 0.78 (0.54, 1.14)  177 91 (51) 1.15 (0.78, 1.71)  157  105 (67) 0.40 (0.20, 0.80) 
High (≥ 2) 199 74 (37) 0.59 (0.39, 0.88)  130 66 (51) 1.10 (0.72, 1.70)  135    74 (55) 0.15 (0.07, 0.31) 
  Overall p value, p trend   0.03, 0.01    0.76, 0.59    < 0.001, < 0.001 
Place of residence            
Major city 542 258 (48) 1d  386 206 (53) 1d  362  258 (71) 1d 
Inner Regional 163 74 (45) 0.84 (0.55, 1.28)  119 50 (50) 0.90 (0.59, 1.38)  104    74 (71) 0.68 (0.32, 1.46) 
Outer regional / remote  76 31 (41) 0.61 (0.33, 1.10)  53 19 (36) 0.48 (0.26, 0.89)    42    31 (74) 0.44 (0.13, 1.50) 
  Overall p value, p trend   0.22, 0.09    0.07, 0.04    0.31, 0.13 
Socio-economic status - quintiles 
 
    
 
       
Most disadvantaged 156 73 (47) 1d  110 55 (50) 1d  101  73 (72) 1d 
Second 171 80 (48) 0.77 (0.46, 1.31)  123 65 (53) 1.01 (0.60, 1.72)  113  80 (71) 0.51 (0.19, 1.32) 
Third 158 68 (43) 0.78 (0.46, 1.34)  113 50 (44) 0.72 (0.42, 1.24)    95  68 (72) 0.95 (0.34, 2.65) 
Fourth 160 77 (48) 0.85 (0.50, 1.45)  107 56 (52) 0.95 (0.55, 1.65)  109  77 (71) 0.56 (0.21, 1.50) 
Least disadvantaged 136 65 (48) 0.93 (0.53, 1.64)  105 59 (56) 1.19 (0.68, 2.07)    90  65 (72) 1.56 (0.55, 4.46) 
  Overall p value, p trend   0.86, 1.00    0.50, 0.69    0.18, 0.43 
  
 
  (1) All Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectable 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total N (%) Adjusted ORb  (95% CI) 
 
  Total     N (%) Adjusted ORb  (95% CI)  Total   N (%) Adjusted ORb (95% CI) 
Tumour site            
Head/neck/uncinate process 647 298 (46) 1d  463 240 (52) 1d  424  298 (70) 1d 
Body 40 14 (35) 0.46 (0.21, 0.99)  29 8 (28) 0.33 (0.14, 0.77)    19    14 (74) 0.98 (0.19, 4.99) 
Tail 43 33 (77) 3.62 (1.58, 8.33)  27 21 (78) 3.09 (1.20, 7.94)    37    32 (89) 3.39 (0.85, 13.57) 
Multiple/other 33 13 (39) 0.55 (0.24, 1.24)  25 8 (32) 0.45 (0.18, 1.10)    16    13 (81) 1.25 (0.19, 8.13) 
  Overall p value   0.001    0.001    0.39 
HEALTH SERVICE FACTORS            
Evidence of MDT review            
No / not stated 518 239 (46) 1f  355 193 (54) 1f  356  239 (67) 1f 
Yes 268 126 (47) 0.60 (0.42, 0.86)  206   92 (45) 0.33 (0.14, 0.78)  154  126 (82) 1.09 (0.54, 2.21) 
   Overall p value   0.01    0.01    0.81 
First facility volumeg            
 30 + 411 226 (55) 1f  275 153 (56) 1f  289  226 (78) 1f 
10 – 29 232 97 (42) 0.70 (0.47, 1.05)  170   84 (49) 0.92 (0.61, 1.38)  146    97 (66) 0.52 (0.20, 1.537) 
< 10 132 42 (32) 0.57 (0.34, 0.97)  107   48 (45) 0.88 (0.53, 1.45)    73    42 (58) 0.51 (0.15, 1.67) 
Overall p value, p trend   0.06, 0.02    0.85, 0.58    0.34, 0.19 
Specialist first seen            
Hepatobiliary surgeon 235 87 (60) 1f  87 44 (51) 1f  102    87 (85) 1f 
Gastroenterologist 235 123 (52) 0.99 (0.61, 1.61)  173 97 (56) 1.42 (0.83, 2.43)  159  123 (66) 0.75 (0.29, 1.94) 
General Surgeon 292 118 (40) 0.70 (0.43, 1.13)  222 108 (49) 1.11 (0.66, 1.89)  178  118 (66) 0.64 (0.25, 1.63) 
Other 114 37 (32) 0.67 (0.36, 1.25)  79 36 (46) 1.08 (0.56, 2.08)    71    37 (52) 0.58 (0.19, 1.79) 
  Overall p value   0.24    0.52    0.77 
Seen by hepato-biliary surgeon           
No / not stated 395 106 (27) 1f  308 129 (42) 1f  216 106 (49) 1f 
Yes 391 259 (66) 3.77 (2.63, 5.39)  253 156 (62) 1.95 (1.35, 2.82)  294 259 (88) 6.78 (3.38, 13.59) 
Overall p value   < 0.001    < 0.001    < 0.001 
Pancreas protocol computerised tomography          
No / not stated 406 173 (43) 1f  294 150 (51) 1f  262 173 (66) 1f 
Yes 380 192 (51) 0.96 (0.68, 1.35)  267 135 (51) 0.97 (0.61, 1.23)  248 192 (77) 1.33 (0.71, 2.50) 
Overall p value   0.82    0.42    0.37 
Plain computerised tomography           
No / not stated 261 133 (51) 1f  189 104 (55) 1f  176 133 (76) 1f 
Yes 525 232 (44) 0.76 (0.54, 1.12)  372 181 (49) 0.79 (0.55, 1.15)  334 232 (69) 0.40 (0.19, 0.83) 
Overall p value   0.17    0.22    0.01 
  
 
  (1) All Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectable 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total N (%) Adjusted ORb  (95% CI) 
 
  Total     N (%) Adjusted ORb  (95% CI)  Total   N (%) Adjusted ORb (95% CI) 
Endoscopic ultrasound          
No / not stated 434 186 (43) 1f  311 168 (54) 1f  291 186 (64) 1f 
Yes 352 179 (51) 0.85 (0.60, 1.20)  250 117 (47) 0.60 (0.41, 0.86)  219 179 (82) 1.12 (0.59, 2.10) 
Overall p value   0.35    0.006    0.74 
Laparoscopy            
No / not stated 648 252 (39) 1f  455 201 (44) 1f  394 252 (64) 1f 
Yes 138 113 (82) 4.84 (2.92, 8.02)  106 84 (79) 4.70 (2.77, 7.98)  116 113 (97) 12.15 (3.40, 43.40) 
Overall p value   < 0.001    < 0.001    < 0.001 
Endoscopic retrograde cholangiopancreatography          
No / not stated 399 190 (48) 1f  276 134 (49) 1f  257 190 (74) 1f 
Yes 387 175 (45) 1.04 (0.74, 1.47)  285 151 (53) 1.26 (0.89, 1.79)  253 175 (69) 0.86 (0.46, 1.63) 
Overall p value   0.81    0.20    0.65 
Magnetic resonance imaging /cholangiopancreatography          
No / not stated 642 285 (44) 1f  462 236 (51) 1f  416 285 (69) 1f 
Yes 144 80 (56) 1.10 (0.72, 1.68)  99 49 (49) 0.81 (0.51, 1.27)  94     80 (85) 1.42 (0.60, 3.35) 
Overall p value   0.67    0.36    0.43 
a Based on clinical staging including imaging or exploratory laparoscopy. b Crude and adjusted odds ratios (ORs,) calculated using logistic regression. 
Adjustment variables: c Place of residence (major city, inner regional, outer regional/remote/very remote); d Age at diagnosis (<60, 60-69, 70-79, 80+ years) and performance status (0, 
1, 2+, not stated); e Age at diagnosis; f Age at diagnosis, performance status and place of residence. 
g Results from a mixed effects model with hospital as random intercept to adjust for hospital clustering. 
Place of residence groups defined by Accessibility/Remoteness Index of Australia (ARIA); Performance status defined by Eastern Cooperative Oncology Group (ECOG); SES Socio-
Economic Status defined by Socio-Economic Indexes for Areas; First facility volume by the number of study participant initial presentations.  
Missing data: SES, n = 5; Place of residence, n = 5; Tumour site, n = 23; ECOG, n = 106; Charlson comorbidity index, n = 4; First inpatient facility volume, n = 11. 
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There was no difference in the proportion of patients who proceeded to attempted resection 
according to location of residence. After adjustment for age and performance status people living in 
more remote regions had non-significant lower odds compared to patients living in major cities. 
Most health system factors and investigations were significantly associated with attempted 
resection, but after adjusting for patient factors, only being seen by a hepatobiliary surgeon (AOR 
6.78; 95% CI: 3.38 – 13.59) and having a laparoscopy (AOR 12.15; 95% CI: 3.40 – 43.40) were 
positively associated with attempted resection.  
Associations between age, location of residence and health system factors 
Age and place of residence were not significantly associated with each other, but both were 
associated with being assessed by a hepatobiliary surgeon, the specialist first seen and the facility 
volume where the patient was first an inpatient (Appendix E – Table 9-4 ). Patients living in more 
remote regions were less likely to undergo EUS and ERCP than those living in major cities, and 
older patients were less likely to undergo pancreas-protocol CT and MRI or MRCP, EUS or have 
laparoscopies as part of their clinical staging investigations.  The likelihood of laparoscopy (8% 
versus 22%, p = 0.001) and EUS (33% versus 53%, p<0.001) was also lower for patients initially 
admitted to a low rather than high volume facility.  
Discussion 
In this population-based cohort of patients with non-metastatic pancreatic cancer we found, as 
expected, that those with more advanced disease and those who were older, who had poorer 
performance status or more co-morbidities were more likely to die within one or two years and had 
poorer overall survival. Lower survival was observed for people who lived in regional or remote 
areas compared with those living in capital cities, even after adjusting for differences in patient and 
tumour factors.  
The percentage of patients with non-metastatic disease alive at one year (42%) in our cohort was 
considerably higher than the ~30% reported in some previous population-based studies12, 33, 107 but 
similar to estimates from studies using more recent registry data.60, 294 Our findings that clinical 
disease stage, performance status, presence of co-morbidities and age influence survival are 
consistent with international and national reports.285, 286, 289, 295  
The proportion of our cohort classified as having potentially resectable disease was higher than that 
in previous international studies (65% versus 37% - 45%)10, 294 with some studies suggesting that 
age, sex, medical insurance and site of the tumour are associated with resectability.10, 195 Almost 
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three-quarters of those identified as resectable proceeded to an attempted resection which is 
considerably higher than the ~20-60% in earlier reports.10, 12, 106, 294 The higher likelihood of being 
classified as having resectable disease and  higher rates of attempted resection in this study may be 
due to temporal changes in the definition of resectability as surgical techniques have improved.296   
The association between place of residence and survival has been observed in other settings285 with 
travelling distance to receive treatment297 and the lack of high-volume specialist centres in more 
rural areas142 being suggested as reasons for this. Our results suggest that the poorer survival of 
patients living in regional and remote areas may be at least partially due to them being less likely to 
be classified as having resectable disease. Although they are equally likely to undergo surgery once 
classified as resectable, this results in a lower overall proportion undergoing surgery. While patients 
living in lower socio-economic areas or more distant from health services may choose not to 
undergo treatment, it is important that adequate staging to determine resectability is undertaken in 
order that they can make an informed decision about their treatment pathways. 
 We found that only half of the patients were reviewed by a hepatobiliary surgeon at any time 
during their disease course, and the proportion was significantly higher in metropolitan areas than 
in regional and remote areas and in younger than in older patients. Similarly, older patients and 
those living in remote areas were less likely to be first admitted to a high volume hospital. These 
results are inconsistent with guidelines6, 94, 291 and the views of clinical experts298 which recommend 
that all patients diagnosed with non-metastatic disease should be reviewed by an experienced 
hepatobiliary surgeon, ideally supported by a multidisciplinary team. A recent study reported that 
patients with non-metastatic pancreatic cancer had a greater likelihood of having surgical treatment 
when clinical staging was established in a specialised pancreatic cancer centre.122 EUS is used to 
assess the tumour, vascular invasion, tissue diagnosis, lymph node disease, small volume liver 
disease and peritoneal ascites, all of which help to ascertain the resectability of the tumour. This 
may explain why patients who had this investigation were less likely to be classified as resectable. 
Laparoscopy, which is used selectively in most specialised units, tends to be used in patients 
thought to be resectable to detect potential small-volume peritoneal disease, so patients were more 
likely to proceed to surgery following this investigation. We also demonstrated that being seen by a 
hepatobiliary surgeon was associated with a greater likelihood of being diagnosed with resectable 
disease. While this may be due to reverse causality, being seen by a hepatobiliary surgeon appears 
to mediate the association between location of residence and classification of tumour resectability, 
suggesting that improving access to specialist care may increase the proportion of patients living in 
non-metropolitan areas who undergo surgery.   
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Review by a MDT is the standard of care for patients without metastatic disease6 and has been 
shown to improve survival.170, 299 We found that review by an MDT was associated with a lower 
likelihood of being classified as having resectable disease, most likely because clinicians tended to 
present patients with borderline resectable disease to the MDT. Despite this, after adjustment for 
patient factors, MDT review was associated with improved overall survival, both for patients who 
did and did not undergo surgery (Appendix E: Table 9-5), suggesting that MDT management is an 
indicator of improved overall care.  A follow-up study focussed specifically on multidisciplinary 
care is needed to determine which patients are presented to MDTs and to understand the 
consequences of not being presented to a specialist MDT in a high-volume hospital. 
Given the challenges of pancreatic cancer surgery and its subsequent survival even after potentially 
curative resection, it is appropriate that consideration of quality of life and other patient factors 
influence the decision to proceed to recommending resection. In keeping with this, we found that 
age, poor performance status or the presence of co-morbidities were given as the reason for surgery 
not to proceed in patients with potentially resectable disease. Our results may, however, indicate 
that in some cases older patients may be considered to have non-resectable disease by default and 
without adequate staging or review by an expert team. In the absence of poor performance status or 
significant comorbidities age is not necessarily a contraindication to surgery220 and may indicate a 
nihilistic attitude amongst some clinicians.300 This emphasises the importance of a full staging work 
up so that patients can make informed decisions about their treatment, irrespective of their age. 
Major strengths of our study include the large population-based sample and the comprehensive data 
collected. However, our classification of clinical disease stage as confined to the pancreas, locally 
advanced or metastatic disease, did not allow for the separate classification of borderline resectable 
disease. Pancreatic cancers are categorised on a continuum from resectable to unresectable 
according to involvement of adjacent structures and the presence of distant metastases296, 301 but this 
categorization was performed by numerous surgeons in this study and may not be consistent. 
International more robust criteria for defining resectable disease were introduced after the study 
period.6, 105 It is also possible that at least some of the associations with hospital volume, 
laparaoscopy and hepatobiliary surgeon review arose due to reverse-causality.  
In conclusion this study found disparities in survival dependent on where patients live and where 
and by whom they are managed. Initial accurate clinical staging is a critical element in the 
provision of optimal management, with access to hepatobiliary surgeons, high volume specialist 
facilities and multidisciplinary teams shown to be important. Many patients do not meet the 
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guidelines that recommend an early review by a hepatobiliary surgeon and by a MDT, with access 
to these services partly dependent on where patients live. Designing health services and referral 
patterns that ensure all patients receive appropriate staging and expert assessment, regardless of 
where and how they enter the health system, has the potential to lead to improvements in survival. 
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7.1. INTRODUCTION 
This chapter includes a paper published in the Medical Journal of Australia. The aims of this 
publication were to: 
1. Investigate factors associated with the quality-of-care score for patients with pancreatic
cancer and
2. Examine the association between the quality-of-care score and overall survival
7.2. CONTRIBUTION OF CANDIDATE 
My contribution to this publication included conceptualising the research question (70%) with 
significant input from REN and support from DO and the study team. I completed all data 
collection to develop the score and 20% of the patterns-of-care study data. I also completed the 
majority of the data cleaning (90%) and statistical analyses (70%) with the help of REN and DO. I 
was responsible for the interpretation of the results (40%) in consultation with the study team and 
in particular REN.  I wrote (55%), edited (34%) and submitted the manuscript (90%) with REN 
providing significant writing and editing assistance and with valuable contributions from the study 
team. 
7.3. MANUSCRIPT 
The following manuscript has been published by the Medical Journal of Australia: 
MJA 2016; 10 (25): 459-465. 
Factors associated with quality of care in patients with pancreatic cancer. 
Burmeister EA, O’Connell DL, Jordan SJ, Goldstein D, Merrett ND, Wyld D, Beesley VL, 
Gooden HG, Janda M, Neale RE.  
Authors have provided permission to include this publication in this thesis (Appendix I). 
Abstract 
Introduction 
Caring for patients with pancreatic cancer is challenging and there is evidence that the quality of 
care differs according to sociodemographic factors. Our aim was to develop a composite quality-of-
care score, to examine variation in care by patient and health-service factors and to assess whether 
the score is associated with survival of Australian patients with pancreatic cancer.  
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Methods 
Patients diagnosed with pancreatic cancer between July 2009 and July 2011 in Queensland and 
New South Wales were allocated a quality-of-care score based on a list of care items derived using 
a Delphi process. The score ranged from 0 to 1, with a higher score indicating better quality care. 
Associations between patient and health-service factors and the score were tested using linear 
regression. We examined associations with survival using Kaplan-Meier and Cox proportional 
hazards methods. 
Results 
Scores were assigned to 1571 patients. Significantly higher scores were observed for patients living 
in major cities versus more rural areas (adjusted difference: 0.11), in least versus most 
disadvantaged areas (adjusted difference: 0.08), who were younger, had better performance status 
and who first presented to a highvolume centre. Higher scores were associated with improved 
survival; after adjusting for patient factors each 10% absolute increase in the score reduced the risk 
of dying by 6% (hazard ratio 0.94; 95% CI 0.91-0.97).  
Conclusion 
This study provides evidence that place of residence influences the quality of care received and that 
survival outcomes may improve for patients with pancreatic cancer if they receive optimal 
management. 
 The known: Treating patients with pancreatic cancer is challenging and sociodemographic 
factors can influence receipt of treatment modalities such as surgery and chemotherapy. 
 The new: We developed a composite quality-of-care score and found that it was lower for 
patients who lived in rural or socially disadvantaged areas. It was higher for patients who first 
presented to a high volume hospital. The score was significantly associated with survival. 
 The implications: Strategies need to be developed to ensure that all patients with pancreatic 
cancer have the opportunity to receive optimal care delivered by or in conjunction with high 
volume expert centres. 
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Introduction  
In Australia, pancreatic cancer is the 10th most common cancer and the 4th leading cause of 
cancer-related death.35 One-year overall survival is 20%; five-year survival is 6%.36 Pancreatic 
cancer presents distinct management challenges, requiring highly specialised care. 
A systematic review has shown that optimal care increases the likelihood of desired health 
outcomes in pancreatic cancer.251 Studies from Australia and internationally have shown that fewer 
patients receive recommended treatment than expected,12, 293 receipt of recommended care is 
inconsistent,10, 119 and that sociodemographic factors influence management.10, 220 Treatment in 
non-specialised centres appears to be at least partly responsible for these associations.93, 302 
Previous studies have tended to focus on individual management modalities, such as surgery or 
chemotherapy. We took a more holistic approach and calculated an overall quality-of-care score for 
Australian patients diagnosed with pancreatic cancer. We examined variation in the score by patient 
and health-service factors and analysed the association between the quality of care delivered and 
survival.  
Methods 
This analysis was nested within a population-based study of patterns of care in Australian patients 
with pancreatic cancer. Eligible patients were residents of Queensland and New South Wales 
diagnosed with pancreatic cancer between July 2009 and June 2011. Trained research nurses 
collected information about patient management from medical records in public and private 
facilities.293 We excluded patients who died within a month of diagnosis or had clinical staging data 
unavailable from this care score analysis. 
We calculated a quality-of-care score based on results of our previously reported Delphi process.298 
Briefly, clinicians from a range of specialties involved in pancreatic cancer care were asked “What 
is important in the care of patients with pancreatic cancer”. Thematic analysis of the responses 
resulted in a list of statements. The clinicians were asked to score each statement ranging from 0 
(disagree, not important) to 10 (strongly agree, very important). The mean and coefficient of 
variation (CV) were determined for each statement.  
Calculating the quality-of-care score 
We used the mean scores from the Delphi process to calculate a quality-of-care score, selecting 
statements where there was reasonable consensus from the Delphi participants (CV ≤ 0.4) and 
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where information to assess whether or not the item of care had been delivered was available in our 
database. Eighteen items were included (Table 7-1). 
For each patient we calculated a potential score by identifying the items which applied to their 
clinical situation and summing the mean scores obtained from the Delphi survey for these items. 
For example, items relating to surgical volume were only included for patients who underwent 
attempted resection. We then ascertained the items where there was evidence that the specified care 
had been delivered and summed their mean Delphi scores to create a care-delivered score. The 
proportional care score was calculated by dividing the care-delivered score by the potential score. 
Details of the clinical information used to determine eligibility and whether or not the care 
specified in each item was delivered are shown in Table 7-1. 
  
 
Table 7-1 : Statements about care for pancreatic cancer deemed to be most important in a Delphi process, patient eligibility criteria and 
definition of care received 
Care Statement Weighta Eligibleb N eligible (% metc)          Care received 
All patients with potentially resectable disease should be referred 
to an hepatobiliary surgeond 
9.3 Non-metastatic 781 (51) Anye referral or consultation with HPB 
All patients with technically resectable disease should be offered a 
resection or valid reason why not 
9.2 
Potentially 
resectable 
519 (98) Surgery attempted or valid reason for no surgery 
Surgery should be performed by surgeons who perform more than 
5 pancreatic surgeries per year 
9.0 
Resection 
attempted 
366 (43) Surgeon performed more than 5 surgeries per annum 
Tumour resectability should be assessed by a MDT at a tertiary 
hospital 
9.0 Non-metastatic 781 (29) 
If MDT prior to attempted surgery or within 40 days of 
diagnosis if no surgery. 
All patients should have a triple phase/ pancreas protocol CT scan 
for staging 
8.9 All patients 1571 (43) Evidence of pancreas protocol CT 
Entry into a clinical trial should be considered for all patients 8.8 All patients 1571 (7) 
Clinical trial discussed, considered, offered or participated 
in a trial 
Surgery should take place in tertiary institutions where > 15 
resectionsf are performed annually 
8.6 
Resection 
attempted 
366 (42) 
If attempted resection was performed at a hospital where 
> 11 resections were performed each yearf 
Each patient should have a care-coordinator assigned with an 
individualised treatment/ clinical plan 
8.5 All patients 1571 (22) Evidence of a navigator, care-plan or nursing referral 
Tissue diagnosis should be obtained where possible  8.3 All patients 1571 (80) Histology or cytology analysis completed 
All patients should be presented to a MDT 8.3 All patients 1571 (31) Evidence of presentation to a MDT  
Biliary obstruction should routinely be managed endoscopically in 
non-resectable patients 
8.2 
Non-resectable with 
biliary obstruction 
416 (83) Evidence of endoscopic biliary stent not bypass surgery 
All patients should be offered adjuvant therapy post operatively, 
assuming performance status is adequate 
8.1 
Resection 
attempted 
366 (67) Evidence of any adjuvant chemo- or radiation therapy 
All patients should be offered psychosocial support 8.0 All patients 1571 (19) Evidence of referral or consult by psychological services 
Pancreatic enzyme replacement therapy should be considered for 
all patients 
7.9 All patients 1571 (22) Evidence of pancreatic enzyme replacement 
All patients should see a medical oncologist 7.9 All patients 1571 (86) Seen by a medical oncologist or valid reason why not seen 
A specialist HPB surgeon should be the initial/primary specialist 
unless the patient has obvious metastases 
7.3 Non-metastatic 781 (19) HPB was the first specialist seen  
  
 
Care Statement Weighta Eligibleb N eligible (% metc)          Care received 
All patients should be referred to a dietitian soon after diagnosis 7.3 All patients 1571 (64) Evidence of referral or consult by dietician 
Patients with confirmed metastatic disease should be referred to 
palliative care  
6.0 Metastases 790 (82) Anye evidence of palliative care consult or referral. 
a  Weight: final mean average score of importance following Delphi process    
b  Eligible: patients eligible for care as per classification on clinical staging   
c  % met: percentage of patients eligible who received the item of care. 
d Hepatobiliary surgeon (HPB) defined as a surgeon who had undergone recognised specialised hepatobiliary surgery training and/or was recognised by their   peers as 
an experienced hepatobiliary surgeon  
e Any: includes all inpatient records and consultations   
 f Only 3 hospitals from the patterns-of-care study actually supported this number of 15 resections per annum, therefore using previous Australian data and the 
literature this high-volume classification was amended to hospitals where 11 or more resections were performed each year. 
 CT: computerized tomography;    MDT: multidisciplinary team meeting 
 
 
  
 
Measurement of potential determinants of care 
Patient characteristics included: age at diagnosis, sex, Eastern Cooperative Oncology Group 
(ECOG) performance status, and Charlson comorbidity index.244  Based on area of residence at the 
time of diagnosis, each person was allocated a socio-economic index for areas (SEIFA)245 score and 
Accessibility/Remoteness Index of Australia (ARIA)246 category. We grouped the SEIFA score into 
quintiles and collapsed the ARIA into three groups: major city; inner regional; and outer 
regional/remote/very remote (hereafter referred to as rural). 
Tumour factors included the stage of the tumour following staging investigations. The tumour was 
staged as potentially resectable or not and also as confined to the pancreas, locally advanced or 
metastatic.  
Health-service factors included the type of specialist first seen and the volume of the facility where 
the patient was first treated as an inpatient (according to the number of patient presentations in the 
patterns-of-care study). 
Statistical analysis  
The proportion of eligible patients who received each item of care was reported and compared 
across socioeconomic status categories and place of residence; p-values were calculated using Chi-
squared tests to determine the statistical significance of any differences.   
We used linear regression analyses, with the proportional score as the outcome, to examine 
variation in the score by patient, tumour and health-service factors. Mean proportional scores for 
levels of each exposure variable were calculated and beta (β) coefficients reported with 95% 
confidence intervals (CI). The coefficients can be interpreted as the difference in mean score 
between patients in a category and those in the reference category. Multivariable models included 
age, ECOG performance status and comorbidity score.  
Survival time was taken from the date of diagnosis until death or date of final follow-up (February 
2014). Patients were divided into quartiles based on their proportional care score, Kaplan-Meier 
graphs generated and log-rank tests used to examine the difference in survival according to score 
category. We also performed the analysis with the score as a continuous variable, reporting 
associations per 10% absolute increase in score, using Cox proportional hazard models to adjust for 
patient factors and clinical stage. The association between the score and survival was investigated 
further by calculating adjusted hazard ratios for each care score item separately. Analyses were 
performed within the total patient group and separately among patients who did and did not have 
  
 
metastases identified on clinical staging. We used Stata 14 (Statacorp, Texas) for analyses. All p-
values were two-sided and p < 0.05 used as an indication of statistical significance. 
Results 
In total, 1896 patients were eligible for inclusion in the patterns-of-care study. We were unable to 
locate medical records for 33, 259 died within one month of diagnosis and 33 were missing staging 
information, leaving 1571 (83%) for this analysis. On clinical staging, 781 patients (49.7%) had 
non-metastatic and 790 (50.3%) metastatic disease. Most lived in major cities (n = 1076; 68%) 
compared to inner regional (n = 338; 22%) and rural areas (n = 157; 10%) and 55% of patients 
were men (n = 867).  Almost three-quarters (n = 1151; 73%) of patients died within one year of 
diagnosis. The median survival time was 6 months (11 months for those without metastases; 4 
months for those with metastases).  
Younger patients and those with better performance status had higher care scores than older and 
less mobile patients (Table 7-2). 
Place of residence, area-level socioeconomic status, age, performance status, facility volume and 
specialist first seen were all associated with the score (Table 7-3). After adjustment the estimated 
care scores were lower by 11% for patients living in rural areas than for patients living in major 
cities (β coefficient: -0.11; 95% CI -0.13 to -0.08). Similarly, those living in more disadvantaged 
areas had estimated care scores lower by 8% than those patients living in the least disadvantaged 
areas (β -0.08; 95% CI -0.11 to -0.06). Patients presenting to a low volume hospital (<10 
presentations annually) had lower care score estimates than those presenting to hospitals with more 
than 30 presentations (β -0.13; 95% CI -0.15 to -0.11).  Care scores were higher for patients whose 
first specialist was a hepatobiliary surgeon, with patients seeing a general surgeon predicted to have 
scores lower by 10% (β -0.10; 95% CI -0.13 to -0.08). To further investigate the association 
between place of residence and care score, models were also adjusted for the volume of the first 
hospital attended and the first specialist seen. This reduced the adjusted mean score differences 
between major cities and rural areas (β -0.05; 95% CI -0.08 to -0.03) and between least 
disadvantaged and most disadvantaged areas (β -0.06; 95% CI -0.08 to -0.03).   
 
  
 
Table 7-2: Mean proportional care scores according to patient, tumour and health system characteristics in 1) all patients; 2) patients with no 
evidence of metastases; and 3) patients with evidence of metastases on clinical staging. 
 N (%)    Total mean proportional score  (95% CI) 
 All patients (N = 1571)  Non-Metastatic ( N = 781)  Metastatic (N = 790) 
Age group (years)         
< 60 307 (20) 0.48 (0.46, 0.50)  145 (19) 0.51 (0.48, 0.53)  162 (21) 0.46 (0.43, 0.49) 
60 - 69 417 (27) 0.49 (0.48, 0.51)  221 (28) 0.51 (0.49, 0.53)  196 (25) 0.47 (0.45, 0.50) 
70 - 79 471 (30) 0.43 (0.41, 0.44)  233 (30) 0.44 (0.42, 0.46)  238 (30) 0.41 (0.39, 0.43) 
80 + 376 (24) 0.34 (0.32, 0.36)  182 (23) 0.32 (0.29, 0.34)  194 (25) 0.36 (0.34, 0.39) 
   Overall p valuea  < 0.001   < 0.001   < 0.001 
Sex         
Female 704 (45) 0.43 (0.41, 0.44)  350 (45) 0.43 (0.41, 0.45)  354 (45) 0.43 (0.41, 0.45) 
Male 867 (55) 0.44 (0.43, 0.45)  431 (55) 0.46 (0.44, 0.48)  436 (55) 0.42 (0.40, 0.44) 
   Overall p value  0.17   0.01   0.57 
Charlson Comorbidity score        
0 680 (44) 0.45 (0.44, 0.46)  342 (44) 0.46 (0.44, 0.48)  338 (44) 0.44 (0.42, 0.46) 
1 498 (32) 0.43 (0.42, 0.44)  242 (31) 0.44 (0.41, 0.46)  256 (33) 0.42 (0.40, 0.45) 
2 370 (24) 0.43 (0.41, 0.44)  194 (25) 0.43 (0.40, 0.46)  176 (23) 0.42 (0.39, 0.45) 
   Overall p valuea  0.05   0.07   0.52 
Performance Status         
0 431 (27) 0.48 (0.47, 0.50)  270 (35) 0.49 (0.47, 0.51)  161 (20) 0.47 (0.45, 0.50) 
1 538 (34) 0.46 (0.45, 0.47)  250 (32) 0.47 (0.45, 0.49)  288 (36) 0.45 (0.43, 0.47) 
2+ 373 (24) 0.39 (0.37, 0.40)  152 (19) 0.37 (0.34, 0.40)  221 (28) 0.40 (0.38, 0.42) 
Not stated 229 (15) 0.36 (0.33, 0.38)  109 (14) 0.38 (0.35, 0.41)  120 (15) 0.34 (0.30, 0.37) 
   Overall p valuea  < 0.001   < 0.001   < 0.001 
Place of residence         
Major City 1076 (68) 0.45 (0.44, 0.46)  548 (70) 0.46 (0.45, 0.47)  528 (67) 0.45 (0.43, 0.46) 
Inner Regional 338 (22) 0.40 (0.38, 0.42)  159 (20) 0.43 (0.40, 0.46)  179 (23) 0.38 (0.35, 0.40) 
Ruralb  157 (10) 0.37 (0.34, 0.40)  74 (9) 0.36 (0.32, 0.40)  83 (11) 0.38 (0.34, 0.42) 
   Overall p valuea  < 0.001   < 0.001   < 0.001 
  
 
 N (%)    Total mean proportional score  (95% CI) 
 All patients (N = 1571)  Non-Metastatic ( N = 781)  Metastatic (N = 790) 
Socio-economic status-quintiles        
Least disadvantaged 266 (17) 0.48 (0.46, 0.50)  138 (18) 0.49 (0.47, 0.52)  128 (16) 0.47 (0.44, 0.50) 
2 327 (21) 0.45 (0.43, 0.47)  160 (20) 0.46 (0.44, 0.49)  167 (21) 0.45 (0.42, 0.47) 
3 322 (21) 0.42 (0.40, 0.44)  160 (20) 0.42 (0.39, 0.44)  162 (21) 0.42 (0.39, 0.44) 
4 338 (22) 0.42 (0.40, 0.43)  169 (22) 0.42 (0.40, 0.45)  169 (21) 0.41 (0.38, 0.43) 
Most disadvantaged 318 (20) 0.41 (0.39, 0.43)  154 (20) 0.43 (0.40, 0.46)  164 (21) 0.39 (0.36, 0.42) 
   Overall p valuea  < 0.001   < 0.001   < 0.001 
Clinical Stage of disease        
Confined to pancreas 227 (14) 0.52 (0.50, 0.54)       
Locally advanced 554 (35) 0.52 (0.51, 0.53)       
Metastatic 790 (50) 0.48 (0.46, 0.49)       
   Overall p valuea  0.03       
Tumour site         
Head/neckc 1024 (72) 0.46 (0.44, 0.47)  643 (85) 0.45 (0.44, 0.47)  381 (57) 0.46 (0.44, 0.48) 
Body 134 (9) 0.43 (0.40, 0.46)  37 (5) 0.42 (0.37, 0.48)  97 (15) 0.43 (0.40, 0.47) 
Tail 144 (10) 0.40 (0.38, 0.43)  44 (31) 0.43 (0.38, 0.48)  100 (15) 0.39 (0.36, 0.43) 
Multiple sites 119 (8) 0.42 (0.39, 0.45)  34 (5) 0.44 (0.39, 0.49)  85 (13) 0.41 (0.38, 0.45) 
   Overall p valuea  0.002   0.63   0.002 
First facility volume         
> 30 756 (49) 0.49 (0.48, 0.50)  415 (54) 0.49 (0.48, 0.51)  341 (45) 0.48 (0.47, 0.50) 
29 - 10 460 (30) 0.42 (0.41, 0.44)  236 (31) 0.41 (0.39, 0.43)  224 (29) 0.44 (0.42, 0.46) 
< 10 315 (21) 0.33 (0.32, 0.35)  119 (15) 0.35 (0.32, 0.38)  196 (26) 0.33 (0.30, 0.35) 
   Overall p valuea  0.002   0.63   0.002 
First specialist seen         
Hepatobiliary surgeon 234 (15) 0.55 (0.53, 0.57)  146 (19) 0.58 (0.56, 0.60)  88 (11) 0.51 (0.47, 0.54) 
Gastroenterologist 402 (26) 0.44 (0.43, 0.46)  240 (31) 0.44 (0.42, 0.46)  162 (21) 0.45 (0.43, 0.48) 
General Surgeon 501 (32) 0.43 (0.42, 0.44)  289 (37) 0.42 (0.40, 0.44)  212 (27) 0.45 (0.43, 0.47) 
Otherd 434 (28) 0.37 (0.35, 0.38)  106 (14) 0.35 (0.32, 0.38)  328 (42) 0.37 (0.35, 0.39) 
   Overall p valuea  < 0.001   < 0.001   < 0.001 
CI – confidence interval     
a p-value calculated using one-way analysis of variance (ANOVA); b Includes outer regional, remote and very remote ; c Includes tumour in uncinate process;   
d Includes oncologists and palliative care physicians.  
  
 
Table 7-3: Associations between patient, tumour and health service characteristics and proportional care scoresa in 1) all patients; 2) patients 
with no evidence of metastases; and 3) patients with evidence of metastases on clinical staging. 
   β coefficient (95% confidence interval)   
 Crude Adjustedb  Crude Adjustedb  Crude Adjustedb 
 All  patients (N = 1571)  Non-metastatic (N = 781)  Metastatic (N = 790) 
Age group (years)         
< 60 ref ref  ref ref  ref ref 
60 - 69 0.01 (-0.01, 0.03) 0.01 (-0.01, 0.03)  0.01 (-0.03, 0.04) 0.01 (-0.02, 0.04)  0.01 (-0.03, 0.05) 0.00 (-0.03, 0.04) 
70 - 79 -0.06 (-0.08,-0.03) -0.05 (-0.08, -0.03)  -0.06 (-0.10, -0.03) -0.05 (-0.08, -0.02)  -0.05 (-0.09, -0.02) -0.06 (-0.09, -0.03) 
80 + -0.14 (-0.17, -0.12) -0.13 (-0.15, -0.10)  -0.19 (-0.23, -0.16) -0.16 (-0.20, -0.13)  -0.10 (-0.13, -0.06) -0.10 (-0.13, 0.06) 
Overall p value, p trend < 0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001 
Sex         
Female ref ref  ref ref  ref ref 
Male 0.12 (-0.01, 0.03) -0.01 (-0.02, 0.01)  0.03 (0.01, 0.06) 0.01 (-0.01, 0.03)  -0.01 (-0.03, 0.08) -0.03 (-0.05, -0.00) 
  Overall p value 0.17 0.34  0.01 0.40  0.57 0.03 
Charlson Comorbidity score        
0 ref ref  ref ref  ref ref 
1 -0.02 (-0.04, 0.00) -0.01 (-0.03, 0.01)  -0.03 (-0.06, 0.00) -0.00 (-0.03, 0.02)  -0.01 (-0.04, 0.16) -0.01 (-0.03, 0.02) 
2 -0.02 (-0.05, -0.00) -0.01 (-0.03, 0.01)  -0.03 (-0.06, -0.00) -0.01 (-0.04, 0.02)  -0.02 (-0.05, 0.02) -0.01 (-0.04, 0.02) 
Overall p value, p trend 0.05, 0.02 0.64, 0.38  0.07, 0.03 0.88,  0.63  0.52, 0.27 0.89, 0.66 
Performance Status         
0 ref ref  ref ref  ref ref 
1 -0.02 (-0.05, -0.00) -0.01 (-0.03, 0.01)  -0.02 (-0.05, 0.01) -0.01 (-0.04, 0.02)  -0.02 (-0.06, -0.01) -0.01 (-0.04, 0.02) 
2+ -0.10 (-0.12, -0.07) -0.06 (-0.08, -0.03)  -0.12 (-0.16,-0.09) -0.06 (-0.09, -0.03)  -0.07 (-0.11, -0.04) -0.05 (-0.08, -0.02) 
Not stated -0.13 (-.015, -0.10) -0.09 (-0.12, -0.06)  -0.11 (-0.15, -0.07) -0.07 (-0.11, -0.03)  -0.14, (-0.18, -0.10) -0.11, (-0.15, -0.07) 
Overall p value, p trend < 0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001 
Place of residence         
Major City ref ref  ref ref  ref ref 
Inner Regional -0.05 (-0.07,-0.03) -0.06 (-0.08, -0.04)  -0.03 (-0.06, 0.00) -0.03 (-0.06, -0.00)  -0.07, (-0.10, -0.04) -0.08 (-0.11, -0.05) 
Ruralc -0.08 (-0.11, -0.05) -0.11 (-0.13, -0.8)  -0.10 (-0.14, -0.06) -0.11 (-0.15, -0.08)  -0.07 (-0.11, -0.03) -0.09 (-0.13, -0.06) 
Overall p value, p trend < 0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001 
  
 
   β coefficient (95% confidence interval)   
 Crude Adjustedb  Crude Adjustedb  Crude Adjustedb 
 All  patients (N = 1571)  Non-metastatic (N = 781)  Metastatic (N = 790) 
Socio-economic status-quintiles        
Least disadvantaged ref ref  ref ref  ref ref 
2 -0.03 (-0.06,-0.00) -0.03 (-0.06,-0.01)  -0.03 (-0.07, 0.01) -0.04 (-0.07, -0.00)  -0.03 (-0.07,0.01) -0.03 (-0.07,0.01) 
3 -0.07 (-0.10, -0.04) -0.07 (-0.10, -0.04)  -0.08 (-0.12, -0.04) -0.08 (-0.12, -0.05)  -0.06 (-0.10, -0.02) -0.06 (-0.10, -0.02) 
4 -0.07 (-0.10, -0.04) -0.08 (-0.11, -0.05)  -0.07 (-0.11, -0.03) -0.08 (-0.12, -0.05)  -0.07 (-0.11, -0.03) -0.08 (-0.12, -0.04) 
Most disadvantaged -0.07 (-0.10, -0.05) -0.08 (-0.11, -0.06)  -0.06 (-0.10, -0.02) -0.07 (-0.10, -0.03)  -0.08 (-0.12, -0.04) -0.10 (-0.13, -0.06) 
Overall p value, p trend < 0.001, < 0.001 < 0.001, < 0.001  0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001 
Clinical Stage of disease         
Confined to pancreas ref ref       
Locally advanced -0.02 (-0.04, 0.01) -0.02 (-0.04, 0.01)  n/a n/a  n/a n/a 
Metastatic -0.03 (-0.06, -0.01) -0.02 (-0.04, 0.00)       
Overall p value, p trend 0.03, 0.01 0.26, 0.14       
First facility volume         
> 30 ref ref  ref ref  ref ref 
29 - 10 -0.06,( -0.08, -0.05) -0.06 (-0.08, -0.04)  -0.08 (-0.11, -0.06) -0.07 (-0.10, -0.05)  -0.04 (-0.07, -0.02) -0.04 (-0.07, -0.02) 
< 10 -0.16 (-0.18, -0.13) -0.13 (-0.15, -0.11)  -0.14 (-0.18, -0.11) -0.10 (-0.13, -0.07)  -0.16 (-0.19, -0.13) -0.15 (-0.17, -0.12) 
   Overall p value, p trend < 0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001  < 0.001, < 0.001 < 0.001, < 0.001 
First specialist seen         
Hepatobiliary surgeon ref ref  ref ref  ref ref 
Gastroenterologist -0.11 (-0.14, -0.08) -0.09 (-0.11, -0.06)  -0.14 (-0.18, -0.11) -0.12 (-0.15, -0.09)  -0.05 (-0.10, -0.01) -0.03 (-0.07, 0.01) 
General Surgeon -0.12 (-0.15, -0.10) -0.10 (-0.13, -0.08)  -0.16 (-0.19, -0.13) -0.13 (-0.16, -0.10)  -0.06 (-0.10, -0.02) -0.05 (-0.09, -0.01) 
Other -0.19 (-0.21 , -0.16) -0.14 (-0.16, -0.11)  -0.23 (-0.27, -0.19) 0.17 (-0.21, -0.13)  -0.14 (-0.18, -0.10) -0.10 (-0.14, -0.06) 
   Overall p value < 0.001 < 0.001  < 0.001 < 0.001  < 0.001 < 0.001 
a The higher the proportional care score the higher the quality of care. 
b Adjusted for age at diagnosis (< 60, 60 - 69, 70 - 79, 80 + years); performance status(0, 1, 2+, not stated); and Charlson comorbidity index score (0, 1, 2+) 
c Includes patients in outer regional, remote and very remote areas  
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For patients clinically staged with non-metastatic disease the factors most strongly associated with 
higher care scores were being first seen by a hepatobiliary surgeon compared to a general surgeon 
(β -0.17; 95% CI -0.21 to -0.13), living in a major city rather than a rural area (β -0.11; 95% CI -
0.15 to -0.08) and being less than 60 years of age compared to 80 years or older (β -0.16; 95% CI -
0.20 to -0.13). For patients diagnosed with metastatic disease, being seen at a higher volume 
facility (β -0.15; 95% CI -0.17 to -0.12) and having better performance status (β -0.11; 95% CI -
0.15 to -0.07) were most strongly associated with the quality of care. 
Regarding individual items of care, a small proportion of patients were presented to 
multidisciplinary teams (MDTs) (31%), received psychosocial support (19%), participated in 
clinical trials (7%) and were first seen by a hepatobiliary surgeon (19%) (Table 7-1). Most eligible 
patients were offered a resection (or had a valid reason why not) (98%), had a tissue diagnosis 
(80%), saw a medical oncologist (86%) and were referred to palliative care (82%). There were 
significant differences for patients by place of residence and area-level socioeconomic status. For 
example, 41% of patients in rural areas were referred to a hepatobiliary surgeon compared with 
53% of patients in metropolitan areas (Appendix G: Table 9-6 and Table 9-7). 
Patients with scores in the highest quartile had an estimated median survival of 8 months, double 
that for those with scores in the lowest quartile. Median survival for patients with non-metastatic 
disease in the highest and lowest score quartiles respectively was 14 and 7 months; in those with 
metastatic disease it was 5 and 3 months (Figure 7-1). 
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P values calculated using log-rank test to test the equality of survivor functions across quartiles of 
proportional care score groups. 
Figure 7-1: Kaplan-Meier survival curves by quartiles of proportional care score for all 
patients, patients with non-metastatic disease and patients with metastatic 
disease on clinical staging. 
p < 0.001
0.00
0.25
0.50
0.75
1.00
P
ro
p
o
rt
io
n
 S
u
rv
iv
in
g
398 255 144 85 62 49 38Highest quartile score
388 215 112 71 47 39 333rd quartile score
393 189 89 58 41 34 292nd quartile score
392 141 77 43 35 32 25Lowest quartile score
Number at risk
0 6 12 18 24 30 36
Time in months
Lowest quartile score 2nd quartile
3rd quartile Highest quartile score
p <0.001
0.00
0.25
0.50
0.75
1.00
P
ro
p
o
rt
io
n
 S
u
rv
iv
in
g
203 178 120 79 60 48 37Highest quartile score
215 169 96 64 43 36 323rd quartile score
199 144 79 51 36 29 242nd quartile score
164 89 53 31 24 23 17Lowest quartile score
Number at risk
0 6 12 18 24 30 36
Time in months
Lowest quartile score 2nd quartile
3rd quartile Highest quartile  score
p = 0.05
0.00
0.25
0.50
0.75
1.00
P
ro
p
o
rt
io
n
 S
u
rv
iv
in
g
195 77 24 6 2 1 1Highest quartile score
173 46 16 7 4 3 13rd quartile score
194 45 10 7 5 5 52nd quartile score
228 52 24 12 11 9 8Lowest quartile score
Number at risk
0 6 12 18 24 30 36
Time in months
Lowest quartile score 2nd quartile
3rd quartile Highest quartile score
 148 
 
After adjusting for age, performance status, comorbidities and clinical stage, each 10% absolute 
increase in proportional care score was associated with a statistically significant 6% reduction in 
the risk of dying (HR 0.94; 95% CI: 0.91 to 0.97) (Table 7-4).  
Table 7-4: Association between total care score and survival by stage of pancreatic cancer at 
diagnosis. 
 Number Hazard ratio[HR] (95% confidence interval) 
 
of 
patients 
HR Adjusted HR a 
All  patients 1571 0.90 (0.87,  0.93) 0.94 (0.91, 0.97) 
p value 
 
< 0.001 < 0.001 
   
 
Non-metastatic    778 0.87 (0.83, 0.91) 0.91 (0.87, 0.95) 
p value  < 0.001 < 0.001 
   
 
Metastatic 790 0.95 (0.91, 0.98) 0.95 (0.91, 0.99) 
p value  0.006 0.013 
HRs refer to the change in the risk of dying associated with a 10 percentage point increase in care score. 
a HR adjusted for age group (<60, 60-69, 70-79, 80+), performance status (0, 1, 2+, not stated), Charlson comorbidy 
score (0, 1, 2+), clinical stage (confined, locally advanced, metastatic). 
 
This was more marked for patients who were diagnosed with non-metastatic disease than for those 
diagnosed with metastatic disease with adjusted HRs of 0.91 (95% CI: 0.87 to 0.95) and 0.95 (95% 
CI: 0.91 to 0.99), respectively. Individual care score items that were statistically significantly 
associated with survival included having a diagnostic tissue sample collected (HR 0.66; 95% CI: 
0.57 to 0.77), being offered adjuvant chemotherapy (HR 0.43; 95% CI: 0.33 to 0.56), being referred 
to a hepatobiliary surgeon if  potentially resectable (HR 0.82; 95% CI: 0.69 to 0.96), being 
presented to an MDT (HR 0.86; 95% CI: 0.77 to 0.96), being offered psychosocial support (HR 
1.24; 95% CI: 1.09 to 1.12), having evidence of pancreatic enzyme replacement therapy (HR 0.83; 
HR 95% CI: 0.73 to 0.94) and, if diagnosed with metastatic disease, evidence of referral to 
palliative care (HR 1.42; 95% CI: 1.17 to 1.74) ( Appendix G: Table 9-8). 
Discussion 
We found that the quality of care of patients with pancreatic cancer differs according to their age, 
where they live and the volume of the hospital at which they first present. We also found that the 
quality of care is associated with improved survival and that this association is strongest for 
patients clinically staged with non-metastatic pancreatic cancer, where there is more scope for 
treatment to make a survival difference.  
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Previous studies have found that receipt of surgery, chemotherapy and palliative care is influenced 
by patients’ age, education, place of residence, race and marital status.10, 12, 13 By examining a 
composite measure of care, including a broad range of factors, we have shown that age and 
performance status influence the overall quality of care received. While this is unsurprising, it is 
important that age alone is not seen as a barrier to delivery of high quality care. The more 
concerning finding is that care differs according to place of residence and area-level socioeconomic 
status. This is at least partially mediated by access to specialists and care in a high volume centre, 
suggesting that interventions to ensure all patients are managed by high-volume teams could 
improve the quality of care. 
Our analysis of individual care items showed that the proportion of people who received the 
recommended care was particularly low for items relating to where and by whom treatment was 
received. For example, less than a third of patients had evidence of MDT referral, only half of 
potentially resectable patients were referred to a hepatobiliary surgeon, and clinical trial 
involvement was only rarely considered, even though these factors have consistently been found to 
influence quality of care.93-95 These aspects of care were particularly poorly met for patients living 
in more rural areas. Distance presents distinct challenges in Australia, 303-305 but these should not be 
insurmountable.  Studies have shown that a multilevel approach (which could involve holding 
telemedicine MDTs and formalising referral relationships between regional and metropolitan 
centres) can improve outcomes.306 
Patients with lower care scores had poorer survival, consistent with previous observations that 
delivery of high quality care improves survival.307-309 This association was stronger for patients 
diagnosed with non-metastatic disease, where there is more scope to influence survival by ensuring 
adequate staging, surgery in high-volume centres and access to adjuvant chemotherapy. For 
patients with metastatic disease a focus on quality-of-life indicators is arguably more important and 
this should be explored in future studies of care quality.  
Some individual care items were associated with higher estimates of dying if the care was received, 
such as patients should be “offered psychosocial support”, “patients with metastatic disease should 
be referred to palliative care” and “patients with technically resectable disease should be offered a 
resection or a valid reason for no surgery”. Receipt of psychosocial and palliative care is more 
likely to occur as expected survival time shortens which is likely to explain the results (i.e. reverse 
causation).  The item regarding resection was classified as having been delivered if a valid reason 
for the resection not being offered was recorded. This applied to 28% of patients eligible for 
resection; the reasons for no surgical attempt were older age, comorbidity and poor performance 
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status, all of which are associated with poor survival. When these items were omitted from the 
overall care score, the risk of dying was 2% lower for each 10 percentage point increase in care 
score. 
This study is comprehensive, reasonably large and population-based and is the first Australian 
study to consider the overall quality of care in a single score. Nevertheless, it does have some 
limitations. Firstly, different weights for the care items may have been obtained if the mix of 
specialists who participated in the Delphi study had been different. Secondly, the Delphi study 
highlighted the importance of communication between patients and clinicians. This cannot be 
adequately captured through review of medical records so could not be incorporated into our score, 
but might have influenced decisions regarding care. Thirdly, some patients may have been 
incorrectly classified as resectable which caused them to be ineligible (or eligible) for care items, 
with appropriate care (or not) delivered.  Finally, while we controlled for age, performance status 
and comorbidities this may not have completely accounted for confounding by patient factors.  
In conclusion, this population-based study provides evidence that place of residence and other 
factors influence the quality of care received by Australian patients with pancreatic cancer and that 
survival gains can be realised by ensuring optimal care is provided. Systems need to be 
implemented to ensure delivery of equitable care for all Australian patients with pancreatic cancer. 
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The research included in this thesis provides a comprehensive understanding of the management of 
patients diagnosed with pancreatic cancer in QLD and NSW. It has also identified indicators of 
optimal care, and factors associated with receipt of high-quality care. 
This final chapter summarises the contribution and significance of the work contained in this thesis, 
compares the findings with those from other studies and discusses the strengths and limitations of 
the research. The directions for further investigation and implications of the results conclude the 
chapter and thesis. 
8.1. OVERVIEW OF FINDINGS 
The findings from a Delphi process used to identify indicators of care that clinicians deem 
important in providing optimal care for patients with pancreatic cancer were described in Chapter 4. 
Approximately a quarter of the items derived from the initial open-ended question related to 
presentation and staging, and over a third of items related to when and where care should occur and 
which specialists should be involved. All items derived were reflected in the State of Victoria’s 
Department of Health and Human Services optimal care pathway,95 including the importance of 
communication. Consensus was reached for many items, such as the need for patients to be 
assessed by a hepatobiliary surgeon, for surgery to occur in a high-volume centre and the 
importance of management by a multidisciplinary team, although there was some variability 
according to the specialty of the clinician. Surgeons tended to prioritise surgical factors, while other 
clinicians considered supportive care to be of higher importance. The mean scores of items for 
which consensus was reached and for which information was available in the medical records were 
used to calculate a quality-of-care score as described in Chapter 7. 
Chapter 5 described the cohort of patients included in the patterns-of-care study and provided a 
broad overview of their management. Almost 60% of patients were diagnosed with metastatic 
disease and approximately three-quarters of tumours affected the head, neck or uncinate process. 
Approximately 20% of patients underwent an attempted resection but this was not completed for 
25% of these, so the proportion resected was 15%. Approximately 75% of patients who underwent 
a complete resection received adjuvant chemotherapy, and for the 43% of patients in whom the 
resection was aborted or not attempted, palliative chemotherapy was their primary treatment 
modality. Only 8% of patients received radiation therapy in either the adjuvant or palliative setting. 
The median survival was 4.5 months for the entire cohort.  
Chapter 6 focused on determinants of receipt of surgery and survival for patients who were not 
found to have metastatic disease during the initial staging investigations. Patients living in more 
remote areas and those not reviewed by a hepatobiliary surgeon were less likely to be offered 
 153 
 
surgery. Patients presented at a MDT meeting were also less likely to be assessed as having a 
potentially resectable tumour than those with no evidence of a MDT review. Along with age, 
comorbidities and tumour stage, increasing remoteness of residence was associated with poorer 
survival.  
Chapter 7 described the construction of a quality-of-care score based on indicators derived from the 
Delphi process. We showed that quality-of-care scores were lower for older patients, those with 
poorer performance status and those living in rural areas compared with major cities. Rural patients 
were less likely to be assessed by an MDT or hepatobiliary surgeon and less likely to have evidence 
of psychosocial and palliative care support. Patients who first presented to a hospital with a high 
pancreatic cancer case load had higher scores than those presenting at low case-volume hospitals. 
Higher quality-of-care scores were associated with improved survival, particularly for patients 
diagnosed with non-metastatic disease.  
In summary, the Delphi process showed that most clinicians agree on the importance of highly 
expert care in the management of patients with pancreatic cancer. However the patterns-of-care 
study illustrated that not all patients receive this high standard of care. As expected, survival was 
poor, especially for patients diagnosed with metastatic disease, but was also worse for patients 
living in more rural areas. There was inequitable access to surgical staging, and the overall quality-
of-care score varied by region of residence. This work provides impetus for changes in policy and 
practice to ensure that all patients diagnosed with this lethal disease have optimal care.  
8.2. COMPARISON OF FINDINGS WITH PREVIOUS RESEARCH 
8.2.1. Patient cohort 
The demographic characteristics of the patient cohort in this study were consistent with those in 
other Australian and international studies. The median age of 71 years and the proportion male 
(54%) match reports from the United States SEER data274 and the Australian cancer registry data in 
2010.275 With respect to geographical location, the distribution of the cohort is almost identical to 
that of the Australian population,276 suggesting that the risk of pancreatic cancer does not differ 
appreciably according to remoteness of residence. The proportion diagnosed with metastatic 
disease (58%) is comparable to other recent international reports (range 46% - 59%).10, 123, 221 The 
tumour location, with 72% being in the head of the pancreas, is also consistent with other reports 
(range 69% – 79%).33, 106, 107, 294  
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8.2.2. Management of pancreatic cancer patients 
Median survival for the cohort was 4.5 months and 22% survived at least one-year following 
diagnosis which is consistent with recent international and Australian registry data. Although not a 
direct comparison within a single population over time, data from the United States, the United 
Kingdom and NSW indicates that survival rates have improved slightly over the past few decades 
(1-year relative survival from approximately 12% in the 1980s to 20-21% in 2010, 5-year survival 
from 3% in 1985 to 7% for 2010).34, 39, 60 Improvements in survival have been mainly observed for 
patients diagnosed with non-metastatic disease, particularly for patients with a completed resection 
of their disease.91, 294  
We observed that 15% of patients underwent complete resection of their primary tumour. Most 
previous studies have reported 10-15%,10, 13, 62, 216 with no obvious trends over time or by country. 
Previous Australian population-based investigations found that 11% of patients diagnosed during 
2002-2003 in Victoria and 13% of patients diagnosed in Queensland during 2009-2011 underwent 
surgical resection of their tumour.107, 192 Thus we report a small increase, although whether this is a 
real increase or is due to random variation is unclear. 
Almost a third of patients with potentially resectable disease in our series did not undergo resection 
of their tumour (31%). This included 58% of patients with stage I disease which is slightly lower 
than the 64% reported for a series of patients diagnosed in 2004 in the United States.106 Most 
patients (94%) in our cohort with Stage I disease who did not undergo attempted surgery had a 
valid reason for not progressing to surgery. These included age and or comorbidities (61%), refusal 
(24%) and poor performance status (8%).  A reason was not recorded for only three patients (6%). 
In the United States report, age and comorbidities accounted for 22% of those who did not have 
surgery and 6% refused, but for 72% the reasons were unknown.  
We found that approximately 25% of attempted resections were not completed due to the discovery 
of metastases or disease that invaded arteries. A Victorian population-based study indicated that 
32% had an attempted resection that was not completed and was converted to a biliary bypass 
procedure due to previously undiagnosed unresectable disease.107 The high number of incomplete 
resections found in both studies may indicate inadequate staging for patients with borderline 
resectable disease, exacerbated by the lack of consensus guidelines available regarding the 
classification of resectability. It may also suggest that surgeons are more willing to attempt 
resections given the improvements in surgical techniques that have occurred.279 
Adjuvant chemotherapy is current standard of care, as it was at the time the patients in this study 
were diagnosed. We found that 76% of patients received adjuvant chemotherapy following 
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completed resections, the range reported in other international and Australian studies, using data 
from between 2000 and 2010, is between 40% and 83%.10, 18, 62 Only two studies reported rates of 
75% or more, both conducted using more recent data (2005-2010).10, 216 An Australian report from 
2000-2001 showed that approximately half of the patients received adjuvant chemotherapy 
following resection.18 Since the time of this previous Australian data the ESPAC-1 trial,157 
CONKO-001 trial143 and a meta-analysis147 have been published supporting the use of adjuvant 
chemotherapy, which likely accounts for the high proportion of use that we have identified. 
Less than half of the patients in our study who did not undergo a resection of their primary lesion 
received chemotherapy (43%). The range in previous patterns-of-care studies was 20% to 42% but 
comparisons for this group are problematic due to differences in the patient groups included and 
differences in reporting. Studies with low use of palliative chemotherapy may have been biased due 
to the use of administrative data which notoriously under-reports chemotherapy use. The previous 
Victorian patterns-of-care study reported that 32% of patients treated with palliative intent received 
chemotherapy18 so our data suggest some increase in use of palliative chemotherapy in the 
intervening decade. Recent trials of oxaliplatin, irinotecan, fluorouracil, and leucovorin 
(FOLFIRINOX)153 and nab-paclitaxel (Abraxane)310 therapy have shown statistically significant 
survival and quality-of-life benefits over gemcitabine which has been the standard of care since the 
beginning of the century. Following these trial results the proportions of patients receiving 
chemotherapy might have changed since we completed our data collection, and this is likely to 
continue to increase as more evidence unfolds. 
There is limited evidence to suggest that radiotherapy therapy improves the outcomes of patients 
with pancreatic cancer. Nevertheless, guidelines from the United States based on low-level 
evidence and expert opinion suggest that radiation could be used in the following contexts: 1) as 
post-operative adjuvant therapy; 2) for inoperable stage I-II pancreatic cancers; 3) for locally 
advanced stage III cancers; and 4) for symptomatic disease requiring palliation.6 An Australian 
report based on these guidelines estimated that 49% of patients in Australia should receive radiation 
therapy at some point during their disease course, although this did not allow for poor performance 
status.304 We found that only 8% of patients received radiation therapy. We did not investigate 
factors associated with receipt of radiotherapy, but this low proportion almost certainly reflects the 
lack of high-quality evidence to support its use in most patients. The role of radiation in the 
treatment of patients with pancreatic cancer warrants further investigation to provide higher level 
evidence regarding its use. 
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International and Australian recommendations are that all patients, especially those with localised 
disease, should be managed by a MDT.6, 94, 159, 180 We found evidence of review by a MDT for 28% 
of all patients in our cohort and for 34% of those without metastatic disease. While this remains 
low, it is a significant improvement over the 7% reported in the Victorian study from 2000-2001.18 
There are few international data with which to compare our results, largely because most studies 
from the United States use administrative datasets which do not include information about MDT 
review. Further, the definition of a MDT varies. Nevertheless, a recent report from the Netherlands 
reported that 64% of all patients with suspected pancreatic or periampullary cancer were discussed 
within a MDT, perhaps indicating more developed multidisciplinary pathways or more robust 
documentation of MDT review.126  
8.2.3. Associations with access to cancer-directed therapies 
Equitable access to surgery, performed in a highly-skilled setting, has been suggested as the key to 
reducing variation in long-term survival for patients with pancreatic cancer.123, 146 We found that 
older patients, and those with poorer performance status or more comorbidities were less likely to 
have surgery than younger, more active patients or those with fewer comorbidities. These results 
are consistent with the literature.10, 12, 13, 213, 214, 216, 221 Pancreatic resection causes serious morbidity 
and five-year survival in surgical patients is less than 20%,34, 113, 143 so it is appropriate that 
functional status and fitness for surgery influences decisions about resection. However, these 
factors should not necessarily influence the staging classification of the tumour as resectable or not. 
Our observation that they were associated with resectability might indicate inadequate staging 
investigations, potentially denying patients the opportunity to make fully informed decisions about 
their treatment.  
We observed that location of residence in a major city and in a less disadvantaged area, compared 
with rural locations or areas of high disadvantage, was significantly associated with improved 
access to surgery. Literature from the Unites States and Canada all confirm similar significant 
findings.13, 210, 216 In Australia, a recent Queensland government population-based report on 
pancreaticoduodenectomy found that 15% of patients living in affluent areas diagnosed with 
pancreatic cancer between 2009 and 2011 received pancreaticoduodenectomies compared with 
12% of patients living in disadvantaged areas.192 Our findings that the case volume of the hospital 
to which the patient first presented influences access to surgery is consistent with the international 
literature,13, 131, 212 and it is likely that this mediates the association with location of residence.  
We found that higher global quality-of-care scores were associated with improved survival. There 
are few studies with which to compare this finding, but a study from the Unites States found that 
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pancreatic cancer patients whose care was compliant with clinical guidelines had significantly 
reduced odds of dying over the five-year study period  (OR 0.64; 95% CI: 0.53 – 0.77).222 Scores 
were also higher for patients living in metropolitan or less disadvantaged areas than those living in 
more rural or disadvantaged areas. This is likely to be explained by differences in access to 
specialist services at high-volume centres. 
Overall, the management of Australian pancreatic cancer patients appears to be of higher quality 
than that reported in other developed countries. This likely reflects the more contemporary nature 
of our data and our careful review of medical records. We have shown that a large proportion of 
patients received recommended adjuvant therapy and that the overall survival of the cohort is 
slightly improved from previous population-based international and Australian reports, but we have 
also shown that there is evidence of inequitable access to care. There is a paucity of other 
Australian data; therefore, robust analysis of temporal change is not possible. These comprehensive 
data will provide a baseline with which future trends can be compared. 
8.3. RESEARCH STRENGTHS AND LIMITATIONS  
The patterns-of-care study on which this research is based is the most extensive study ever 
completed for patients with pancreatic cancer in Australia. Just over half of the population of 
Australia resides in NSW or QLD; the findings are likely to be broadly generalisable to other states, 
although there may be some disparities due to the different geographic dispersion in the smaller 
states and territories not included in this study. The findings are also likely to be transferrable to 
other countries with similar health care systems and geographical population dispersion.  The 
nurses who collected data were carefully trained to ensure standardisation of the collection. The 
data were also more comprehensive and complete than that obtained from administrative 
datasets.283, 284 Much of the research performed that has not depended on these administrative 
datasets has been in single centres or restricted to clinical trial settings, generating results that are 
not generalisable to the wider population. Accessing the medical records required considerable 
investment of time in navigating human ethics and governance requirements, in addition to the 
challenges related to geographical dispersion of the records. Increased investment in linkage of 
health data may overcome some of these issues, although regulatory requirements continue to be 
inconsistent across state jurisdictions. We captured data for 96% of all patients diagnosed during 
the study period, ensuring minimal bias, although the completeness of records may have varied 
according to patient or health-system characteristics.  
Despite the noted strengths, this study does have some limitations. The data are now already five 
years old due to constraints relating to access to registry data, obtaining ethical and administrative 
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approvals from over 100 hospitals and the management of a large dataset.  With rapidly advancing 
technology, new chemotherapy regimens and updated staging and treatment guidelines since the 
inception of the study, patterns of care may have changed since the data were collected. The study 
was also relatively small with approximately 2000 participants, reducing the statistical power to 
detect associations in some patient subgroups.  
The data used in this study were abstracted from medical records which vary in their completeness. 
The absence of information about a particular care item did not necessarily mean that the care did 
not occur, but just that it was not recorded. Information about discussions with patients was often 
not documented. Thus, we may have classified a care item as inappropriately not delivered, but the 
decision may have been made by the patient after consultation with the treating clinician.  
In developing the quality-of-care score, different items of care or weights for the care items may 
have been obtained if a different mix of clinical specialists had participated in the Delphi process. 
The opinions of patients may have also enriched the final care items and their weights. 
Nevertheless, the final quality-of-care score was shown to be associated with survival indicating its 
relevance and validity for patients with pancreatic cancer. However, as most patients present with 
advanced disease and only a small proportion undergo surgical resection, quality-of-life or other 
patient-reported outcomes may be better indicators of quality of care than survival.  
The classification of tumours as resectable or not may have affected the results, particularly those 
reported in Chapter 6. We did not have centralised assessment of resectability and were therefore 
dependent on the decisions of the clinicians as documented in the medical record. At the time the 
patients were diagnosed, criteria for resectability were unclear and changing, making the decision 
somewhat subjective. To obviate this problem our classification of resectability included 
subclassifications (tumour confined to pancreas; tumour locally advanced but resectable; tumour 
locally advanced and unresectable; and metastatic). We also captured TNM stage where possible 
enabling alternate staging associations to be estimated and reducing the impact of potential 
incorrect resectability classifications.  
8.4.   
These results provide clear indications that while expert high-level care is provided to some 
patients, not all Australian pancreatic cancer patients receive care that is consistent with guidelines 
or the consensus opinion of expert clinicians. There is evidence of inequity in access to cancer-
directed therapies, with patients living further from metropolitan centres particularly susceptible to 
a lack of specialist services and high quality multidisciplinary care.  
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8.4.1. Future research 
Although we have generated sufficient evidence to support immediate changes in policy and 
practice, this work has identified some gaps in knowledge. Firstly, we have shown that rurality of 
residence influences whether or not patients are classified as having potentially resectable disease. 
This is a critical point in the care pathway, as resection of the tumour is currently the only curative 
treatment modality. Given the potential importance of this finding, further research is needed to 
understand this geographic variability in classification of resectability. Ideally an audit of patients’ 
records should occur and the staging investigations of all patients without metastatic disease should 
be reviewed by a centralised audit team to assess the accuracy of surgical decisions. Further 
research focussed specifically on multidisciplinary care to identify the ideal composition of the 
team, who should be presented and at what point/s during their course of disease, and barriers to 
access would increase knowledge in this area. Secondly, we have focussed on survival as the key 
patient outcome. While improving survival remains the ultimate goal of therapy, the effect of 
quality of care on patient-reported outcomes such as quality of life, anxiety and distress should also 
be considered. It is also important that consumers provide input into a care score before it is widely 
implemented to monitor management. Consumers should be involved in a separate Delphi process 
and also asked to score the items identified by clinicians. The quality-of-care score could be 
advanced by testing its validity and impact in other settings. The score is likely to be widely 
generalisable due to the accessibility of item components in medical records. 
The establishment of a population-based clinical registry would enable a tissue bank to support 
investment in improved treatment. 
8.4.2. Translating findings into policy and practice 
Changes at the policy, clinician and patient levels are needed to ensure that all patients receive best 
practice evidence-based care. This will need to be supported by implementation research to 
evaluate the impact of any interventions. At the policy level a starting point would be the 
development of national clinical guidelines, establishing clear referral pathways, either directly 
from the general practitioner or after initial investigations, and including telehealth as appropriate. 
The cornerstone of management for patients with pancreatic cancer is oversight by a highly skilled 
multidisciplinary team. Currently MDTs are recognised by Cancer Australia as providing optimal 
quality care, with increasing access a key element of the Cancer Service Networks National 
Program.180 They are well supported by clinicians, particularly in the public sector.172 MDTs are 
unregulated but resources (including web-based on-line tools)311 are available to facilitate their 
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establishment and functioning.186 Improving access to MDTs will facilitate an integrated team 
approach and help to support collaborative standardised care. In addition to the somewhat ad hoc 
state of MDTs, the physical size of Australia makes accessing MDT care challenging for patients 
who live in rural or remote areas. Improved access to telehealth technology for patients who are 
unable or unwilling to travel, or for rural practitioners, will enable patients and practitioners to 
effectively participate in multidisciplinary care planning and increase referral pathways. There is 
evidence to support the use of telehealth to deliver better health outcomes in regional and remote 
communities, with savings for the governments and support from patients and clinicians, but its use 
needs to be expanded.259, 262, 312  
Hospital and surgeon case-volumes have previously been shown to influence the outcomes of 
patients undergoing pancreatic tumour resection. Our research did not find an effect of hospital 
volume, possibly because some centralisation has already occurred,192 but we did find an effect of 
surgeon volume (Appendix H). Changes need to be implemented by policy makers, hospital boards 
and potentially the College of Surgeons to ensure that hepatobiliary surgeons are performing a 
sufficiently high number of these pancreatic surgeries to optimise patient outcomes. Our data 
suggest that surgeons should perform a minimum of four pancreatic cancer resections annually, but 
our sample size was too small to be confident that this is the ideal number. The Cancer Institute 
NSW has recently released a quality improvement statement indicating that hospital case load 
should be 6 or more pancreatic surgeries per year for optimal care but they did not specify the 
number per surgeon.313 Evidence suggests that there should be ongoing national monitoring of the 
association between hospital/surgeon volume and patient outcomes. 
While we did not formally analyse associations between palliative care referral and patient 
outcomes, our Delphi process highlighted the importance of palliative care involvement, given the 
poor survival outcomes of patients with pancreatic cancer. Early or increased palliative care 
involvement for patients was associated with improved survival for patients with advanced 
cancer.164 Among patients with advanced pancreatic cancer, early referral reduced the use of 
chemotherapy within 14 days of death and reduced hospital admissions within 30 days of death.163 
Palliative Care Australia has set standards for practice and their service provision document 
outlines methods and resources to increase access to palliative care.314 This is particularly critical 
for this vulnerable patient group. 
Our data support the need for significant changes in practice. One way of supporting this change 
would be to implement a system whereby compliance with a series of quality indicators, such as 
those developed through our Delphi process, is continuously measured.   Providing hospitals and 
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individual clinicians with reports which compare their processes and outcomes with that of others 
would enable them to identify where their practice differs from the norm and/or fails to adhere to 
accepted guidelines. The results of any policy or practice changes would be evident through this 
continuous benchmarking approach.  
8.5. CONCLUSION 
People diagnosed with pancreatic cancer suffer the worst five-year survival observed for any 
cancer. Resection of the primary tumour currently provides the greatest potential for cure. 
Increasing the proportion of patients who undergo surgical resection and ensuring that this occurs 
in a high case-volume setting may lead to population-level gains in survival. In addition, access to 
other cancer-directed therapies in both the adjuvant and palliative settings may lead to further 
improvements in both survival and quality of life.  
There is considerable investment in identifying new strategies for diagnosis and treatment of 
pancreatic cancer. However, immediate improvements to patient outcomes could be made by 
implementing policies and procedures that enable all patients, irrespective of their 
sociodemographic characteristics, to be managed by high-performing multidisciplinary teams, 
ensuring accurate staging and receipt of optimal curative and supportive treatment modalities. This 
will also enable full realisation of benefits expected to accrue from the development of new 
treatments over the coming decades.   
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9.2. APPENDIX A 
9.2.1. Pancreatic Cancer Patterns-of-Care Study Group 
This group of clinicians collaborated with the patterns-of-care study team to facilitate data 
collection throughout New South Wales and Queensland. 
Pancreatic Cancer Patterns-of-Care Study Group 
Rick Abraham, FRACP, ICON Cancer Care; Ehtesham A Abdi, FRACP, Griffith University, 
Tweed Cancer Care Centre; Mark N. Appleyard, MD, Royal Brisbane and Women's Hospital; 
Gregory D.  Barclay, FAChPM, University of Wollongong, Illawarra Shoalhaven Local Health 
District; Geoffrey F. Beadle, FRACP,  Royal Brisbane and Women’s Hospital, QIMR Berghofer 
Medical Research Institute; Lourens Bester, MD, University of Notre Dame, St Vincent's Hospital; 
Kate Blackler, RN, Cancer Council NSW; Antonino Bonaventura, FRACP, Calvary Mater 
Hospital, Newcastle; Fabio R. Brecciaroli, FAChPM, ANZSPM, Palliative Care QLD; Karen P. 
Briscoe, FRACP, North Coast Cancer Institute, NSW; Susan Brown, BA, QIMR Berghofer 
Medical Research Institute; Matthew E. Burge, FRACP, Royal Brisbane and Women's Hospital; 
Bryan H. Burmeister, MD,  Princess Alexandra Hospital, University of Queensland; Leighna K. 
Carmichael, SM,  Cancer Council NSW; David R.H. Christie, FRANZCR, Bond University, 
Genesiscare Tugun; Richard Chye, FAChPM, South East Sydney LHD & St Vincent's Network, 
University of New South Wales; Philip R. Clingan, FRACP, University of Wollongong, Illawarra 
Shoalhaven Local Health District; Aniko Cooper, BAppSc, Townsville Hospital; Tracie Corish, 
RN, QIMR Berghofer Medical Research Institute; Paul S. Craft, FRACP, The Canberra Hospital, 
Australian National University; Michelle Cronk, FRACP, Sunshine Coast Hospital and Health 
Service; Mark J. Deuble,  FAChPM, Metro South Palliative Care Service, Brisbane; Benedict M. 
Devereaux, FRACP, University of Queensland; Paul Eliadis, FRACP  Bond University; Jonathan 
Fawcett, DPhil, Princess Alexandra Hospital, University of Queensland; Robert J. Finch, FRACS, 
Royal Brisbane and Women’s Hospital; Jonathan S. Gani, MD, University of Newcastle; David 
Goldstein, FRACP, Prince of Wales Hospital; Peter S. Grimison, PhD,  Chris O’Brien Lifehouse, 
Sydney; Alexander D. Guminski, PhD, University of Sydney, Royal North Shore Hospital; Howard 
P. Gurney, FRACP, University of Sydney, Westmead Hospital; Christine L. Hill, BNP, QIMR 
Berghofer Medical Research Institute; Luke F. Hourigan, FRACP, Princess Alexandra Hospital, 
Greenslopes Private Hospital;  George Hruby, FRANZCR, University of Sydney, Chris O’Brien 
Lifehouse;  Warren L. Joubert, FRACP, Princess Alexandra Hospital, Greenslopes Private 
Hospital; Andrew B. Kneebone, FRANZCR,  Northern Sydney Cancer Centre, University of 
Sydney; Stephen V. Lynch, FRACS, Princess Alexandra Hospital, University of Queensland; 
191 
Karen A. Martin, BHA, QIMR Berghofer Medical Research Institute;  Gavin M. Marx, FRACP, 
University of Sydney, Sydney Adventist Hospital; Neil D. Merrett, FRACS, University of Western 
Sydney; Andrea D. McMurtrie, BN, QIMR Berghofer Medical Research Institute; Robyn Nagel, 
FRACP,  University of Queensland; Weng L. Ng, PhD, Liverpool Hospital, Ingham Health 
Research Institute, Liverpool; Nicholas A. O'Rourke, FRACS, Royal Brisbane and Women's 
Hospital, University of Queensland; Nick Pavlakis, PhD, Royal North Shore Hospital, Sydney 
University; Leigh Rutherford, FRACS, Gold Coast University Hospital; Joseph J. Rutovitz, 
FRACP, Sydney Adventist Hospital, Northern Haematology and Oncology Group; Sabe Sabesan, 
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Yip,  FRACP, The Canberra Hospital, Australian National University. 
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9.3. APPENDIX B 
9.3.1. Pancreatic cancer clinical working group 
This group of clinicians from throughout Australia participated in the Delphi process to develop 
pancreatic cancer quality indicators. 
Pancreatic cancer clinical working group: 
Meera Agar, Flinders University & Braeside Hospital; Luisa Algie, The Princess Alexandra 
Hospital; Fabio Brecciaroli, Caloundra Hospital; Ann Bullen, The Royal Brisbane and Women’s 
Hospital; Matthew Burge, The Royal Brisbane and Women’s Hospital; Bryan H. Burmeister, 
University of Queensland and Princess Alexandra Hospital; Susan Caird, Gold Coast University 
Hospital & Griffith University; Donald Cameron, The Townsville Hospital; Philip Chan, 
University of Queensland & The Royal Brisbane and Women’s Hospital; Lorraine Chantrill, 
Campbelltown Hospital & Garvan Institute; David Christie, Bond University & Genesiscare; Yu Jo 
Chua, The Canberra Hospital; Peter H. Cosman, University of Western Sydney ; John Croese, The 
Prince Charles Hospital; Michelle Cronk, Nambour General Hospital; Mark Deuble, Princess 
Alexandra Hospital; Melissa Eastgate, The Royal Brisbane and Women’s Hospital; David Fletcher, 
University of Western Australia; Jon Gani, John Hunter Hospital; David Goldstein, Prince of Wales 
Hospital;  Peter Grimison, Chris O’Brien Lifehouse; Saurabh Gupta, The Wesley Hospital & 
Princess Alexandra Hospital; George Hruby, University of Sydney & Chris O’Brien Lifehouse; 
Michael Jefford, Peter MacCallum Cancer Centre; Stephen V. Lynch, Mater Private Hospital & 
Princess Alexandra Hospital; Neil Merrett, Bankstown Hospital & University of Western Sydney;  
Jennifer Powell, The Royal Brisbane and Women’s Hospital; David Pryor, Princess Alexandra 
Hospital; Spiro Raftopoulos, Sir Charles Gairdner Hospital; Jaswinder S. Samra, Royal North 
Shore Hospital & Macquarie University Hospital; Kellee Slater, Greenslopes Hospital & Princess 
Alexandra Hospital; Nigel Spry, Sir Charles Gairdner Hospital; Guy Van Hazel, University of 
Western Australia; Jane Whelan, Princess Alexandra Hospital; A. Peter Wysocki, Logan Hospital 
& Griffith University. 
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9.4. APPENDIX C 
9.4.1. Patterns-of-care studies 
Table 9-1: Patterns-of-care studies for patients diagnosed with pancreatic cancer, sorted by region and publication date 
Reference Sample Data source N Aims/outcomes Strengths Limitations 
United States 
Wolfson, 
2015123 
All PC 
 aged 22 – 65 
 1998-2008 
Los Angeles 
Cancer 
Registry 
2,317 
Comparing barriers to 
presentation at NCICCC 
and survival outcomes 
(v. not) 
Clear methods. Standardised 
comprehensive data collection. 
Minimal treatment data. Only used patients < 65years of 
age. No comorbidity adjustment. 
Vijayvergiia, 
2015198 
Metastatic PC 
2000-2010 
Fox chase 
centre, PA 
579 
Comparing POC for 
patients < 65 years 
with those 65+ years 
Single centre cohort. Retrospective chart review. 
Abraham, 
201310 
All PC 
1994-2008 
California 
Cancer 
Registry 
20,312 
Investigate socio-
demographic 
variations in 
resectability, surgery 
and chemotherapy 
receipt. 
Large population-based sample. 
Clear, concise methods and 
completed relevant sensitivity 
analyses.  
Administrative data may cause under-reporting. Unable 
to adjust for performance status or comorbidities. Only 
first-line treatment data. No residential location or 
hospital volume analyses. Excluded patients with 
unknown surgery, chemotherapy or stage. 
Oberstein, 
2013210 
Distant disease 
Stage IV PC, 
≥ 65 years old 
1998-2005 
SEER, 
Medicare 
3,094 
Gemcitabine use for 
metastatic disease  
Population-based. Adjusted for 
some patient factors. 
SEER only covers ~ 20% of population during these years. 
22% excluded due to death within 30 days of diagnosis. 
No performance status recorded. No patterns of use for 
other chemotherapy agents. 
DaCosta, 
2013196 
PC in managed care 
2001-2010 
Private 
database 
5,262 
Costs, treatment 
patterns 
Matched to 15786 controls = 
large sample size. 
Selection-bias, private administrative data. Not 
population-based. 
Singal, 2012211 
Non-metastatic PC, 
1998–2008, 
9 States of 
United States, 
SEER registry 
16,282 
Comparing racial 
differences and 
survival. 
Large sample size. 
SEER only 26% of United States population, over 
represents minority groups therefore not true 
population. Lots of missing information including 
performance status, comorbidities and chemotherapy 
treatment details.  
Seyedin, 
201211 
Non- metastatic PC 
1998-2002 
SEER data 5,908 
Investigate the impact 
of SES on resection 
rates 
Large sample size. 
SES calculated using only income as a measure. Low 
income group only 3.6% of sample. 
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Reference Sample Data source N Aims/outcomes Strengths Limitations 
Gong, 
201133 
All PC, 
 San Francisco 
1995-1999 
SEER, 
California 
Cancer Centre 
1,954 
Population-based 
survival 
Comprehensive data, thorough 
follow-up. 
Small sample size. Majority was administrative data only. 
42% of initial treatment patterns unknown.  
Davilla, 
2009212 
Older than 65 years 
with surgical 
resection for PC 
1992-2002 
SEER - 
Medicare data 1,383 
Surgery and adjuvant 
therapy patterns of 
care. 
All patients had histological 
diagnosis. 
All records had linked medicare 
records so treatments should 
be recorded. 
Identified using administrative data and coding records. 
No resection margin status or performance status. Small 
sample - excluded a lot of patients (eg missing hospital 
data and 30-day post-surgery death) Administrative data 
so under-reporting may occur (8% not covered). 
Shavers, 
2009213 
All PC 
1998 
SEER and 
POC/QOC 
project 
697 Racial/ethnic POC 
Stratified groups. Had details of 
treatment refusal. 
Only a sample of patients included from strata (more 
African Americans and Hispancis). No adjustment for 
facility or type of treatment centre. Old data. 
Cress 
200889 
All PC 
1994-2000 
California 
Cancer 
Registry 
10,612 
Survival by socio-
demographic and 
treatment 
characteristics 
Population-based. 
Large sample size. 
Only basic demographics and tumour characteristics 
through chart review, data linkage for the rest and may 
be under-represented, no completion records. No 
performance status. 
Bilimoria, 
200713 
All PC 
1985-2003 
NCDB 
301,033 
Treatment trends 
(1985 – 1994 vs.  
1995 – 2003) 
Large sample size. Examines 
trends over time and also 
receipt of treatment by hospital 
type. 
Unable to adjust for specific comorbidities or 
performance status. May have selection bias from 
registry and facilities of NCDB - only  captures ~75% of 
population. 
Administrative data, no medical record review – may 
cause under-reporting. 
Eloubeidi, 
2006195 
All PC 
1996-2000 
Alabama 
Cancer 
Registry 
2,230 
Survival prognostic 
factors. 
11% incomplete registry data. 8% did not have 
adenocarcinoma. 
Wasif, 2006315 Non-metastatic PC NCDB 10,674 
Investigate survival by 
distance travelled to 
treatment 
Large sample size. Adjusted for 
comorbidities. Used propensity 
scoring to remove some 
treatment receipt bias. 
Did not adjust for performance status - poorer status less 
likely to travel. Not truly population-based. NCDB only 
captures 70% of patients. 
Krzyzanowska, 
2003214 
Locally advanced 
PC 
1991-1996 
SEER and 
Medicare 
1,696 
Treatment patterns for 
patients with locally 
advanced disease. 
Pathologically confirmed 
pancreatic cancer. Propensity 
scoring used to assess 
effectiveness of treatment to 
alleviate selection bias. 
Data linkage retrospective data. SEER data covers only ¬ 
14% population. Medicare ¬95% population. Linkage has 
94% match rate. Admin data = No performance status, 
limited health service data. 
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Reference Sample Data source N Aims/outcomes Strengths Limitations 
Sener, 1999215 
All PC 
1985-1995 
NCDB 100,313 
Trends in stage, 
patterns and outcomes 
Data collection was 
standardised. Large sample. 
Survey completion 
Only patients that presented to NCDB hospitals – 60% of 
population.  
Janes, 
1996197 
All PC 
1983-1985 and 
1990 
Survey to 
institutions 
16,942 
Time trend for 
methods of diagnosis, 
staging, treatment and 
outcome 
Large sample size Retrospective descriptive data. Voluntary completion of 
surveys. Unreliable completion of survey data. 
Wade, 1996199 
Surgical resection 
PC 
1989-1994 
Dept. of 
Defence 
Hospitals 
698 
Treatment of 
pancreatic cancer and 
Whipples 
Standardised records. 
Includes all pancreatic cancers, and all types of surgical 
procedure. Old data. Low level statistics, no patient 
factor adjustments.  
Canada 
Kagedan, 
2016216 
All PC 
Ontario, Canada 
2005-2010 
Cancer 
registry with 
data linkage 
6,296 
Investigate factors 
influencing the receipt 
of surgery 
Large geographical area. 
Comprehensive surgical 
pathology reports. 
Retrospective administrative data. No performance 
status. Incomplete staging information. Excluded 
patients dying within 6 months surgery for adjuvant 
treatment analyses. 
Europe and Scandinavia 
Soreide, J 
2016194 
Surgical resection 
PC 
Stavanger, Norway 
1986-2012 
Registry 
Pancreatic 
surgery 
219 
Indications, outcomes 
of surgery over time 
Complete patient population 
for hospital. 
Small sample size. Only includes data from 1 hospital. All 
types of pancreatic surgery (eg trauma, IPMN etc) 
Haj 
Mohammad, 
2016131 
Metastatic PC 
2007-2011 
Netherlands 
Cancer 
Registry 
5,385 
Volume of 
chemotherapy 
treatment facility with 
survival. 
Population-based. Varying 
methods of categorising 
treatment facility. 
May have selection bias – fitter patients presenting to 
higher volume centres. No performance status recorded 
which may be better indicator of survival. 
Jooste, 
2016217 
All PC 
2009-2011 
2 Cancer 
Registry areas 
of France 
554 
Wait times from 
presentation to 
treatment and survival 
Complete population-based. 
Accurate, reliable standardised 
data from registries. 
Waiting times unknown for many patients. 
Bernards, 
2015221 
Metastatic PC 
1993-2010 
South 
Netherlands 
Registry 
3,099 
Trends in 
chemotherapy and 
survival 
Population-based 
No performance status recorded – surrogate factor for 
chemotherapy and survival. 
Sharp, 200912 
All PC 
1994-2003 
Ireland Cancer 
Registry Data 
3,173 
Patterns of care.  
Shows treatment 
trends with 
gemcitabine licensed in 
Ireland in 1998. 
Includes all patients, truly 
population-based. Propensity 
score matching for survival and 
treatment receipt removed 
some bias.  
Unknown how data was collected –registry notified and 
does mention chart review in discussion but not in 
methods. 
A large number of unknown stage (37%) 
No performance status or comorbidities recorded. 
196 
Reference Sample Data source N Aims/outcomes Strengths Limitations 
David, M 
200962 
All PC 
Burgundy, France 
1976-2005 
Digestive 
Cancer 
Registry 
Burgundy 
2,986 
Patterns of care and 
survival over time. 
Provided a description of 
patterns of care over a 30 year 
period. 
Limited methods description. Administrative data with 
no quality control. Only one area of France – not full 
population. Included neuro-endocrine tumours. 
Bramhall, 
1995193 
All PC 
West Midlands 
1957-1986 
West 
Midlands 
Health Region 
13,560 
Patterns of care and 
survival over time 
Large sample size with all 
pancreatic adenocarcinomas  
registered. 
Not histologically confirmed (~ 40%) – could include 
other incorrect diagnoses. Incomplete retrospective 
data.   
Australia 
Queensland 
Health, 
2015192 
All PC 
2009-2011 
Queensland 
Cancer Registry 
664 
Queensland oncology 
population based 
report pancreatic 
surgery 
Population-based. All private 
and public inpatient records. 
Linked to cancer registry. 
Coded and administrative data. No staging details. 
Included small intestine and biliary tract cancer. 
Jefford, 
2010,18 Speer, 
2012107 
All PC 
2002-2003 
Victoria 
Cancer 
Registry, 
clinical survey 
765 Patterns of care Population-based. 
Small sample size. ¬17% missing data.  Measurement 
bias of survey. Limited staging details. Only descriptive 
statistics reported. Selection bias due to lack of 
information for the very ill patients.  
Luke, 
2009316 
All PC 
1997-2006 
South 
Australian 
Cancer 
Registry, 
4,166 
Socio-demographic 
determinants of 
survival 
Non adenocarcinomas were 
analysed separately. 
Population-based. 
No treatment details or performance status, unable to 
adjust survival estimates. 
PC: Pancreatic cancer; NCICCC: National Cancer Institute Cancer Care Centre; NCDB: National Cancer Database; SEER: Surveillance, Epidemiology and End Results program;  POC: Patterns of care; 
QOC: quality of care  IPMN: Intraductal papillary mucinous neoplasm; SES: Socio-economic status 
9.5. APPENDIX D 
9.5.1. Case Report Form 
This form was based on a previous patterns-of-care study CRF18 and went through a series of 
modifications. 
Some issues were found with the data collection form; for example: 
 Q11 staging required careful completion. Q11b was completed following all investigations
prior to any treatment and the TNM staging was completed following all pathology
(including surgery). The placement of Q11b preceding Q11a might have enhanced the flow
of the data collection.
 Comorbidities were not coded according to severity and would have been more easily
computed to a Charlson comorbidity index score if they had been collected and coded with
the scoring method/reporting considered a priori.
 Initial treatment intent was difficult to establish with consistency, particularly for those
patients receiving neoadjuvant treatment and locally advanced disease.
 A definition of hepatobiliary surgeon posed some queries as there were no formal
qualifications required for this classification at the time of the study.
 No details of who attended the MDT were collected therefore it was unknown if the MDTs
were formal or informal.
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HOSPITAL CODE WHERE FORM COMMENCED: 
SURVEY FORM: Complete, form finalised 
Incomplete --------->  Additional Sites to be visited 
Tick when complete 
Form finalised 
CXT FORM: Complete, form finalised 
 N/A Incomplete --------->  Additional Sites to be visited 
Tick when complete 
 Form finalised 
RXT FORM: Complete, form finalised 
 N/A Incomplete --------->  Additional Sites to be visited 
Tick when complete 
      Form finalised 
SURVEY FORM ONLY, NO SUBSEQUENT PRESENTATION FORMS COMPLETED 
CHART NOT FOUND 
Date Chart Commenced  
Date Chart Completed Completed By 
TRACKING LOG FORM 
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1. Date of 1st Diagnosis based on imaging:
1a. Date of histological/cytological diagnosis:  N/A 
2a.  What was the final diagnosis? 
Primary pancreatic cancer, complete this review form (if NOS or exocrine malignant tumour type) 
 Ampullary cancer
    IPMN
    Cancer of other organ →      bile duct/cholangiocarcinoma  duodenum      
 stomach  other___________________
 Metastatic pancreatic cancer, name primary site ______________________________________________________ 
 Acute pancreatitis 
 Chronic pancreatitis 
 Other, please specify__________________________________________________________ 
 unknown 
2b.  Which specialist was the patient initially referred to? 
2c.  What was the date of the first Palliative Care consultation? 
 2c.1. What was the date of first referral to palliative care outreach? 
2c.2. Were there letters on file from palliative care services or GPs? 
GP or PC Date on letter 
SECTION 1 :  INITIAL PRESENTATION, INVESTIGATIONS AND STAGING 
Gastroenterologist 
General Surgeon 
Specialist HPB Surgeon 
Upper GI Surgeon 
Radiation Oncologist 
Medical Oncologist 
Interventional Radiologist 
Palliative Care Physician 
Other, please specify _____________________________________________________________________________ 
Not stated 
NS N/A 
NS N/A 
com
plete questio
1, 1a, 2a, 3
-5
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2d.  Where did the patient see the first specialist? 
3. Was histology performed? (please record for ALL cancers) 
→specify type    Biopsy 
 Resection 
 
 
4. Was cytology performed? (please record for ALL cancers) 
                         ----→ specify type EUS guided FNA 
  External U/S  
  CT FNA 
    ERCP brushings 
  Not stated
5. What was the histological / cytological diagnosis?
EXOCRINE PANCREAS
Malignant -----→ specify type 
Public hospital 
Private hospital 
Private specialist rooms (in or not in hospital setting) 
Hospital Code 
N Y SPECIFY SITES: primary tumour 
metastases 
lymph nodes 
liver 
peritoneal 
chest 
other, please specify_______________________ 
not stated 
N Y SPECIFY SITES: 
primary tumour 
metastases 
lymph nodes 
liver 
peritoneal 
chest 
other, please specify_______________________ 
not stated 
Ductal adenocarcinoma , NOS 
Mucinous noncystic carcinoma 
Signet ring cell carcinoma 
Adenosquamous carcinoma 
Undifferentiated (anaplastic) carcinoma 
Undifferentiated carcinoma with osteoclast-like giant cells 
Mixed ductal-endocrine carcinoma 
Serous cystadenocarcinoma 
Mucinous cystadenocarcinoma, specify type 
Invasive 
 Non-invasive 
Intraductal papillary-mucinous carcinoma, specify type 
Invasive 
Non-invasive 
Acinar cell carcinoma, specify type 
Acinar cell cystadenocarcinoma 
 Mixed acinar-endocrine carcinoma 
Pancreatoblastoma 
Solid-pseudopapillary carcinoma 
not stated 
4b.   Was cytology diagnostic? 
N Y 
3b.      Was histology diagnostic? 
N Y 
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Benign → specify type 
Borderline  → specify type 
ENDOCRINE PANCREAS 
 Well-differentiated tumour  →specify type 
 Well-differentiated carcinoma  →specify type 
Poorly-differentiated endocrine carcinoma-small cell carcinoma 
OTHER 
Lymphoma            Other (please specify) 
Not stated 
No diagnostic histology / cytology performed  
6. What was the site of the tumour? (tick multiple sites if overlapping) 
Mucinous cystic neoplasm with moderate dysplasia 
Intraductal papillary-mucinous neoplasm with moderate dysplasia 
Solid-pseudopapillary neoplasm 
benign, NOS 
mature teratoma 
cystadenoma, specify type 
serous 
 mucinous 
Intraductal papillary-mucinous adenoma, specify type 
branch duct 
main duct 
Functioning, specify type 
Insulin-producting (insuloma) 
Glucagon-producting (glucagonoma) 
Somatostatin-producing (somatostatinoma) 
Gastrin-producing (gastrinoma) 
VIP – producing (VIPoma) 
Non-functioning, specify type 
Microadenoma (<0.5cm) 
others 
Functioning, specify type 
Insulin-producting (insuloma) 
Glucagon-producting (glucagonoma) 
Somatostatin-producing (somatostatinoma) 
Gastrin-producing (gastrinoma) 
VIP – producing (VIPoma) 
Serotonin producing with carcinoid syndrome 
ACTH producting with Cushing syndrome 
Non-functioning 
Uncinate process 
Head 
Neck 
Body 
Tail 
Ampulla of Vater 
Common bile duct (cholangiocarcinoma) 
Not stated 
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7. What was the indication that led to diagnosis?
Incidental finding → condition being Ix?  
Clinical investigation for possible symptoms of pancreatic cancer 
8. What were the patient’s symptoms at the time of diagnosis?
9. What diagnostic investigations were performed prior to treatment?
Test Date 1st 
done 
1st Ordered by 
GP Hosp/spec 
CA19.9     
 Xray – plain abdo     
Xray – plain chest     
Endoscopy     
Colonoscopy     
US – abdo     
CT  – plain abdo     
CT scan – pancreas protocol     
CT – IV cholangio     
MRI     
MRCP     
ERCP – Diagnostic     
EUS  (No FNA)     
EUS guided FNA     
PET     
Angiography     
Laparoscopy     
Laparotomy     
Core Bx/CT FNA cytology     
Other, specify     
  
Asymptomatic 
Jaundice  
Back pain 
Abdominal pain 
Vomiting and/or nausea 
Altered bowel habit 
Weight loss 
Anorexia 
Fatigue, lethargy, tiredness 
Ascites 
Cholangitis 
Gastric outlet obstruction 
Acute pancreatitis 
Glucose intolerance 
Other, please specify ________________________________________________________________ 
Not stated 
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10. What was the patient’s ECOG performance status at time of diagnosis?
0 =  fully active ECOG written in chart 
1 =  limited activity 
2 =  in bed < 50% of the day 
3 =  in bed > 50% of the day 
4 =  bed bound 
Not stated 
11a.  What was the TNM stage of this tumour? 
TNM score not stated / cannot be imputed from the records 
11b. Was the tumour considered to be:  (based on imaging or exploratory lap.) 
 resectable   -→      confined to pancreas  non resectable -→  metastatic 
 locally advanced  locally advanced 
12.  Were any comorbidities present prior to diagnosis?                                           ---→ specify all that apply N Y 
Diabetes:  NIDDM  → date of dx  ___ / ___ / _______  and/or IDDM→ date of dx  ___ / ___ / _______
Ischemic Heart Disease → date of dx  ___ / ___ / _______ 
CVA → date of dx  ___ / ___ / _______
COAD, lung disease → date of dx  ___ / ___ / _______
Renal/Kidney disease → date of dx  ___ / ___ / _______
HIV→ date of dx  ___ / ___ / _______
Depression → date of dx  ___ / ___ / _______ 
Other cancer: site,  _________→ date of dx  ___ / ___ / ______ site,  _________→ date of dx  ___ / ___ / _______
Hypertension  
Obesity 
Dementia, confusion 
GORD (reflux) → date of dx  ___ / ___ / _______ 
Other, please specify___________________________________________________________________________ 
Not stated 
NS 
TX     primary tumour cannot be assessed 
TO     no evidence of primary tumour 
Tis     carcinoma in situ 
T1     tumour limited to pancreas, 2cm or less in greatest dimension 
T2     tumour limited to pancreas, more than 2cm in greatest dimension 
T3     tumour extends beyond the pancreas but without involvement of the celiac trunk or superior mesenteric artery 
T4     tumour involves the celiac axis or superior mesenteric artery (unresectable primary tumour) 
NX     regional lymph nodes cannot be assessed 
NO     no regional lymph node metastases 
N1     regional lymph node metastases 
MX     distant metastases cannot be assessed 
MO     no distant metastases 
M1     distant metastases 
11a.2. Was there perineural invasion? 
 Yes 
 No 
 Not stated 
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12b. Was there a past history of pancreatic pathology? 
  Chronic pancreatitis 
 Acute pancreatitis 
 IPMN 
 Other 
If yes, when was it first diagnosed? ____ / ____ / _________ 
12c. What was the patient’s smoking status at the time of diagnosis? 
Never smoker Past smoker  Current smoker Unknown 
12d. Was there a family history of cancer?  
 If yes list family member and site of cancer, 
N Y 
N Y 
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13.  What was the initial treatment intent for this patient? 
           curative 
         palliative  
          not stated 
          patient refused treatment  Surgery     Chemotherapy/radiotherapy 
14.  Was curative surgery for resection attempted? 
                                -----→ please specify reason: 
              Go to Qu 18 
                  -----→ please specify type: 
        -----→ date of surgery                                  or   
 
Place of surgery: (hospital code)   
Surgeon:      (surgeon code) 
Hepatobiliary surgeon 
14b. What was the date of the most recent staging?  
                                                                          
14b.1. Did the most recent staging occur in the same hospital as the surgery? 
 
 
SECTION 2 :  TREATMENT  PHASE 
  Whipple procedure --→    □  pylorus preserved 
    □  feeding jejunostomy 
    □  surgery aborted 
  Total pancreatectomy --→ □  pylorus preserved 
     □  feeding jejunostomy 
    □  surgery aborted 
  Distal pancreatectomy --→ □  surgery completed 
    □  surgery aborted 
  Not stated  
N 
  Peritoneal metastases  
  Liver metastases 
  Locally advanced disease 
  Advanced age 
  Comorbidities 
  Patient declined surgery 
  Deceased prior to scheduled surgery 
  Other, please specify___________________________________________ 
  Not stated 
 
Y 
NS 
N Y NS 
N Y NS 
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15. Did surgical intent change intra-operatively?
         ----→ please specify reason 
16. What margins were achieved with surgery?  Write in clearance margin if available 
 clear < 1mm 
 clear 1 to less than 2mm 
clear 2 to 5mm 
 clear >5mm 
 involved margins 
 clear margins, distance not stated 
 not stated  
17. Was frozen section done during surgery?
18. Did the patient undergo bypass surgery?
          -----→ date of surgery 
 -----→ please specify type  
19a.     Which of the following complications arose (within 30 days) from surgical resection? 
Tick all that apply 
anastamotic leak fistula 
persisting jaundice pulmonary infection 
wound infection not applicable 
intra-abdominal sepsis none 
gastric outlet obstruction other, please specify________________________ 
haemorrhage  not stated 
delayed gastric emptying 
N Y Metastases present   
 Biopsied    Yes     No     Not stated 
Locally advanced disease ----->  specify extent 
 Portal Vein invasion 
   Arterial invasion 
Intra-operative complication 
Other, please specify_____________________________ 
Not stated 
   
N Y NS 
N Y
Cholecystojejunostomy 
Choledochojejunostomy (Rouex en Y) 
Gastrojejunostomy 
Hepaticojejunostomy 
Other, please specify ______________________________ 
Not stated 
NS 
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19b.     Which of the following complications arose (within 30 days) from bypass surgery? 
Tick all that apply 
anastamotic leak fistula 
persisting jaundice pulmonary infection 
wound infection not applicable 
intra-abdominal sepsis none 
gastric outlet obstruction other, please specify________________________ 
haemorrhage  not stated 
delayed gastric emptying 
19c.    If the patient underwent curative OR palliative surgery, record the PRE-operative 
 WBC (x109/L)  ___________ Date___________    Albumin Level (g/L) ___________ Date__________ 
20. Did the patient undergo biliary stenting?
  -----→go to Q 22       -----→ please specify   
21. Which of the following complications arose (within 30 days) from stent insertion?
STENT 1 
Date of insertion 
__ / __ / ____ 
Reason for insertion 
Primary insertion 
blocked/obstructed  
routine replacement  
conversion to metal  
infection  
not stated 
Method of insertion 
Endoscopic Management 
 Endoscopic Stent 
 plastic 
 metal 
 not stated 
 Interventional radiology 
   Percutaneous Stent 
 plastic 
 metal 
 not stated 
Not stated 
STENT 3 
Date of insertion 
__ / __ / ____ 
Reason for insertion 
Primary insertion 
blocked/obstructed  
routine replacement  
conversion to metal  
infection  
not stated 
Method of insertion 
Endoscopic Management 
 Endoscopic Stent 
 plastic 
 metal 
 not stated 
 Interventional radiology 
   Percutaneous Stent 
 plastic 
 metal 
 not stated 
Not stated 
STENT 2 
Date of insertion 
__ / __ / ____ 
Reason for insertion 
Primary insertion 
blocked/obstructed  
routine replacement  
conversion to metal  
infection  
not stated 
Method of insertion 
Endoscopic Management 
 Endoscopic Stent 
 plastic 
 metal 
 not stated 
 Interventional radiology 
   Percutaneous Stent 
 plastic 
 metal 
 not stated 
Not stated 
N Y NS
STENT 3 
pancreatitis 
cholangitis 
persisting jaundice 
bile leak 
haemorrhage 
other, please specify  
____________________ 
none 
not stated 
STENT 2 
pancreatitis 
cholangitis 
persisting jaundice 
bile leak 
haemorrhage 
other, please specify  
____________________ 
none 
not stated 
STENT 1 
pancreatitis 
cholangitis 
persisting jaundice 
bile leak 
haemorrhage 
other, please specify  
____________________ 
none 
not stated 
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22. Did the patient have a duodenal obstruction?
     -----→go to Qu 24               -----→ please specify 
23. Were there any complications following duodenal stent insertion?
24. Was the patient enrolled in a clinical trial for ca pancreas?
no, no mention of a trial in the chart 
no, trial considered but patient not eligible 
no, trial discussed but declined by patient (name of trial)___________________________________________________ 
yes (name of trial)_____________________________________________________________________________________________ 
N NS Y 
Episode 1 
Reason for obstruction: 
tumour growth 
radiation complication 
not stated 
Treatment received: 
No treatment 
Duodenal stent inserted 
Date of insertion 
___ / ___ / _______ 
Bypass -->  specify type 
 laparoscopic 
 surgery 
 not stated 
Date of bypass 
___ / ___ / _______ 
Not stated 
Episode 3 
Reason for obstruction: 
tumour growth 
radiation complication 
not stated 
Treatment received: 
No treatment 
Duodenal stent inserted 
Date of insertion 
___ / ___ / _______ 
Bypass -->  specify type 
 laparoscopic 
 surgery 
 not stated 
Date of bypass 
___ / ___ / _______ 
Not stated 
Episode 2 
Reason for obstruction: 
tumour growth 
radiation complication 
not stated 
Treatment received: 
No treatment 
Duodenal stent inserted 
Date of insertion 
___ / ___ / _______ 
Bypass -->  specify type 
 laparoscopic 
 surgery 
 not stated 
Date of bypass 
___ / ___ / _______ 
Not stated 
Episode 1 
                              --→ describe 
________________________________ 
________________________________ 
Episode 2 
                              --→ describe 
________________________________ 
________________________________ 
Episode 3 
                              --→ describe 
________________________________ 
________________________________ 
N NS Y N NS Y N NS Y 
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25. Did the patient see a MEDICAL oncologist?
      -----→ please specify reason 
     -----→  was the patient offered adjuvant/curative CXT?    →complete box below 
-----→  was the patient offered palliative CXT?    -----→complete box below 
26. Did the patient see a RADIATION oncologist?
      -----→ please specify reason 
     -----→  was the patient offered adjuvant/curative RXT?    →complete box below 
-----→  was the patient offered palliative RXT?    -----→complete box below 
NS 
Y 
Not indicated 
Patient declined 
Too unwell 
Deceased prior to review 
Other, please specify ____________________________________________ 
Treated with adjuvant/curative chemotherapy, please complete CXT form 
Treated with combined adjuvant/curative chemo/radiotherapy, please complete CXT and RXT forms 
Patient declined treatment 
Too unwell to proceed with planned CXT 
Deceased prior to planned CXT commencing 
Other, please specify _____________________________________________________________________________ 
N 
N 
Y 
Y 
N 
Treated with palliative chemotherapy, please complete CXT form 
Treated with combined palliative chemo/radiotherapy, please complete CXT and RXT forms 
Patient declined treatment 
Too unwell to proceed with planned CXT 
Deceased prior to planned CXT commencing 
Other, please specify _____________________________________________________________________________ 
NS 
NS 
what date did the patient first see the med onc? 
NS 
Y 
Not indicated 
Patient declined 
Too unwell 
Deceased prior to review 
Other, please specify ____________________________________________ 
Treated with adjuvant/curative radiotherapy, please complete RXT form 
Treated with combined adjuvant/curative chemo/radiotherapy, please complete CXT and RXT forms 
Patient declined treatment 
Too unwell to proceed with planned RXT 
Deceased prior to planned RXT commencing 
Other, please specify _____________________________________________________________________________ 
N 
N 
Y 
Y 
N 
Treated with palliative radiotherapy, please complete RXT form 
Treated with combined palliative chemo/radiotherapy, please complete CXT and RXT forms 
Patient declined treatment 
Too unwell to proceed with planned RXT 
Deceased prior to planned RXT commencing 
Other, please specify _____________________________________________________________________________ 
NS 
NS 
what date did the patient first see the RAD onc? 
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27a. Was this patient presented at a multidisciplinary team meeting? 
-----→go to Qu 28 -------- -----→go to Qu 27b 
27b. Who referred this patient to the MDT meeting? 
27c. When was the patient first presented to the MDT meeting? 
___ /___/ ____ other dates if multiple presentations ___ /___/ ____ and ___ /___/ ____ or 
The following questions relate to review by allied health professionals 
28a. Was the patient referred to a dietitian? 
    Seen as an inpatient / outpatient 
      Community referral 
28b. Did the patient have evidence of a navigator / care plan? 
    Seen as an inpatient / outpatient 
      Community referral 
28c. Was the patient referred to a psychologist or counsellor? 
 Seen as an inpatient / outpatient 
      Community referral 
28c. Was the patient referred to a social worker? 
  Seen as an inpatient / outpatient 
 Community referral 
28d. Was there evidence that this patient was prescribed pancreatic enzymes (CREON)? 
N NS Y 
Gastroenterologist 
General Surgeon 
Specialist HPB surgeon 
Radiation Oncologist 
Medical Oncologist 
Interventional Radiologist 
Palliative Care Physician 
Other, please specify _____________________________________________________________________________ 
Not stated 
NS 
 
N NS Y 
 
N NS Y 
 
N NS Y 
N NS Y 
Y N 
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28e.     Did the patient have one or more celiac plexus blocks for pain management? 
If yes, please record dates of blocks 
1. ___ /___/ ____
2. ___ /___/ ____
3. ___ /___/ ____
4. ___ /___/ ____
5. ___ /___/ ____
29a.     What was the patient’s status 12 months after diagnosis? 
Alive Deceased Not stated 
 If ALIVE:     What was the disease status? 
 Where was the patient living? 
No sign of recurrence 
Local disease 
Locally advanced disease 
Metastatic disease 
Both local and distant disease 
Disease status unknown 
Independent at home 
Living in hospice 
Inpatient in hospital 
Living in Palliative Care Facility 
Other, please specify _____________________________________________________________ 
Not stated 
Y N 
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29b. What was the patient’s status 6 months after diagnosis? 
Alive Deceased Not stated 
 If ALIVE:     What was the disease status? 
 Where was the patient living? 
29c. If DECEASED: What was the date of death? 
 What was the primary cause of death? 
 What was the place of death? 
No sign of recurrence 
Local disease 
Locally advanced disease 
Metastatic disease 
Both local and distant disease 
Disease status unknown 
Independent at home 
Living in hospice 
Inpatient in hospital 
Living in Palliative Care Facility 
Other, please specify _____________________________________________________________ 
Not stated 
Complications of surgery for cancer 
Complications of other treatment for cancer 
Cancer 
Other please specify _____________________________________________________________ 
Not stated 
Home 
Hospice 
Inpatient in hospital 
Other please specify_____________________________________________________________ 
Not stated 
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30. Did the patient suffer a recurrence / progression after surgery? 
 
 
   Date of recurrence / progression diagnosis (dd/mm/yyyy) 
 31.a.     What treatment did the patient receive for recurrence? 
SECTION 3 :  RECURRENCE / PROGRESSION (after curative surgery) 
N 
Y 
NS N/A 
  None 
  Surgical Resection 
  Palliative radiotherapy 
  Palliative chemotherapy 
  Palliative chemotherapy and radiotherapy 
  Palliative bypass surgery 
  Stent placement---->  specify type   Biliary           Duodenal 
  Pain management ---->  specify type 
         splanchnic nerve block         EUS         CT 
         coeliac plexus nerve block    EUS         CT  
         splanchnectomy                   
     opiod analgesia 
         non-opioid analgesia 
               tramadol 
               anti-inflammatory 
               other, please specify ______________________________________________________________________ 
  Anti-epileptics 
  Therapeutic ascetic tap 
  Blood Transfusion 
  Treatment of cachexia     TPN        drug therapy, name ________________________________________________ 
  Other please specify _________________________________________________________________________________ 
  Not stated 
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Presentation Number 
1. Date of admission:
(dd/mm/yyyy) 
2. Date of discharge:
(dd/mm/yyyy) 
3. Hospital code:
4. Who referred this patient for admission?
5. Which Specialist primarily managed the patient during the admission?
6. Which other Specialist/Allied Health Therapist was consulted during the admission?
SECTION 4:  INPATIENT PRESENTATIONS 
Patient self – referral 
GP 
Transfer from another hospital, hospital code 
Gastroenterologist 
General Surgeon 
Specialist HPB surgeon 
Radiation Oncologist 
Medical Oncologist 
Interventional Radiologist 
Palliative Care Physician 
Other, please specify ____________________________________________________________________________ 
Not stated 
Gastroenterologist 
General Surgeon 
Specialist HPB surgeon 
Radiation Oncologist 
Medical Oncologist 
Interventional Radiologist 
Palliative Care Physician 
Other, please specify _____________________________________________________________________________ 
Not stated 
Gastroenterologist 
General Surgeon 
Specialist HPB surgeon 
Radiation Oncologist 
Medical Oncologist 
Interventional Radiologist 
Palliative Care Physician 
Pain Management Team 
Endocrinologist 
Cardiologist 
Psychiatrist 
Dietician 
Physiotherapist 
Other, please specify ____________________________________________________________________________ 
None 
Admission unrelated to pancreatic cancer 
   (Don’t complete form) 
Primary reason for admission: 
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7a.   What was the PRIMARY reason  
 for this admission?  (tick one)  
9. What was the patient’s ECOG performance status at admission?
0 =  fully active 
1 =  limited activity 
2 =  in bed < 50% of the day 
3 =  in bed > 50% of the day 
4 =  bed bound 
Not stated 
10. What investigations were undertaken during this admission? (tick all that apply, including those not 
able to be completed due to complications) 
Asymptomatic 
Jaundice 
Back pain 
Abdominal pain 
Vomiting and/or nausea 
Altered bowel habits 
Weight loss 
Anorexia 
Cachexia 
Ascites 
Cholangitis 
Gastric outlet obstruction 
Acute pancreatitis 
Glucose intolerance 
Fatigue, lethargy, tiredness 
Other, please specify 
_________________________________ 
Surgical resection (curative pancreatectomy) 
Other surgery ______________________ 
Complications of surgery 
Biliary Stent insertion 
Duodenal Obstruction 
Pain management 
Jaundice 
Ascites 
Chemotherapy 
Complications of chemotherapy 
Further staging work up 
Recurrence 
Palliative admission 
Terminal care 
Other, please specify 
________________________________ 
Not stated 
LFTs 
CEA 
Xray – plain abdominal 
Xray- plain chest 
endoscopy 
US – transabdominal 
CT – was a pancreas specific protocol followed?     N     Y 
CT – intravenous cholangiogram 
PTC - percutaneous transhepatic cholangiogram 
MRI 
MRCP 
ERCP – Diagnostic 
ERCP – Biliary stent placed 
EUS 
PET 
Angiography 
Laparoscopy 
Laparotomy 
Core biopsy/CT guided /EUS FNA cytology/histology of PANCREAS 
Core biopsy/CT guided/EUS FNA cytology/histology of METASTASES 
Other, please specify _____________________________________________________________________________ 
None 
ECOG written in chart 
8a.   What symptoms were present at the 
time of admission? (tick all that apply) 
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11. Did the patient receive treatment during this admission?
     ----→    none recommended 
 Patient declined 
     ----→  (tick all that apply) 
12. What happened at the end of this admission?
Deceased 
Discharged home 
Transferred to another hospital for treatment , hospital code 
Other, please specify__________________________________________________
Not stated 
13. How many days during this admission were spent in HDU / ICU?
N 
Y 
Surgical Resection 
Palliative radiotherapy 
Palliative chemotherapy 
Palliative chemotherapy and radiotherapy 
Palliative bypass surgery 
Stent placement (successful)  ---->  specify type     Biliary  Duodenal 
Attempted (failed) stent placement    ---->  specify type     Biliary     Duodenal 
Pain management ---->  specify type  
 splanchnic nerve block  EUS  CT 
 coeliac plexus nerve block  EUS  CT 
 splanchnectomy      
  opioid analgesia 
 non-opioid analgesia 
 tramadol 
 anti-inflammatory 
 other, please specify ______________________________________________________________________ 
Anti-epileptics 
Therapeutic ascetic tap 
Blood Transfusion 
Treatment of cachexia     TPN        drug therapy, name ________________________________________________ 
Treatment of nausea  ----> Specify drug names___________________________________________________________ 
Other please specify _________________________________________________________________________________ 
Not stated 
 
  
  
  Comments: 
  
 
 
  
 
  
 
  
  
 
9.6. APPENDIX E 
9.6.1. Supplementary tables for Chapter 6 (Survival and determinants of surgery) 
Table 9-2: Association betweeeween patients, tumour and health service factors and attempted resection( adjusted odds ratio) in patients with 
non-metastatic disease (N= 768) 
 
All patients with non-metastatic disease Confined to pancreas disease Locally advanced disease (LAD) 
Exposure Variable Total 
Resection 
 n (%) AOR (95% CI)a Total 
Resection 
n (%) AOR (95% CI)b Total 
Resection 
n (%) AOR (95% CI)b 
Remoteness of residence (ARIA) 
 
  
 
  
 Major City 542 258 (48) 1 156 99 (63) 1 386 159 (41) 1 
Inner Regional 163 74 (45) 0.85 (0.55, 1.32) 44 30 (68) 0.92 (0.29, 2.92) 119   44 (37) 0.81 (0.50, 1.30) 
Remote 76 31 (41) 0.57 (0.30, 1.07) 23 17 (74) 1.09 (0.15, 7.68) 53   14 (26) 0.48 (0.24, 0.99) 
Overall p value, p trend   0.20, 0.08   0.99, 0.99   0.12, 0.05 
Socioeconomic status of residence 
 
  
 
  
   Most disadvantaged (1) 156 73 (47) 1 46 32 (70) 1 110 41 (37) 1 
  2 171 80 (47) 0.81 (0.47, 1.40) 48 31 (65) 0.78 (0.18, 3.42) 123 49 (40) 0.82 (0.45, 1.49) 
  3 158 68 (43) 0.77 (0.43, 1.35) 45 30 (67) 0.39 (0.08, 1.89) 113 38 (34) 0.76 (0.41, 1.41) 
  4 160 77 (48) 0.79 (0.45, 1.39) 53 34 (64) 0.59 (0.14, 2.47) 107 43 (40) 0.86 (0.46, 1.60) 
  Least disadvantaged (5) 136 65 (48) 1.04 (0.58, 1.86) 31 19 (61) 2.50 (0.48, 12.92) 105 46 (44) 1.01 (0.54, 1.88) 
  Overall p value, p trend   0.76, 0.95   0.34, 0.58   0.87, 0.91 
Sex 
   
  
 
  
 Female 364 143 (39) 1 102 60 (59) 1 262 83 (32) 1 
Male 422 222 (53) 1.30 (0.91, 1.85) 123 88 (72) 1.33 (0.52, 3.44) 299 134 (45) 1.33 (0.90, 1.96) 
Overall p value   0.15   0.55   0.15 
Age-groupc 
   
  
 
  
 < 60 141 103 (73) 1 43 43 (100) 
Omittedf 
98 60 (61) 1 
60 - 69 218 135 (62) 0.59 (0.36, 0.98) 55 49 (89) 163 86 (53) 0.67 (0.40, 1.14) 
70 - 79 223 107 (48) 0.37 (0.22, 0.61) 62 49 (79)  161 58 (36) 0.42 (0.24, 0.71) 
80 + 204 20 (10) 0.04 (0.02, 0.07) 65 7 (11)  139    13 (9) 0.09 (0.04, 0.18) 
Overall p value, p trend   < 0.001, < 0.001      < 0.001, < 0.001 
  
 
 
All patients with non-metastatic disease Confined to pancreas disease Locally advanced disease (LAD) 
Exposure Variable Total 
Resection 
 n (%) AOR (95% CI)a Total 
Resection 
n (%) AOR (95% CI)b Total 
Resection 
n (%) AOR (95% CI)b 
Charlson scorec 
   
  
 
  
 0 340 184 (54) 1 88 73 (83) 1 252 111 (44) 1 
1 243 105 (43) 0.76 (0.52, 1.10) 66 43 (65) 0.54 (0.22, 1.31) 177   62 (35) 0.81 (0.54, 1.24) 
2 199 74 (37) 0.57 (0.38, 0.85) 69 31 (45) 0.29 (0.12, 0.70) 130   43 (33) 0.74 (0.46, 1.17) 
Overall p value, p trend   0.02, 0.005   0.02, 0.01   0.38, 0.17 
Performance status on presentation 
 
  
 
  
 Fully active 260 183 (70) 1d 100 91 (91) 1d 160 92 (58) 1d 
Not fully active 420 134 (32) 0.29 (0.19, 0.42) 55 33 (60) 0.05 (0.1, 0.15) 185 73 (39) 0.40 (0.26, 0.61) 
Overall p value   < 0.001   < 0.001   < 0.001 
Clinical staging 768 365 (46)        
   Confined disease   1 225  148 (66)     
   Locally advanced   0.21 (0.14, 0.33)    561 217 (39)  
   Overall p value   < 0.001       
Site tumour 
   
 
  
 
  Head/neck 647 298 (46) 1 184 114 (62) 1 463  184 (40) 1 
Body 40 14 (35) 0.47 (0.21, 1.04) 11      8 (73) 1.98 (0.23, 17.24) 29  6 (21) 0.33 (0.12, 0.86) 
Tail 43 33 (77) 3.64 (1.50, 8.84) 16  16 (100) Omitted 27  17 (63) 2.35 (0.95, 5.80) 
Multiple/other 33 13 (39) 0.53 (0.22, 1.27) 8      7 (88) 0.66 (0.04, 9.82) 25 6 (24) 0.42 (0.15, 1.15) 
Overall p value   0.003   0.79   0.01 
Majority admissions          
Public 535 226 (42) 1 125 79 (63) 1 410 147 (36) 1 
Private 249 139 (56) 1.25 (0.85, 1.83)   99 69 (70) 1.65 (0.62, 4.43) 150   70 (47) 1.29 (0.84, 1.99) 
Overall p value   0.26   0.32   0.24 
Attended MDT 
   
 
  
 
  No / Not stated 518  239 (46) 1 163 107 (66) 1 355  132 (37) 1 
Yes 268   126 (47) 0.67 (0.46, 0.97)  62   41 (66)    0.29 (0.09, 0.93) 206   85 (41) 0.74 (0.50, 1.11) 
Overall p value   0.04   0.04   0.14 
  
 
 
All patients with non-metastatic disease Confined to pancreas disease Locally advanced disease (LAD) 
Exposure Variable Total 
Resection 
 n (%) AOR (95% CI)a Total 
Resection 
n (%) AOR (95% CI)b Total 
Resection 
n (%) AOR (95% CI)b 
First specialist seen        
HPB 145 87 (60) 1 58 48 (83) 1 87 39 (45) 1 
Gastroenterologist 235 123 (52) 1.17 (0.70, 1.93) 62 44 (71) 0.96 (0.26, 3.54) 173 79 (46) 1.34 (0.76, 2.36) 
General Surgeon 292 118 (40) 0.79 (0.48, 1.29) 70 41 (59) 0.29 (0.08, 1.07) 222 77 (35) 0.99 (0.57, 1.71) 
Other 114 37 (32) 0.68 (0.36, 1.28) 35 15 (43) 0.32 (0.06, 1.63) 79 22 (28) 0.81 (0.39, 1.68) 
Overall p value   0.18   0.15   0.38 
Seen at major hospital   (  ≥ 6 resections, yr-1)       
No 579 235 (41) 1 147 84 (57) 1 432 151 (35) 1 
Yes 207 130 (63) 2.11 (1.40, 3.19)   78 64 (82) 4.46 (1.42, 13.94) 129    66 (51) 1.89 (1.20, 2.97) 
Overall p value   < 0.001   0.01   0.01 
Initial facility case-volume        
30 + 411 226 (55) 1 136  100 (74) 1 275 126 (46) 1 
10 – 29 232   97 (42) 0.72 (0.48, 1.07)   62 36 (58) 0.61 (0.19, 1.96) 170   61 (36) 0.74 (0.48, 1.14) 
< 10  132   42 (32) 0.66 (0.39, 1.10)   25 12 (48) 0.33 (0.07, 1.57) 107   30 (28) 0.67 (0.39, 1.16) 
Overall p value, p trend   0.13, 0.05   0.32, 0.13   0.22,0.10 
Notes: Adjustment variables: a age group (<60, 60-69, 70-79, 80+ years); performance status (0, 1, 2+, not stated); and clinical staging (confined to 
pancreas, locally advanced disease); b age group (<60, 60-69, 70-79, 80+ years); performance status (0, 1, 2+, not stated);  c performance status; d age 
group, e not adjusted.  f omitted as all reference category patients had attempted surgery. g includes uncinate process 
Missing (not stated) data: Place of residence, n = 5; SES, n = 5; Charlson, n = 4; Performance status, n = 106; Initial facility volume, n =11; Majority 
of admissions, n = 2. 
Place of residence groups defined by Accessibility/Remoteness Index of Australia (ARIA); Performance status defined by Eastern Cooperative 
Oncology Group (ECOG); SES Socio-Economic Status defined by Socio-Economic Indexes for Areas; First facility volume by the number of study 
participant initial presentations.  
 
  
 
Table 9-3: Unadjusted associations between patient, tumour and health-service factors and (1) attempted resection (n = 786); (2) classification 
of disease resectability (n=561); (3) attempted resection for patients classified as resectable (n = 510) 
  (1) Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectablea 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Crude ORb  (95% CI) 
 
Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb (95% CI) 
Patient / tumour factors            
Age at diagnosis, years            
< 60 141 103 (73) 1.00  98 62 (63) 1.00  105  103 (98) 1.00 
60 - 69 218 135 (62) 0.60 (0.38, 0.95)  163 91 (56) 0.73 (0.44, 1.23)  146  135 (92) 0.24 (0.05, 1.10) 
70 - 79 223 107 (48) 0.34 (0.22, 0.54)  161 76 (47) 0.52 (0.31, 0.87)  138  107 (78) 0.07 (0.02, 0.29) 
 ≥ 80 204 20 (10) 0.04 (0.02, 0.07)  139 56 (40) 0.39 (0.23, 0.67)  121  20 (17) 0.00 (0.00, 0.02) 
 Overall p value, p trend   <0.001, <0.001    0.002, < 0.001    <0.001, <0.001 
Sex            
Men 422 222 (53) 1.00  299 164 (55) 1.00  287  222 (77) 1.00 
Women 364 143 (39) 0.58 (0.44, 0.77)  262 121 (46) 0.71 (0.51, 0.99)  223  143 (64) 0.52 (0.35, 0.77) 
 Overall p value   <0.001    0.04    0.001 
Performance status            
Fully active  260  183 (70) 1.00  160 95 (59) 1.00  195  183 (94) 1.00 
Not fully active  420 134 (32) 0.20 (0.14, 0.28)  325 156 (48) 0.63 (0.43, 0.93)  251  134 (53) 0.08 (0.04, 0.14) 
Overall p value   <0.001    0.02    < 0.001 
Charlson comorbidity index (score)           
Low (0) 340 184 (54) 1.00  252 126 (50) 1.00  214  184 (86) 1.00 
Medium (1) 243 105 (43) 0.65 (0.46, 0.90)  177 91 (51) 1.06 (0.72, 1.55)  157   105 (67) 0.34 (0.20, 0.56) 
High (≥ 2) 199 74 (37) 0.50 (0.35, 0.72)  130 66 (51) 1.03 (0.68, 1.57)  135  74 (55) 0.20 (0.12, 0.34) 
Overall p value, p trend   < 0.001, < 0.001    0.96, 0.85    < 0.001, < 0.001 
Place of residence            
Major city 542 258 (48) 1.00  386 206 (53) 1.00  362  258 (71) 1.00d 
Inner Regional 163 74 (45) 0.92 (0.64, 1.30)  119 50 (50) 0.89 (0.59, 1.34)  104  74 (71) 0.99 (0.61, 1.61) 
Outer regional / remote 76 31 (41) 0.76 (0.47, 1.23)  53 19 (36) 0.49 (0.27, 0.89)    42  31 (74) 1.14 (0.55, 2.34) 
   Overall p value, p trend   0.51, 0.26    0.06, 0.03    0.94, 0.80 
  
 
  (1) Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectablea 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Crude ORb  (95% CI) 
 
Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb (95% CI) 
SES - quintiles 
 
    
 
        
Most disadvantaged 156 73 (47) 1.00  110 55 (50) 1.00  101  73 (72) 1.00 
Second 171 80 (48) 1.00 (0.65, 1.54)  123 65 (53) 1.12 (0.67, 1.88)  113  80 (71) 0.93 (0.51, 1.69) 
Third 158 68 (43) 0.86 (0.55, 1.34)  113 50 (44) 0.79 (0.47, 1.34)    95  68 (72) 0.97 (0.52, 1.80) 
Fourth 160 77 (48) 1.05 (0.68, 1.64)  107 56 (52) 1.10 (0.64, 1.87)  109  77 (71) 0.92 (0.51, 1.68) 
Least disadvantaged 136 65 (48) 1.04 (0.66, 1.65)  105 59 (56) 1.28 (0.75, 2.19)    90  65 (72) 1.00 (0.53, 1.88) 
  Overall p value, p trend   0.90, 0.81    0.48, 0.46    1.00, 0.98 
Tumour site            
Head/neck/uncinate process 647 298 (46) 1.00  463 240 (52) 1.00  424  298 (70) 1.00 
Body 40 14 (35) 0.63 (0.32, 1.23)  29 8 (28) 0.35 (0.15, 0.82)    19    14 (74) 1.18 (0.42, 3.36) 
Tail 43 33 (77) 3.86 (1.87, 7.97)  27 21 (78) 3.25 (1.29, 8.20)    37    32 (89)     3.49 (1.21, 10.05) 
Multiple/other 33 13 (39) 0.76 (0.37, 1.56)  25 8 (32) 0.44 (0.19, 1.03)    16    13 (81) 1.83 (0.51, 6.54) 
  Overall p value   < 0.001    0.001    0.11 
Health Service Factors            
Evidence of MDT review            
No / not stated 518 239 (46) 1.00  355 193 (54) 1.00  356  239 (67) 1.00 
Yes 268 126 (47) 1.04 (0.77, 1.39)  206   92 (45) 0.68 (0.48, 0.96)  154  126 (82) 2.20 (1.38, 3.51) 
  Overall p value   0.82    0.03    0.001 
First facility case-volumeg            
 30 + 411 226 (55) 1.00  275 153 (56) 1.00  289  226 (78) 1.00 
10 – 29 232 97 (42) 0.59 (0.42, 0.81)  170   84 (49) 0.78 (0.53, 1.14)  146    97 (66) 0.55 (0.35, 0.86) 
< 10 132 42 (32) 0.38 (0.25, 0.58)  107   48 (45) 0.65 (0.41, 1.02)    73    42 (58) 0.38 (0.22, 0.65) 
Overall p value, p trend   < 0.001, < 0.001    0.13, 0.05    < 0.001, < 0.001 
Specialist first seen            
Hepatobiliary surgeon 235 87 (60) 1.00  87 44 (51) 1.00  102    87 (85) 1.00 
Gastroenterologist 235 123 (52) 0.73 (0.48, 1.11)  173 97 (56) 1.25 (0.74, 2.09)  159  123 (66) 0.59 (0.30, 1.14) 
General Surgeon 292 118 (40) 0.45 (0.30, 0.68)  222 108 (49) 0.93 (0.56, 1.52)  178  118 (66) 0.34 (0.18, 0.64) 
Other 114 37 (32) 0.32 (0.19, 0.54)  79 36 (46) 0.82 (0.44, 1.51)    71    37 (52) 0.19 (0.09, 0.39) 
  Overall p value   < 0.001    0.36    < 0.001 
Seen by hepato-biliary surgeon           
No / not stated 395 106 (27) 1.00  308 129 (42) 1.00  216 106 (49) 1.00 
Yes 391 259 (66) 5.35 (3.94, 7.26)  253 156 (62) 2.23 (1.59, 3.13)  294 259 (88) 7.68 (4.93, 11.95) 
Overall p value   < 0.001    < 0.001    < 0.001 
  
 
  (1) Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectablea 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Crude ORb  (95% CI) 
 
Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb (95% CI) 
Pancreas protocol computerised tomography          
No / not stated 406 173 (43) 1.00  294 150 (51) 1.00  262 173 (66) 1.00 
Yes 380 192 (51) 1.38 (1.04, 1.82)  267 135 (51) 0.98 (0.70, 1.37)  248 192 (77) 1.76 (1.19, 2.61) 
Overall p value   0.03    0.91    0.005 
Plain computerised tomography           
No / not stated 261 133 (51) 1.00  189 104 (55) 1.00  176 133 (76) 1.00 
Yes 525 232 (44) 0.76 (0.57, 1.03)  372 181 (49) 0.77 (0.55, 1.10)  334 232 (69) 0.74 (0.49, 1.11) 
Overall p value   0.07    0.15    0.15 
Endoscopic ultrasound          
No / not stated 434 186 (43) 1.00  311 168 (54) 1.00  291 186 (64) 1.00 
Yes 352 179 (51) 1.38 (1.04, 1.83)  250 117 (47) 0.75 (0.54, 1.05)  219 179 (82) 2.53 (1.66, 3.84) 
Overall p value   0.03    0.09    <0.001 
Laparoscopy            
No / not stated 648 252 (39) 1.00  455 201 (44) 1.00  394 252 (64) 1.00 
Yes 138 113 (82) 7.10 (4.48, 11.26)  106 84 (79) 4.82 (2.91, 7.99)  116 113 (97) 21.22 (6.62, 68.03) 
Overall p value   < 0.001    < 0.001    < 0.001 
Endoscopic retrograde cholangiopancreatography          
No / not stated 399 190 (48) 1.00  276 134 (49) 1.00  257 190 (74) 1.00 
Yes 387 175 (45) 0.91 (0.69, 1.20)  285 151 (53) 1.19 (0.86, 1.66)  253 175 (69) 0.79 (0.54, 1.16) 
Overall p value   0.50    0.29    0.23 
Magnetic resonance imaging /cholangiopancreatography          
No / not stated 642 285 (44) 1.00  462 236 (51) 1.00  416 285 (69) 1.00 
Yes 144 80 (56) 1.57 (1.09, 2.25)  99 49 (49) 0.94 (0.61, 1.45)  94 80 (85) 2.63 (1.44, 4.81) 
Overall p value   0.02    0.77    0.002 
a Based on clinical staging including imaging or exploratory laparoscopy. 
b Crude odds ratios (ORs,) estimated using logistic regression. 
g Results from a mixed effects model with hospital as random intercept to adjust for hospital clustering. 
Place of residence groups defined by Accessibility/Remoteness Index of Australia (ARIA); Performance status defined by Eastern Cooperative Oncology 
Group (ECOG); SES Socio-Economic Status defined by Socio-Economic Indexes for Areas; First facility volume by the number of study participant initial 
presentations.  
Missing data: SES, n = 5; Place of residence, n = 5; Tumour site, n = 23; Performance status, n = 106; Charlson comorbidity index, n = 4; First inpatient facility 
volume, n = 11. 
  
  
 
Table 9-4: Associations between patient, tumour and health-service factors and (1) place of residence and (2) age, for patients with non-
metastatic disease on clinical staging. 
  Place of residence, n (%)  (n = 781)  Age in years, n (%) (n = 786) 
Exposure variable 
Major  
city 
(n = 542) 
Inner 
regional 
(n = 163) 
Rural 
(n = 76) P valueb 
 
< 60 
(n = 141) 
60 – 69 
(n =218) 
70 – 79 
(n = 223) 
≥ 80 
(n = 204) P valueb 
Patient / Tumour factors           
Age at diagnosis, years    0.44       
< 60 89 (16) 33 (20) 19 (25)   
Not applicable 
 
60 - 69 161 (29) 40 (25) 17 (22)    
70 - 79 158 (29) 45 (28) 20 (26)    
≥ 80 139 (25) 45 (28) 20 (26)    
Sex 
   
0.89      < 0.001 
Men 292 (54) 85 (52) 42 (55) 
 
 85 (60) 139 (64) 110 (49) 88 (43)  
Women 85 (46) 78 (48) 34 (45) 
 
 56 (40) 79 (36) 113 (51) 116 (57)  
ECOG performance status           
0 173 (32) 56 (34) 27 (36) 0.41  67 (48) 95 (44) 64 (29) 34 (17) < 0.001 
1 159 (29) 57 (35) 24 (32)   52 (37) 73 (33) 73 (33) 42 (21)  
2+ 131 (24) 30 (18) 19 (25)   12 (9) 21 (10) 49 (22) 98 (48)  
Not stated 79 (15) 20 (12) 6 (8)   10 (7) 29 (13) 37 (17) 30 (15)  
Charlson comorbidity index (score) 
   
      
Low (0) 244 (45) 63 (39) 30 (40) 0.61  82 (58) 92 (42) 98 (44) 68 (34) 0.002 
Medium (1) 164  (30) 55 (34) 23 (31) 
 
 32 (23) 68 (31) 72 (32) 71 (35)  
High (≥ 2) 132 (24) 44 (27) 22 (29) 
 
 27 (19) 57 (26) 52 (23) 63 (31)  
Place of residence          0.50 
Major city      89 (63) 157 (73) 157 (71) 139 (68)  
Inner Regional Not applicable   33 (23) 40 (19) 45 (20) 45 (22)  
Rural     19 (13) 17 (8) 20 (9) 20 (10)  
Socioeconomic status    < 0.001      0.62 
Most disadvantaged 82 (15) 41 (25) 33 (43)   27 (19) 32 (15) 51 (23) 46 (23)  
Second 84 (16) 72 (44) 15 (20)   34 (24) 44 (21) 50 (23) 43 (21)  
Third 110 (20) 30 (18) 18 (24)   31 (22) 49 (23) 38 (17) 40 (20)  
Fourth 133 (25) 17 (10) 10 (13)   30 (21) 47 (22) 46 (21) 37 (18)  
Least disadvantaged 133 (25) 3 (2) 0   19 (13) 42 (20) 37 (17) 38 (19)  
  
 
  Place of residence, n (%)  (n = 781)  Age in years, n (%) (n = 786) 
Exposure variable 
Major  
city 
(n = 542) 
Inner 
regional 
(n = 163) 
Rural 
(n = 76) P valueb 
 
< 60 
(n = 141) 
60 – 69 
(n =218) 
70 – 79 
(n = 223) 
≥ 80 
(n = 204) P valueb 
Tumour site    0.47      0.85 
Head/neck/uncinate 
process 
452 (85) 135 (88) 57 (78)   115 (83) 182 (85) 180 (83 ) 170 (87)  
Body 27 (5) 7 (5) 6 (8)   8 (6) 9 (4) 14 (6) 9 (5)  
Tail 31 (6) 5 (3) 7 (10)   9 (7) 12 (6) 15 (7) 7 (4)  
Multiple/other 23 (4) 7 (5) 3 (4)   6 (4) 11 (5) 7 (3) 9 (5)  
Clinical Stage    0.85      0.46 
Confined to the pancreas 158 (29) 44 (27) 23 (30)   43 (31) 55 (25) 62 (28) 65 (32)  
Locally advanced disease 389 (71) 119 (73) 53 (70)   98 (69) 163 (75) 161 (72) 139 (68)  
Health System Factors           
Evidence of MDT review 
   
0.13      < 0.001 
No / not stated 351 (65) 105 (64) 58 (76) 
 
 71 (50) 133 (61) 149 (67) 165 (81)  
Yes 191 (35) 58 (36) 18 (24) 
 
 70 (50) 85 (39) 74 (33) 39 (19)  
Specialist first seen 
   
< 0.001      < 0.001 
Hepatobiliary surgeon 121 (22) 22 (14) 2 (3)   24 (17) 60 (28) 42 (19) 19 (9)  
Gastroenterologist 174 (32) 38 (23) 21 (28)   52 (37) 56 (26) 73 (33) 54 (26)  
General Surgeon 170 (31) 86 (53) 33 (43)   52 (37) 77 (35) 78 (35) 85 (42)  
Other 77 (14) 17 (10) 20 (26)   13 (9) 25 (11) 30 (13) 46 (23)  
First inpatient facility volume  < 0.001      < 0.001 
30 + 339 (63) 58 (36) 13 (17)   84 (60) 127 (58) 117 (52) 83 (41)  
10 – 29 139 (26) 54 (34) 36 (48)   35 (25) 68 (31) 67 (30) 62 (30)  
< 10 56 (10) 49 (30) 26 (35)   19 (13) 21 (10) 36 (16) 56 (27)  
Reviewed by hepato-biliary surgeon   0.009      < 0.001 
No / not stated 262 (48) 80 (49) 51 (67)   54 (38) 86 (39) 101 (45) 154 (75)  
Yes 280 (52) 83 (51) 25 (33)   87 (62) 132 (61) 122 (55) 50 (25)  
Chemotherapy    0.32      < 0.001 
No / not stated 259 (48) 83 (51) 43 (57)   36 (26) 56 (26) 119 (53) 176 (86)  
Yes 283 (52) 80 (49) 33 (43)   105 (74) 162 (74) 104 (47) 28 (14)  
Pancreas protocol computerised tomography  0.20      < 0.001 
No / not stated 269 (50) 93 (57) 42 (55)   59 (42) 101 (46) 118 (53) 128 (63)  
Yes 273 (50) 70 (43) 34 (45)   82 (58) 117 (54) 105 (47) 76 (37)  
  
 
  Place of residence, n (%)  (n = 781)  Age in years, n (%) (n = 786) 
Exposure variable 
Major  
city 
(n = 542) 
Inner 
regional 
(n = 163) 
Rural 
(n = 76) P valueb 
 
< 60 
(n = 141) 
60 – 69 
(n =218) 
70 – 79 
(n = 223) 
≥ 80 
(n = 204) P valueb 
Plain computerised tomography   0.01      0.22 
No / not stated 196 (36) 44 (27) 17 (22)   50 (35) 82 (38) 64 (29) 65 (32)  
Yes 346 (64) 119 (73) 59 (78)   91 (65) 136 (62) 159 (71) 139 (68)  
Endoscopic ultrasound    < 0.001      < 0.001 
No / not stated 273 (50) 104 (64) 55 (72)   61 (43) 110 (50) 113 (51) 150 (74)  
Yes 269 (50) 59 (36) 21 (28)   80 (57) 108 (50) 110 (49) 54 (26)  
Laparoscopy    0.11      < 0.001 
No / not stated 439 (81) 135 (83) 69 (91)   107 (76) 174 (80) 168 (75) 199 (98)  
Yes 103 (19)   28 (17)     7 (9)   34 (24) 44 (20) 55 (25) 5 (2)  
Endoscopic retrograde cholangiopancreatography  0.02      0.69 
No / not stated 269 (50) 79 (48) 50 (66)   76 (54) 114 (52) 111 (50) 98 (48)  
Yes 273 (50) 84 (52) 26 (34)   65 (46) 104 (48) 112 (50) 106 (52)  
Magnetic resonance imaging/cholangiopancreatography 0.93      <0.001 
No / not stated 444 (82) 132 (81) 63 (83)   105 (74) 170 (78) 181 (81) 186 (91)  
Yes 98 (18) 31 (19) 13 (17)   36 (26) 48 (22) 42 (19) 18 (9)  
a Tumour status based on imaging or exploratory laparoscopy. b Chi-square test.  c Missing data: SES, n = 5; Tumour site, n = 21; Charlson comorbidity 
index, n = 4; Clinical stage , n = 43, First facility volume, n = 11.  
  
 
Table 9-5: Association between evidence of presentation at a multidisciplinary team meeting and survival, stratified by whether or not 
resection was attempted. 
 Attempted resection  No attempted resection 
 n (%) HR (95% CI)a AHR (95% CI)b  n (%) HR(95% CI) AHR(95% CI)b 
MDTc        
No 239 (65) 1.00 1.00  279 (66) 1.00 1.00 
Yes 126 (35) 0.80 (0.63, 1.03) 0.77 (0.59, 1.00)  142 (34) 0.76 (0.62, 0.93) 0.80 (0.64, 1.00) 
a HR = Hazard ratio;   AHR = Adjusted HR; CI = Confidence Interval. 
b Adjusted for performance status, age, place of residence and clinical stage of disease 
c MDT= Review by multidisciplinary team 
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9.7. APPENDIX F 
9.7.1. Introduction  
This invited editorial has been published in Cancer Forum. The aim of this publication was to 
describe equity of access issues for patients with pancreatic cancer in Australia.  
9.7.2. Contribution of candidate 
Associate Professor Rachel Neale conceptualised, designed, wrote and submitted this invited 
editorial. My contribution included referencing (50%) and editing the publication (10%). 
9.7.3. Manuscript 
The following invited editorial was published in Cancer Forum, March 2016: 
Patterns of care – improving equity of access to optimal care 
Rachel E Neale, Elizabeth Burmeister. Cancer Forum; 40 (1). 
Abstract 
People diagnosed with pancreatic cancer suffer the worst five-year survival of any cancer. Resection 
of the primary tumour currently provides the only potential for cure. Increasing the proportion of 
patients who undergo surgical resection and ensuring that this occurs in a high-volume setting may 
lead to population-level survival gains. Access to chemotherapy in both adjuvant and palliative 
settings may lead to further improvements.  
Worse survival has been reported for patients from lower socio-economic and rural areas than those 
who are wealthier and living in major cities. Management in higher-volume hospitals tends to be 
associated with higher survival. Differences in patient factors such as age, performance status and the 
presence of co-morbidities may partly explain the survival discrepancies; however, international and 
limited Australian data suggest that not all patients receive optimal treatment, and that variability in 
care may be related to socio-demographic factors.  
There is considerable investment in identifying new strategies for diagnosis and treatment. However, 
immediate improvements could be made by implementing policies and procedures that enable all 
patients to be managed by high-performing multidisciplinary teams, ensuring receipt of optimal 
curative and supportive treatment modalities. This will also enable full realisation of benefits 
expected to accrue from the development of new treatments over the coming decades.   
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Introduction 
Pancreatic cancer is the tenth most commonly occurring cancer in Australia, affecting over 2,700 
people each year. It has the worst five-year survival of any cancer at less than five percent, so takes 
the lives of over 2,500 Australians annually and is the fourth-leading cause of cancer death in both 
men and women.35 There has been little change in the mortality to incidence ratio since the early 
1980s, in contrast with a number of other cancers. As a result it has been estimated that within the 
next decade it will become the second-leading cause of cancer death in the United States40 and this is 
likely also to be the case in Australia. 
The dismal prognosis in patients with pancreatic cancer is due firstly to the late stage at which most 
people are diagnosed. Consistent with international estimates,317 almost 60% of pancreatic cancer 
patients in Australia are diagnosed with metastatic disease which precludes resection of the 
tumour.293 A further 20-30% of patients have locally advanced disease and, although surgical 
techniques have improved, the vascular involvement is frequently too extensive to permit resection.  
The second reason for the poor survival has been the lack of efficacious systemic treatments. Until 
recently, administration of gemcitabine was considered the standard of care in both adjuvant and 
palliative settings, despite only small improvements in survival. The use of new regimens such as 
FOLFIRINOX and albumin-bound paclitaxel for treatment of inoperable pancreatic cancer, and 
increased investment in discovery of new therapies, may lead to further improvements in pancreatic 
cancer survival in the next decade. 
Ensuring all patients receive optimal treatment will help to realise potential survival gains. However, 
international data suggests that patients from lower socioeconomic and rural areas may have worse 
survival than their counterparts from wealthier and metropolitan areas89, 308 and similar trends for 
geographic location have been observed in Australia.303, 304 While differences in patient factors such 
as age and the presence of co-morbidities may partly explain the survival discrepancies, it is likely 
that differential access to treatment also plays a role. 
Increasing the proportion of patients who undergo resection of the primary tumour 
Surgical resection of the primary tumour improves five-year survival from less than 5% to up to 
20%,157 but, consistent with international estimates, only 15% of patients in two states of Australia 
underwent resection between 2009 and 2011.293 Population-level survival estimates would improve if 
this proportion could be increased. It has been estimated that increasing the proportion of patients 
diagnosed with stage one and two (i.e., operable) disease from 6% to 19%, with a concomitant 
decrease in the proportion of patients with metastatic disease, would double five-year survival.317  
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Earlier diagnosis might increase the proportion of patients diagnosed with operable disease. Some 
studies,318, 319 although not all,320 indicate that diagnostic delay is associated with later stage disease 
and poorer outcomes. However, a substantial component of the delay occurs as a result of the non-
specific nature of symptoms which do not prompt early presentation to medical practitioners, and it 
is unlikely that this will be amenable to significant improvement. Implementation of screening 
programs has more potential to lead to a shift in the distribution of the stage of disease at diagnosis 
but considerable challenges remain.  Population-wide screening is not feasible due to the relative 
rarity of pancreatic cancer. Indeed, modelling studies suggest that such an approach would reduce 
life expectancy due to false positive results and unnecessary surgery.321 Screening is therefore 
currently restricted to people with genetic predisposition to pancreatic cancer and is only occurring 
within the context of research studies. Attempts to identify other subgroups of the population that 
have sufficiently high risk to make screening viable have so far proven unsuccessful.322 Further, 
current screening relies on either computed tomography or magnetic resonance imaging; these are 
insufficiently accurate for identifying small tumours, may not be easily accessible and are expensive. 
Until these issues are resolved and screening becomes a feasible option it is doubtful that there will 
be any discernible increase in the proportion of patients diagnosed with early stage, operable disease. 
A second approach to increasing the proportion of patients who undergo surgery is to ensure that this 
treatment option is offered to all patients with resectable tumours and acceptable performance status. 
International data show that there is currently inequitable access to surgical intervention, with 
patients who are Black, unmarried, have low education or socioeconomic status, and who come from 
rural rather than metropolitan areas being less likely to undergo resection of the primary tumour10-13 
This is most probably associated with the expertise of the facility at which patients are staged. 
Patients who are managed at high volume or accredited cancer centres have higher likelihood of 
undergoing surgery than those who are treated at lower volume centres, and there is evidence that 
centralisation of care can increase resection rates.129  There is limited published Australian 
information about patient factors such as education which might influence access to surgical 
treatment, but our unpublished data suggests that remoteness of residential location is inversely 
associated with resection, and a Queensland report shows a slightly higher resection proportion in 
more affluent patients with cancers of the pancreas, biliary tract and small intestine combined.192 
Guidelines suggest that all patients without metastatic disease should be assessed for tumour 
resectability by a multidisciplinary team that includes a specialist hepatobiliary surgeon;6 developing 
referral pathways or telehealth facilities that enable implementation of this guideline has the potential 
to increase the number of patients in Australia that are offered a resection of their tumour. 
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Surgical volume and mortality / survival 
Pancreatic cancer surgery is challenging due to the anatomic location of the pancreas with its close 
proximity to large blood vessels into which the tumour has frequently invaded. The experience of the 
hospital at which patients are treated is therefore an important determinant of outcomes. A meta-
analysis of 11 studies, most from the United States and none from Australia, found that patients 
treated in higher volume hospitals had lower post-operative mortality and longer overall survival.114 
The cut points for high and low volume varied markedly, however, so volume is likely to be a 
marker of expertise and multidisciplinary care but there is little evidence upon which to base 
recommendations about the minimum number of surgeries that should be performed. This is 
reflected in the guidelines which are inconsistent, with the NCCN recommending a minimum of 15 
surgeries per year, the National Cancer Institute Guidelines recommending five and the British 
Society of Gastroenterology not specifying a particular number. There are no specific Australian 
guidelines. Between 2005 and 2008 in New South Wales pancreatic cancer surgery took place at 37 
hospitals. Only six of these performed more than 6 pancreatic cancer surgeries annually, and 15 
(41%) undertook fewer than two procedures each year.209 Between 2002 and 2011 in Queensland 23 
hospitals performed pancreaticoduodenectomies; by 2011 this number had dropped to 13,192 
indicating that centralisation of care has been occurring in some jurisdictions. 
Adjuvant chemotherapy 
There is a high risk of recurrence after resection of the primary pancreatic tumour, with median 
disease-free survival of less than one year.143 Clinical practice guidelines therefore recommend 
adjuvant chemotherapy or chemo-radiotherapy,6 although the type of therapy to be used is not 
specified, probably due to a lack of consensus about the interpretation of clinical trial data. As with 
surgery, international evidence suggests variable implementation of adjuvant therapy. A recent report 
from the Netherlands found that only about half of patients received adjuvant chemotherapy, but this 
was higher in patients who underwent their resection at a high-volume hospital.323 Similarly, studies 
from the United States found that receipt of adjuvant therapy was higher among patients treated at 
high volume hospitals (vs low volume) and at academic rather than community hospitals13 and in 
white rather than black patients.10 In Australia chemotherapy with gemcitabine has been the standard 
of care, particularly since the publication of the CONKO-01 trial in 2007.143 Presumably as a result 
of this key publication, use of adjuvant chemotherapy increased from 47% in Victorian patients 
diagnosed in 2002-2003 to 76% in patients from Queensland and New South Wales diagnosed 
almost a decade later. Patients who did not receive adjuvant treatment had worse performance status 
or a complicated post-operative course (unpublished data). This suggests that most Australian 
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patients who undergo surgery are now receiving appropriate multi-modality postoperative care in 
accordance with guidelines. 
Chemotherapy in advanced pancreatic cancer 
The majority of patients present with metastases or locally advanced inoperable disease. For these 
patients there have been limited curative treatment options and symptom control has been the 
primary aim of management. In 1997 a landmark study was published which showed that, although 
gemcitabine resulted in only a modest survival benefit over 5-flurouracil, it delivered substantial 
improvements in pain, performance status and weight.149 It subsequently became the standard of care 
for first line treatment in patients with advanced disease. As with surgery and adjuvant 
chemotherapy, there is evidence from the United States that socioeconomic disadvantage is 
associated with lower use of palliative chemotherapy.10, 210 Elderly patients with advanced cancer are 
also less likely to receive chemotherapy than younger patients, even though there is evidence of 
benefit in older patients.218, 219 In our population-based study in Queensland and New South Wales 
only 43% of people diagnosed with inoperable disease received chemotherapy293 but there are 
currently no recent published data about determinants of receipt of therapy. Newer chemotherapy 
regimens with greater impacts on survival and quality of life are now used for treatment of advanced 
pancreatic cancer, including FOLRIRINOX and albumin-bound paclitaxel and Gemcitabine. 151-153 
Ensuring equitable access to these and other novel systemic treatments as they become available will 
be an important contributor to improvements in survival in the coming decade. 
Conclusion 
Pancreatic cancer continues to have unacceptably high mortality and patients report extremely high 
supportive care needs throughout the course of disease.167 International and limited Australian data 
suggest that not all patients receive optimal treatment, and that variability in care may be related to 
socio-demographic factors. There is considerable investment in new strategies for diagnosis and 
treatment and there now appears to be light at the end of the tunnel. However immediate 
improvements could be made by implementing policies and procedures that enable all patients to be 
managed by high-performing multidisciplinary teams, ensuring receipt of optimal curative and 
supportive treatment modalities. This will also enable full realisation of benefits expected to accrue 
from the development of new treatments over the coming decades.  
  
  
 
9.8. APPENDIX G 
9.8.1. Chapter 7 (Quality-of-care score) supplementary tables 
Table 9-6: Proportions of eligible patients for whom each quality-of-care item was met, by place of residence 
  N eligible (% met criteria) 
Item     Major city  Inner regional             Rural   P valuea 
All patients with potentially resectable disease should be referred to an hepatobiliary surgeon 548 (53) 159 (52) 74 (41) 0.003 
All patients with technically resectable disease should be offered a resection or have a valid reason 
for no surgery  
368 (99) 105 (96) 154 (96) 0.10 
Surgery should be performed by surgeons who perform more than 5 pancreatic surgeries per year 260 (40) 74 (57) 32 (38) 0.19 
Tumour resectability should be assessed by a MDT at a tertiary hospital 548 (30) 159 (33) 74 (15) <0.001 
All patients should have a triple phase/ pancreas protocol CT scan for staging 1076 (45) 338 (36) 157 (47) 0.015 
Entry into a clinical trial should be considered for all patients 1076 (7) 338 (6) 157 (2) 0.03 
Surgery should take place in tertiary institutions where > 11 resections are performed annually 260 (39) 74 (53) 32 (41) 0.39 
Each patient should have a care-coordinator assigned with an individualised treatment/ clinical 
plan 
1076 (22) 338 (26) 157 (13) 0.005 
Tissue diagnosis should be obtained where possible  1076 (82) 338 (78) 157 (69) 0.001 
All patients should be presented to a MDT 1076 (35) 338 (26) 157 (22) < 0.001 
Biliary obstruction should routinely be managed endoscopically in non-resectable patients 286 (85) 88 (82) 42 (76) 0.78 
All patients should be offered adjuvant therapy post operatively, assuming performance status is 
adequate 
260 (67) 74 (68) 32 (66) 0.62 
All patients should be offered psychosocial support 1076 (23) 338 (12) 157 (7) < 0.001 
Pancreatic enzyme replacement therapy should be considered for all patients  1076 (23) 338 (19) 157 (19) 0.20 
All patients should see a medical oncologist 1076 (88) 338 (82) 157 (82) 0.004 
A specialist HPB surgeon should be the initial/primary specialist unless the patient has obvious 
metastases 
548 (23) 159 (13) 74 (3) < 0.001 
All patients should be referred to a dietitian soon after diagnosis 1076 (68) 338 (52) 157 (59) < 0.001 
Patients with confirmed metastatic disease should be referred to palliative care 528 (85) 179 (74) 83 (75) 0.004 
aP value calculated using Pearson chi2 to test differences between place of residence and proportion that met the criteria for each item.  
MDT: Multidisciplinary team; CT: computerised tomography   
  
 
Table 9-7 : Proportions of eligible patients for whom each quality-of-care item was met, by area-level socioeconomic status. 
   N eligible (% met criteria)  
 Quintiles of  Index of Relative Socio-Economic Disadvantage scores  
Item 
Least 
disadvantaged 
2 3 4 
Most 
disadvantaged 
P valuea 
All patients with potentially resectable disease should be referred to a hepatobiliary 
surgeon 
138 (55) 160 (51) 160 (42) 169 (50) 154 (59) 0.04 
All patients with technically resectable disease should be offered a resection or have a 
valid reason for no surgery 
91 (100) 111 (99) 100 (99) 115 (95) 102 (98) 0.05 
Surgery should be performed by surgeons who perform more than 5 pancreatic surgeries 
per year 
66 (68) 78 (42) 68 (29) 81 (40) 73 (38) <0.001 
Tumour resectability should be assessed by a MDT at a tertiary hospital 138 (30) 160 (34) 160 (29) 169 (28) 154 (26) 0.64 
All patients should have a triple phase/ pancreas protocol CT scan for staging 266 (39) 327 (49) 322 (41) 338 (42) 318 (43) 0.17 
Entry into a clinical trial should be considered for all patients 266 (8) 327 (10) 322 (6) 338 (4) 318 (5) 0.02 
Surgery should take place in tertiary institutions where > 11 resections are performed 
annually 
66 (53) 78 (44) 68 (32) 81 (33) 73 (47) 0.06 
Each patient should have a care-coordinator assigned with an individualised treatment/ 
clinical plan 
266 (20) 327 (26) 322 (21) 338 (26) 318 (17) 0.01 
Tissue diagnosis should be obtained where possible  266 (87) 327 (80) 322 (78) 338 (78) 318 (76) 0.03 
All patients should be presented to a MDT 266 (37) 327 (34) 322 (35) 338 (26) 318 (27) 0.01 
Biliary obstruction should routinely be managed endoscopically in non-resectable patients 73 (86) 88 (83) 80 (83) 84 (86) 91 (79) 0.74 
All patients should be offered adjuvant therapy post operatively, assuming performance 
status is adequate 
66 (80) 78 (60) 68 (68) 81 (65) 73 (62) 0.20 
All patients should be offered psychosocial support 266 (35) 327 (17) 322 (21) 338 (14) 318 (11) < 0.001 
Pancreatic enzyme replacement therapy should be considered for all patients 266 (27) 327 (28) 322 (17) 338 (20) 318 (19) 0.002 
All patients should see a medical oncologist 266 (91) 327 (86) 322 (87) 338 (85) 318 (83) 0.05 
A specialist HPB surgeon should be the initial/primary specialist unless the patient has 
obvious metastases 
138 (25) 160 (20) 160 (13) 169 (16) 154 (20) 0.08 
All patients should be referred to a dietitian soon after diagnosis 190 (71) 327 (63) 322 (60) 338 (61) 318 (65) 0.03 
Patients with confirmed metastatic disease should be referred to palliative care 128 (83) 167 (84) 162 (82) 169 (80) 164 (81) 0.91 
aP value calculated using Pearson chi2 to test differences between quintiles of  Index of Relative Socio-Economic Disadvantage scores and proportion 
that met the criteria for each item. MDT: Multidisciplinary team; CT: computerised tomography 
  
 
Table 9-8 :  Hazard ratios for the association between receipt of care for each care score item and survival in  1) all patients;  2) non-
metastatica  and 3) metastatic  patientsa eligible for the care. 
 
Hazard ratio (95% CI)b for patients receiving item care compared to those not receiving care 
p value 
Item              All patients        Non-metastatic Metastatic 
All patients with potentially resectable disease should be referred to an hepatobiliary surgeon 
0.82 (0.69, 0.96) 
0.015 
 
0.82 (0.69, 0.96) 
0.015 
 n/ac 
All patients with technically resectable disease should be offered a resection or have a valid reason 
for no surgery 
1.94 (0.90, 4.15) 
0.09 
 
1.94 (0.90, 4.15) 
0.09 
 n/ac 
Surgery should be performed by surgeons who perform more than 5 pancreatic surgeries per year 
0.83 (0.65, 1.06) 
0.14 
 
0.83 (0.65, 1.06) 
0.14 
 n/ac 
Tumour resectability should be assessed by a MDT at a tertiary hospital 
0.93 (0.79, 1.11) 
0.43 
 
0.93 (0.79, 1.11) 
0.43 
 n/ac 
All patients should have a triple phase/ pancreas protocol computerised tomography (CT) scan for 
staging 
0.90 (0.81, 1.00) 
0.06 
 
0.97 (0.83, 1.13) 
0.68 
 
0.87 (0.75, 1.01) 
0.06 
Entry into a clinical trial should be considered for all patients 
1.01 (0.82, 1.25) 
           0.90 
 
1.23 (0.87, 1.74) 
0.24 
 
0.92 (0.70, 1.21) 
0.54 
Surgery should take place in tertiary institutions where > 11 resections are performed annually 
0.90 (0.70, 1.16) 
0.43 
 
0.90 (0.70, 1.16) 
0.43 
 n/ac 
Each patient should have a care-coordinator assigned with an individualised treatment/ clinical plan 
 1.00 (0.88, 1.13) 
          0.98 
 
0.98 (0.81, 1.18) 
0.84 
 
0.98 (0.83, 1.17) 
0.86 
Tissue diagnosis should be obtained where possible  
0.66 (0.57, 0.77) 
<0.001 
 
0.59 (0.47, 0.75) 
<0.001 
 
0.70 (0.58, 0.84) 
<0.001 
All patients should be presented to a MDT 
0.86 (0.77, 0.96) 
0.01 
 
0.89 (0.76, 1.05) 
0.17 
 
0.84 (0.72, 0.99) 
0.04 
Biliary obstruction should routinely be managed endoscopically in non-resectable patients 
0.97 (0.74, 1.27) 
0.82 
 
1.10 (0.72, 1.70) 
0.66 
 
0.84 (0.59, 1.21) 
0.35 
All patients should be offered adjuvant therapy post operatively, assuming performance status is 
adequate 
0.43 (0.33, 0.56) 
<0.001 
 
0.43 (0.33, 0.56) 
<0.001 
 n/ac 
All patients should be offered psychosocial support 
1.24 (1.09, 1.12) 
0.001 
 
1.46 (1.20, 1.76) 
<0.001 
 
1.05 (0.87, 1.26) 
0.62 
Pancreatic enzyme replacement therapy should be considered for all patients 
0.83 (0.73, 0.94) 
0.005 
 
0.82 (0.69, 0.97) 
0.02 
 
0.83 (0.66, 1.00) 
0.05 
All patients should see a medical oncologist 
1.04 (0.88, 1.23) 
0.63 
 
0.98 (0.79, 1.22) 
0.85 
 
1.06 (0.82, 1.36) 
0.65 
A specialist hepatobiliary surgeon should be the initial/primary specialist unless the patient has 
obvious metastases 
0.95 (0.77, 1.17) 
0.62 
 
0.95 (0.77, 1.17) 
0.62 
 n/ac 
All patients should be referred to a dietitian soon after diagnosis 
1.00 (0.90, 1.12) 
0.98 
 
0.96 (0.80, 1.14) 
0.65 
 
1.01 (0.87, 1.17) 
0.90 
Patients with confirmed metastatic disease should be referred to palliative care  
1.42 (1.17, 1.74) 
0.001 
 n/ac  
1.42 (1.17, 1.74) 
0.001 
a according to clinical staging;   b adjusted for age, performance status, comorbidities and clinical stage;  c n/a: not applicable;  MDT: multidisciplinary team 
 
 232 
 
9.9. APPENDIX H 
9.9.1. Introduction  
This work was published in the Journal of Gastrointestinal Surgery. The aim of this publication was 
to determine mortality and complication rates following surgery and factors associated with these 
rates including hospital- and surgeon-case volume. 
9.9.2. Contribution of candidate 
My contribution to this study included research question conceptualisation (20%), data collection 
(15%), data cleaning (80%), data analysis (20%), interpretation of the results (20%) and writing and 
editing the publication (20%) with the majority of the work completed by MAW under the guidance 
of REN with valuable comments from the study team. 
9.9.3. Manuscript 
The following manuscript was published in the Journal of Gastrointestinal Surgery: 
J Gastrointest Surg. 2016; 20 (8):1471-81 
Determinants of outcomes following resection for pancreatic cancer - a 
population-based study 
Mary A Waterhouse,  Elizabeth A Burmeister, Dianne L O’Connell, Emma L Ballard, Susan J 
Jordan, Neil D Merrett, David Goldstein, David Wyld, Monika Janda, Vanessa L Beesley, Madeleine 
E Payne, Helen M Gooden, Rachel E Neale.    . 
 
ABSTRACT  
Background 
Patient and health system determinants following pancreatic cancer resection, particularly the 
relative importance of hospital and surgeon volume, are unclear. Our objective was to identify 
patient, tumour and health-service factors related to mortality and survival among a cohort of 
patients who underwent completed resection for pancreatic cancer.   
Methods  
Eligible patients were diagnosed with pancreatic adenocarcinoma between July 2009 and June 2011, 
and had a completed resection performed in Queensland or New South Wales, Australia, with either 
tumour-free (R0) or microscopically involved margins (R1) (n = 270). 
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Associations were examined using logistic regression (for binary outcomes) and Cox proportional 
hazards or stratified Cox models (for time-to-event outcomes). 
Results 
Patients treated by surgeons who performed < 4 resections/year were more likely to die from a 
surgical complication (versus ≥ 4 resections/year, P = 0.04), had higher one-year mortality (P = 
0.03), and worse overall survival up to 1.5 years after surgery (adjusted hazard ratio 1.58, 95% 
confidence interval 1.07-2.34). Among patients who had ≥ 1 complication within 30 days of surgery, 
those aged ≥ 70 years had higher one-year mortality compared to patients aged < 60 years. Adjuvant 
chemotherapy treatment improved recurrence-free survival (P = 0.01). There were no significant 
associations between hospital volume and mortality or survival. 
Conclusions 
Systems should be implemented to ensure that surgeons are completing a sufficient number of 
resections to optimize patient outcomes. These findings may be particularly relevant for countries 
with a relatively small and geographically dispersed population.   
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INTRODUCTION 
Pancreatic cancer has the worst survival of any cancer. The only potentially curative option is 
surgical removal of the tumour.86 Surgery is technically demanding and may require complex 
vascular reconstructions and is associated with significant morbidity and mortality. However, 
successful resection combined with multimodality therapy improves five-year survival from 5%324 to 
more than 20%.86 
Lymph node positivity ratio (number of positive lymph nodes divided by total number of nodes 
examined), treatment with adjuvant chemotherapy and pathologic T stage were the three most 
important predictors of long-term survival (≥ 10 years from diagnosis) after resection surgery in a 
recent, large study.325 Poor tumour differentiation325-327 and involved margins325, 326, 328-330 are 
associated with poor prognosis, and worse outcomes have been reported for older patients331, 332 and 
those with a lower socioeconomic status (SES).327 
Convincing evidence of an association between increasing hospital volume (number of attempted 
resections/year) and both lower short-term mortality114, 333-335 and better long-term survival114 after 
pancreatic surgery has led to a push for greater centralisation of care. Also, some studies have 
reported better outcomes with increasing surgeon volume.133, 138, 336 It has been suggested that higher 
volume providers may have lower rates of involved margins128 and complications,337, 338 use multi-
modal therapies more extensively,13 or offer superior post-operative care.86 Alternatively, the 
associations might reflect differences in case-mix. 
We used data from an Australian population-based study of patients with pancreatic cancer to 
identify patient, tumour and health-service factors related to mortality and survival following 
completed resection. We also examined associations with margins and complications, which may 
mediate effects on mortality and survival.  
METHODS 
Study sample and data collection 
A detailed description of the study sample, ethics approval and data collection methods has been 
published.339 Briefly, the study sample comprised patients aged ≥ 18 years who were diagnosed with 
pancreatic ductal adenocarcinoma or pancreatic cancer of unknown morphological subtype (ICD-10 
code C25) between 1 July 2009 and 30 June 2011 and notified to the Queensland (QLD) Cancer 
Registry, or between 1 July 2009 and 31 December 2010 and notified to the New South Wales 
(NSW) Central Cancer Registry. We obtained demographic data and details regarding the initial 
diagnosis from the cancer registries, and trained research nurses collected clinical data from medical 
records. Date of death was obtained from either the medical records or cancer registries.  
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Outcomes 
Overall survival (OS) was defined as the number of months from surgery until death from any cause 
or, if the person did not die, until the end of the study (25 February 2014). Recurrence-free survival 
(RFS) was defined as the number of months from surgery until recurrence (the first date that imaging 
detected metastases or disease at the primary site) or death or, if neither occurred, until the end of the 
study. We analysed death from surgical complications, 90-day and one-year mortality (from date of 
surgery), complications within 30 days of surgery (any complication, wound infection, intra-
abdominal sepsis, anastomotic leak and haemorrhage), and margin status as binary outcomes. Margin 
status was categorised into involved or clear < 1 mm (reference category) and clear ≥ 1 mm.340  
Factors of interest 
Factors analysed included age at diagnosis, area-level socioeconomic status (SES), place of 
residence, Charlson comorbidity index, Eastern Cooperative Oncology Group (ECOG) performance 
status, preoperative assumed tumour status (i.e. clinical stage: confined to pancreas or locally 
advanced), TNM stage (Union for International Cancer Control (UICC) 7th Edition),81 presence of 
positive lymph nodes, tumour differentiation, tumour site, pre-operative white blood cell (WBC) 
count and albumin level, time from diagnosis to resection, hospital type where surgery was 
performed (public or private), complications within 30 days of surgery, margin status, adjuvant 
chemotherapy treatment, surgeon volume, hospital volume, and combined hospital and surgeon 
volume.  
SES was assigned based on residential location, and remoteness of place of residence was measured 
using the Accessibility/Remoteness Index of Australia. Categorisation of these was described 
previously.339 Surgical volume, calculated as the number of attempted resections in our dataset 
performed per year, was categorised as high-volume (HV) and low-volume (LV). The thresholds 
used to define HV were ≥ 4 and ≥ 6 resections/year for surgeon volume and hospital volume, 
respectively. These were chosen primarily to enable robust statistical analyses, but we explored a 
range of other cut points and found no change in our conclusions. 
Exclusions 
We restricted analyses of outcomes to 270 patients who had a completed resection performed in 
NSW or QLD, with either tumour-free (R0) or microscopically involved margins (R1) (n = 270). 
Nine patients who died during their surgical resection admission (n = 9) were excluded from 
analyses of recurrence and analyses where the factor of interest was adjuvant chemotherapy 
treatment.  
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Statistical analysis 
Chi-squared tests (and Fisher’s exact test, as required) were used to examine associations between 
factors. Logistic regression was used to estimate crude and adjusted odds ratios (ORs, AORs). To 
test whether the association between age and mortality was modified by complications (none, any 
within 30 days of surgery), we included an interaction term for age by complications, and analyses 
were repeated within strata defined by complications.  
Median survival and survival curves were estimated using Kaplan-Meier methods. We used Cox 
proportional hazards (PH) or stratified Cox models to estimate crude and adjusted hazard ratios 
(HRs, AHRs). The PH assumption was assessed using log-log survival curves and Schoenfeld 
residuals. Since the OS curves for any complication within 30 days of surgery, age, and surgeon 
volume appeared to converge over time (Figures 1A to 1C), we partitioned survival time into two 
intervals (before and after a specified time point) and used an extended Cox model to estimate a 
constant HR for each interval. Models were fitted using different time points; the value used in the 
final model was the maximum number of months for which the 95% confidence interval (CI) for the 
HR in the first time interval did not contain one. 
We used directed acyclic graphs to guide selection of potential confounding factors to be included in 
adjusted models.341 For associations between surgeon or hospital volume and outcomes (excluding 
complications), we also fitted models with a continuous propensity score as the only adjustment 
variable. Propensity scores were estimated using logistic regression models that included age, sex, 
state and remoteness of residence, SES, smoking status, family history of cancer, Charlson 
comorbidity index, ECOG performance status, TNM stage, positive lymph nodes, tumour 
differentiation and site, pre-operative WBC count and albumin level, jaundice and weight loss at 
diagnosis, any stenting prior to resection surgery, and hospital type. We also estimated a propensity 
score for chemotherapy treatment using the model above but with pre-operative WBC and albumin 
level omitted, and surgeon/hospital volume, any complications, and total length of stay included. Fit 
was assessed using the C-statistic of the receiver operating characteristic curve.  
When analysing surgeon or hospital volume, we accounted for patient clustering using generalised 
estimating equations with an exchangeable correlation matrix or robust sandwich estimates of 
standard errors. Statistical analyses were performed in SAS version 9.4 (SAS Institute, Inc, Cary, 
NC). Figures were produced using the survival package (version 2.38) in R.342 All P-values are two-
sided and we used a statistical significance level of P < 0.05. 
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RESULTS 
Of 369 attempted resections, 365 were performed in NSW or QLD, of which 87 (24%) were aborted. 
There were no associations between patient or health system factors and whether or not the surgery 
was completed. A further eight patients were excluded because distant metastases were found during 
surgery, leaving 270 patients (average age 64 years, 63% men) for analyses of surgical outcomes. 
Characteristics of these patients are shown in the second column of Table 9-9.   
Table 9-9: Patient and tumour characteristics 
  
All attempted 
resections  
(n=365) 
Completed 
resections 
(n=278) 
Aborted  
resections 
(n=87) 
Variable N (%) N (%) N (%) 
Sex 
   Male 220 (60) 174 (63) 46 (53) 
Female 145 (40) 104 (37) 41 (47) 
Age at diagnosis, years 
   <60 104 (28) 79 (28) 25 (29) 
60-69 133 (36) 101 (36) 32 (37) 
≥70 128 (35) 98 (35) 30 (34) 
Place of residence 
   Major City 258 (71) 199 (72) 59 (69) 
Inner Regional 73 (20) 53 (19) 20 (23) 
Outer regional/remotea 32 (9) 25 (9) 7 (8) 
Missing 2 1 1 
Socioeconomic status - quintiles 
   Most disadvantaged 74 (20) 62 (22) 12 (14) 
Second 81 (22) 60 (22) 21 (24) 
Third 67 (18) 47 (17) 20 (23) 
Fourth 75 (21) 55 (20) 20 (23) 
Least disadvantaged 66 (18) 53 (19) 13 (15) 
Missing 2 1 1 
TMN Stage 
   Stage I 36 (10) 35 (13) 1 (1) 
Stage II 257 (71) 227 (83) 30 (34) 
Stage III 23 (6) 3 (1) 20 (23) 
Stage IV 44 (12) 8 (3) 36 (41) 
Missing 5 5 0 
Positive lymph nodes 
   No 112 (34) 91 (33) 21 (35) 
Yes 221 (66) 182 (67) 39 (65) 
Missing 32 5 27 
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All attempted 
resections  
(n=365) 
Completed 
resections 
(n=278) 
Aborted  
resections 
(n=87) 
Variable N (%) N (%) N (%) 
Tumour site 
   Uncinate process 77 (22) 56 (21) 21 (25) 
Head 209 (59) 159 (58) 50 (59) 
Neck 11 (3) 9 (3) 2 (2) 
Body 28 (8) 17 (6) 11 (13) 
Tail 32 (9) 31 (11) 1 (1) 
Missing 8 6 2 
Was tumour considered resectable? 
  Nob 5 (1) 1 (0.4) 4 (5) 
Yes, confined to pancreas 148 (41) 120 (43) 28 (32) 
Yes, locally advanced 199 (55) 146 (53) 53 (61) 
Yes, no other details 12 (3) 10 (4) 2 (2) 
Missing 1 1 0 
Charlson Comorbidity Index (score) 
  Low (0) 183 (50) 143 (52) 40 (46) 
Medium (1) 106 (29) 81 (29) 25 (29) 
High (≥2) 74 (20) 52 (19) 22 (25) 
Missing 2 2 0 
ECOG performance status 
   Fully active 184 (58) 145 (59) 39 (53) 
Not fully active 134 (42) 99 (41) 35 (47) 
Missing 47 34 13 
a Includes very remote locations. b Resection attempted even though the tumour was thought to be 
non-resectable on staging 
ECOG, Eastern Cooperative Oncology Group; TNM, tumour node metastases 
 
Sixteen of 50 hospitals and 14 of 79 surgeons were categorised as HV providers. Concordance 
between hospital volume and surgeon volume is shown in Table 2. The C-statistic for the propensity 
score models for both surgeon and hospital volume was 0.80, and for chemotherapy treatment it was 
0.86. A greater percentage of patients treated by LV surgeons were aged ≥ 70 years (versus HV: 43% 
versus 28%), and HV hospitals were more likely to treat patients with TNM stage II/III tumours 
(versus LV: 90% versus 79%) (Table 9-10).  
  
  
 
Table 9-10:  Selected patient and tumour characteristics classified by surgeon and hospital volumea and hospital type (n=270)b: chi-squared 
test. 
 
  N (%) 
   
Surgeon volume 
 
Hospital volume 
 
Hospital type 
  Overall   
High 
(n=144) 
Low 
(n=126) p-value   
High 
(n=184) 
Low  
(n=86) p-value   
Public 
(n=164) 
Private 
(n=106) p-value 
Age at diagnosis, years 
             
<60 77 (29) 
 
38 (26) 39 (31) 0.003 
 
50 (27) 27 (31) 0.47 
 
47 (29) 30 (28) 0.33 
60-69 99 (37) 
 
66 (46) 33 (26) 
  
72 (39) 27 (31) 
  
55 (34) 44 (42) 
 
≥70 94 (35) 
 
40 (28) 54 (43) 
  
62 (34) 32 (37) 
  
62 (38) 32 (30) 
 
Charlson comorbidity index (score) 
            
Low (0) 139 (52) 
 
75 (52) 64 (52) 0.50 
 
98 (53) 41 (49) 0.70 
 
78 (48) 61 (59) 0.18 
Medium (1) 79 (29) 
 
39 (27) 40 (32) 
  
54 (29) 25 (30) 
  
54 (33) 25 (24) 
 
High (≥ 2) 50 (19) 
 
30 (21) 20 (16) 
  
32 (17) 18 (21) 
  
32 (20) 18 (17) 
 
ECOG performance status 
             
Fully active 139 (59) 
 
84 (62) 55 (54) 0.23 
 
102 (62) 37 (52) 0.16 
 
70 (50) 69 (73) <0.001 
Not fully active 97 (41) 
 
51 (38) 46 (46) 
  
63 (38) 34 (48) 
  
71 (50) 26 (27) 
 
Tumour site 
             
Head/Neck/Uncinate process 218 (83) 
 
124 (86) 94 (78) 0.10 
 
152 (84) 66 (80) 0.38 
 
134 (85) 84 (79) 0.24 
Body/Tail 46 (17) 
 
20 (14) 26 (22) 
  
29 (16) 17 (20) 
  
24 (15) 22 (21) 
 
Pre-operative tumour statusc 
             
Confined 119 (46) 
 
64 (46) 55 (46) 0.94 
 
77 (43) 42 (53) 0.12 
 
62 (39) 57 (55) 0.01 
Locally advanced 140 (54) 
 
76 (54) 64 (54) 
  
103 (57) 37 (47) 
  
97 (61) 47 (45) 
 
TNM stage 
             I 35 (13) 
 
16 (11) 19 (15) 0.32 
 
18 (10) 17 (21) 0.02 
 
17 (11) 18 (17) 0.13 
II/IIId 230 (87)  126 (89) 104 (85)    165 (90) 65 (79)    143 (89) 87 (83)   
a Surgeon volume classified as high (≥ 4) and low (<4 resections/year). Hospital volume classified as high (≥ 6) and low (<6 resections/year). 
b Analysis based on 270 people who had a completed resection and were not found to have distant metastases.  
c Confined: Considered resectable and confined to pancreas; Locally advanced: consider non-resectable or considered resectable and locally advanced. 
ECOG, Eastern Cooperative Oncology Group. 
d Only 3 people had a TNM stage III tumour. 
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Mortality, overall and recurrence-free survival  
Nine patients (3%) died during their index admission; eight of these deaths were attributed to 
surgical complications and seven of the eight patients were aged 70 years or over. The percentages of 
patients dying within 90 days and one year of surgery were 4% (n = 12) and 34% (n = 93), 
respectively. Cause of death was not stated for three patients. Cancer progression was the most 
common cause of death within one year of surgery (n=79, 88%), followed by surgical complications 
(n=8, 9%). Median OS and RFS were 20 and 13 months, respectively.  
Ninety-day mortality was higher for patients who were older (≥ 70 versus < 60 years, 11% versus 
1%), had poor ECOG performance status (not fully active versus fully active, 7% versus 1%), or had 
≥ 1 complication within 30 days of surgery (versus none, 8% versus 1%) (all P < 0.05). Patients 
treated by LV surgeons had higher 90-day mortality, although this was not statistically significant 
(7% in LV versus 2% in HV, P = 0.10).  
One-year mortality was higher and OS was lower for patients with positive lymph nodes, margins 
that were involved or clear < 1 mm, and with declining performance status (Table 9-11). Only 13% 
of patients had stage I disease and they had better OS than patients with stage II/III disease. 
Patients who had ≥ 1 complication within 30 days of surgery had a greater hazard of dying in the first 
8 months following surgery but there was no difference after 8  months (< 8 months: AHR 1.79, 95% 
CI 1.04-3.08, ≥ 8 months: AHR 0.94, 95% CI 0.66-1.34); OS continued to appear worse up to 16 
months following surgery, but this difference was not statistically significant (< 16 months: AHR 
1.34, 95% CI 0.93-1.95) (Figure 9-1).  
  
 
 
A 
 
B 
 
C 
 
D 
 
  
 
E 
 
F 
 
 
Figure 9-1: Kaplan-Meier survival curves by margin status (A), any complication within 30 days of surgery (B), age at diagnosis (C), surgeon 
volume (D), adjuvant chemotherapy (E), and hospital volume (F) for people who had a completed resection for pancreatic cancer 
and who were not found to have distant metastases during surgery (n=270). 
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Compared with patients who did not have adjuvant chemotherapy treatment, those who received 
treatment had lower odds of dying within one year (AOR 0.33, 95% CI 0.16-0.69). Using the 
standard model the AHR was not statistically significant, but when a propensity score-adjusted 
model was fitted, patients who received chemotherapy treatment had improved OS (versus no 
treatment: AHR 0.51, 95% CI 0.34-0.76). However, these results should be interpreted with caution 
because the PH assumption was violated (i.e., the HRs may vary with time).  
Patients who were older, had more comorbidities, or lived in the most disadvantaged SES areas had a 
greater likelihood of dying within one year of surgery (Table 9-11). There was significant interaction 
between age and any complication occurring within 30 days of surgery (P = 0.005). Among patients 
who had ≥ 1 complication, those aged ≥ 70 years had greater odds of dying within one year (versus < 
60 years: 61% versus 26%, OR 4.41, 95% CI 1.67-11.69); 27% of deaths in those aged ≥ 70 years 
were due to surgical complications whereas nobody aged < 60 years died from surgical 
complications. In contrast, one-year mortality did not differ by age amongst patients who did not 
have any complications (P = 0.35). Compared to patients aged < 70 years, patients aged ≥ 70 years 
had worse OS up to 19 months following surgery (HR 1.55, 95% CI 1.09-2.21) (Figure 9-1).  
We examined the effects of SES further by comparing patients living in the most disadvantaged areas 
with all other patients (reference group). Those living in the most disadvantaged areas were less 
likely to see a medical oncologist (85% versus 96%) and to be offered (79% versus 92%) or receive 
(62% versus 76%) adjuvant chemotherapy treatment (all P < 0.05), but they were no less likely to 
see a HV surgeon (53% versus 54%, P = 0.86). Adjustment for chemotherapy treatment slightly 
attenuated the association with one-year mortality (unadjusted OR 2.47, 95% CI 1.37-4.46; with 
adjustment, AOR 2.16, 95% CI 1.15-4.05), whereas the estimated OR was not meaningfully changed 
after adjustment for TNM stage, Charlson comorbidity index, performance status, hospital type, or 
age (data not shown).  
Patients operated on by a LV surgeon were more likely to die from a surgical complication (versus 
HV: 5.6% versus 0.7%, P = 0.04), and had higher one-year mortality (AOR 1.75, 95% CI 1.06-2.87) 
(Table 9-11). The association was stronger when a propensity score-adjusted model was fitted (AOR 
1.99, 95% CI 1.07-3.70), but not statistically significant after adjusting for any complications within 
30 days of surgery (P ≥ 0.10 for both standard and propensity score analyses). Using an extended 
Cox model, we found that OS was statistically significantly worse up to 19 months following surgery 
for patients who were operated on by a LV surgeon (AHR 1.58, 95% CI 1.07-2.34), after which time 
surgeon volume was not associated with OS (AHR 0.97, 95% CI 0.56-1.68) (Figure 9-1).  
  
Table 9-11: Associations between selected exposure variables and mortalitya and overall survivalb (n=270)c: logistic regression, Cox 
proportional hazards and stratified Cox modelsd. 
  
1-year mortality (deaths=93) a  Overall survival b 
Exposure variable N (%) % dead 
Crude  
OR (95% CI) 
Adjusted  
OR (95% CI) e 
 
Median 
(months) 
Crude  
HR (95% CI) 
Adjusted  
HR (95% CI) e 
Age at diagnosis, years 
    
 
   <60 77 (29) 27.3 1 1  23.5 1f 1f 
60-69 99 (37) 32.3 1.27 (0.66, 2.45) 1.27 (0.66, 2.45)  19.7 1.15 (0.80, 1.66) 1.15 (0.80, 1.66) 
≥70 94 (35) 42.6 1.98 (1.03, 3.77) 1.98 (1.03, 3.77)  15.7 1.31 (0.91, 1.88) 1.31 (0.91, 1.88) 
p-value, p-trend 
  
0.10, 0.03 0.10, 0.03  
 
0.36, 0.15 0.36, 0.15 
Socioeconomic status - quintiles         
Most disadvantaged 59 (22) 50.8 1 1  11.4 1 1 
Second 59 (22) 30.5 0.42 (0.20, 0.90) 0.42 (0.20, 0.90)  21.4 0.79 (0.51, 1.23) 0.79 (0.51, 1.23) 
Third 47 (17) 27.7 0.37 (0.16, 0.84) 0.37 (0.16, 0.84)  21.1 0.77 (0.48, 1.22) 0.77 (0.48, 1.22) 
Fourth 54 (20) 24.1 0.31 (0.14, 0.69) 0.31 (0.14, 0.69)  25.7 0.76 (0.49, 1.18) 0.76 (0.49, 1.18) 
Least disadvantaged 50 (19) 36.0 0.54 (0.25, 1.18) 0.54 (0.25, 1.18)  19.2 0.89 (0.57, 1.40) 0.89 (0.57, 1.40) 
p-value, p-trend 
  
0.03, 0.06 0.03, 0.06  
 
0.71, 0.58 0.71, 0.58 
Place of residence 
    
 
   Major City 192 (71) 33.3 1 1  22.8 1 1 
Inner Regional 52 (19) 34.6 1.06 (0.56, 2.02) 1.16 (0.58, 2.34)  18.4 1.15 (0.80, 1.65) 1.14 (0.79, 1.65) 
Outer regional/remote/very remote 25 (9) 40.0 1.33 (0.57, 3.13) 1.70 (0.65, 4.44)  15.7 1.35 (0.83, 2.19) 1.43 (0.86, 2.39) 
p-value 
  
0.80 0.54  
 
0.41 0.35 
Charlson comorbidity index (score)  
   
 
   Low (0) 139 (52) 32.4 1 1  21.1 1 1 
Medium (1) 79 (29) 29.1 0.86 (0.47, 1.57) 0.72 (0.38, 1.38)  25.4 0.83 (0.59, 1.16) 0.77 (0.53, 1.11) 
High (≥ 2) 50 (19) 50.0 2.09 (1.08, 4.04) 2.09 (1.05, 4.18)  12.3 1.27 (0.87, 1.85) 1.22 (0.82, 1.82) 
p-value 
  
0.04 0.02  
 
0.14 0.11 
ECOG performance status 
    
 
   Fully active 139 (59) 25.9 1 1  25.8 1f 1f 
Not fully active 97 (41) 44.3 2.28 (1.31, 3.96) 2.25 (1.28, 3.98)  13.3 1.63 (1.19, 2.21) 1.61 (1.18, 2.19) 
p-value 
  
0.004 0.01  
 
0.002 0.003 
  
  
1-year mortality (deaths=93) a  Overall survival b 
Exposure variable N (%) % dead 
Crude  
OR (95% CI) 
Adjusted  
OR (95% CI) e 
 
Median 
(months) 
Crude  
HR (95% CI) 
Adjusted  
HR (95% CI) e 
TNM stage h                
I 35 (13) 22.9 1 1  30.3 g 1 1 
II/III 230 (87) 36.1 1.91 (0.83, 4.39) 1.91 (0.83, 4.39)  19.2 2.26 (1.33, 3.83) 2.26 (1.33, 3.83) 
p-value     0.13 0.13    0.003 0.003 
Positive lymph nodes                
No 90 (34) 21.1 1 1  41.9 1 1 
Yes 175 (66) 41.1 2.61 (1.45, 4.71) 2.61 (1.45, 4.71)  16.6 2.15 (1.54, 3.02) 2.15 (1.54, 3.02) 
p-value     0.001 0.001    <0.0001 <0.0001 
Poorly differentiated / undifferentiated tumour  
No 83 (63) 36.1 1 1  22.5 1 1 
Yes 49 (37) 38.8 1.12 (0.54, 2.32) 1.12 (0.54, 2.32)  14.0 1.30 (0.86, 1.95) 1.30 (0.86, 1.95) 
p-value     0.76 0.76    0.22 0.22 
Tumour site                
Head/Neck/Uncinate process 218 (83) 35.3 1 1  19.2 1 1 
Body/Tail 46 (17) 32.6 0.89 (0.45, 1.74) 0.89 (0.45, 1.74)  30.4 0.73 (0.49, 1.10) 0.73 (0.49, 1.10) 
p-value     0.73 0.73    0.13 0.13 
Hospital type 
    
 
   Public 164 (61) 35.4 1 1  19.5 1 1 
Private 106 (39) 33.0 0.90 (0.54, 1.51) 1.14 (0.65, 2.02)  21.5 0.88 (0.66, 1.19) 0.99 (0.72, 1.37) 
p-value 
  
0.69 0.65  
 
0.41 0.95 
Any complications within 30 days of surgery 
No 141 (53) 29.8 1 1  21.1 1 1 
Yes 125 (47) 39.2   1.52 (0.91, 2.53)   1.46 (0.87, 2.45)  19.1   1.14 (0.85, 1.52) 1.15 (0.85, 1.54) 
p-value 
  
0.11 0.15  
 
0.37 0.37 
Margin status i 
    
 
   Involved or clear < 1 mm 148 (57) 40.5 1 1  16.2 1 1 
Clear ≥ 1 mm 113 (43) 28.3   0.58 (0.34, 0.98)   0.57 (0.32, 0.99)  32.1   0.52 (0.38, 0.71) 0.49 (0.36, 0.67) 
p-value   0.04 0.04   <0.0001 <0.0001 
  
  
1-year mortality (deaths=93) a  Overall survival b 
Exposure variable N (%) % dead 
Crude  
OR (95% CI) 
Adjusted  
OR (95% CI) e 
 
Median 
(months) 
Crude  
HR (95% CI) 
Adjusted  
HR (95% CI) e 
Treated with adjuvant chemotherapy j      
   No  57 (24) 57.9 1 1  10.3 1f 1f 
Yes 177 (76) 25.4   0.25 (0.13, 0.46)   0.33 (0.16, 0.69)  21.6   0.61 (0.43, 0.86) 0.72 (0.48, 1.08) 
p-value 
  
<0.0001 0.003  
 
0.005 0.11 
Surgeon volume, resections/year  
   
 
   ≥ 4 144 (53) 31.3 1 1  21.3 1f 1 
< 4 126 (47) 38.1 1.33 (0.80, 2.22) 1.75 (1.06, 2.87)  18.2 1.12 (0.84, 1.49) 1.14 (0.80, 1.63) 
p-value 
  
0.27 0.03  
 
0.44 0.45 
Hospital volume, resections/year  
   
 
   ≥ 6 184 (68) 33.7 1 1  19.8 1 1 
< 6 86 (32) 36.0 1.09 (0.60, 1.98) 1.00 (0.52, 1.93)  21.3 0.96 (0.68, 1.35) 0.99 (0.67, 1.44) 
p-value 
  
0.79 0.99  
 
0.81 0.94 
Combined surgeon and hospital volumes, resections/year 
≥ 4 and ≥ 6 (both high) 130 (48) 29.2 1 1  21.5 1f 1 
≥ 4 and < 6 14 (5) 50.0 2.70 (0.75, 9.74) 1.17 (0.27, 5.11)  14.7 1.12 (0.49, 2.54) 0.78 (0.29, 2.07) 
< 4 and ≥ 6 54 (20) 44.4 2.14 (1.11, 4.15) 1.62 (0.71, 3.68)  13.6 1.31 (0.86, 1.99) 1.19 (0.76, 1.84) 
< 4 and < 6 (both low) 72 (27) 33.3 1.32 (0.76, 2.28) 1.22 (0.63, 2.39)  22.0 1.02 (0.71, 1.46) 1.08 (0.73, 1.60) 
p-value     0.08 0.72    0.65 0.82 
a Crude and adjusted odds ratios (ORs) calculated using logistic regression.  
b Median survival calculated using Kaplan-Meier methods. Crude hazard ratios (HRs) calculated using Cox proportional hazards (PH) models. 
Adjusted HRs calculated using Cox PH or stratified Cox models. 
c Restricted to patients who had a completed resection and who were not found to have distant metastases during surgery.  
d When analysing associations with hospital and surgeon volume, we adjusted for patient clustering using GEEs with an exchangeable correlation 
matrix (mortality) and robust sandwich estimates of standard errors (overall survival). 
e Adjustment variables: Age, Socio-economic status, TNM stage, Positive lymph nodes, Poorly differentiated / undifferentiated tumour, Tumour 
site – none; Place of residence – age at diagnosis, Charlson comorbidity index and adjuvant chemotherapy treatment; Charlson comorbidity index – 
age at diagnosis and socio-economic status; ECOG performance status – age at diagnosis and Charlson comorbidity index; Hospital type – age at 
diagnosis, Charlson comorbidity index, ECOG performance status, TNM stage and hospital volume; Any complication – surgeon volume and hospital 
volume; Margin status – age at diagnosis, Charlson comorbidity index, ECOG performance status and TNM stage; Treated with adjuvant 
chemotherapy – age at diagnosis, Charlson comorbidity index, ECOG performance status, TNM stage, any complication within 30 days of surgery 
  
and total length of stay; Surgeon volume, Hospital volume, Combined surgeon and hospital volumes – age at diagnosis, Charlson comorbidity 
index, ECOG performance status, TNM stage and adjuvant chemotherapy treatment. 
f PH assumption violated for exposure variable. 
g Median value not available due to censoring; mean survival given instead. 
h Only 3 people had a TNM stage III tumour. 
i “Clear margins, distance not stated” assumed to be clear ≥ 1 mm. 
j Excludes patients who died during their acute admission. 
ECOG, Eastern Cooperative Oncology Group; GEE, generalised estimating equation; TNM, tumour node metastases.  
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In neither standard models (Table 9-11) nor propensity score-adjusted models (data not shown) was 
there an association between hospital volume and one-year mortality or OS (Figure 9-1); associations 
remained statistically non-significant after including surgeon volume as a potential confounder (data 
not shown). Mortality and OS were not associated with place of residence, tumour differentiation or 
site, hospital type, combined hospital and surgeon volume (Table 9-11), WBC count, albumin level 
or time from diagnosis to surgery (data not shown, OS: all P > 0.50). Results for RFS were similar to 
those for OS Of interest, however, chemotherapy treatment conferred a benefit (versus no treatment: 
median RFS, 14.3 versus 6.0 months; AHR 0.59, 95% CI 0.39-0.88 [standard model]; AHR 0.42, 
95% CI 0.28-0.64 [propensity score-adjusted model]) (Table 9-14). 
Complications and margin status 
Approximately half (47%) of all patients experienced ≥ 1 complication within 30 days of resection. 
LV surgeons had statistically non-significantly higher rates of any complications within 30 days 
(versus HV, 52% versus 42%, P = 0.17) (see Supplementary Table 4). The three most common 
complications were intra-abdominal sepsis (n=37), wound infection (n=27) and anastomotic leak 
(n=27). Wound infections were more common for LV surgeons (15% versus 6%) and LV hospitals 
(versus HV: 17% versus 7%), and LV surgeons had higher rates of intra-abdominal sepsis (20% 
versus 9%) (all P < 0.05). There were no statistically significant associations with anastomotic leak 
or haemorrhage.  
Of the 261 patients with a valid margin status, 43% (n = 113) had margins that were clear ≥ 1 mm. 
Preoperative assumed tumour status was the only factor statistically significantly associated with 
margin status; 36% of patients with locally advanced tumours had clear margins compared with 53% 
of those with confined disease (P = 0.01) (Table 9-12). Propensity score adjustment did not 
meaningfully change estimates of association between surgeon / hospital volume and margin status. 
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Table 9-12: Associations between selected exposure variablesa and margin status (n=261)b: 
logistic regressionc. 
  
N (%) 
Clear ≥1 mm (n=113) 
Exposure variable N (%)d 
Crude  
OR (95% CI) 
Adjusted  
OR (95% CI) e 
Preoperative assumed tumour status 
   Confined to pancreas 117 (46) 39.3 1 1 
Locally advanced 138 (54) 39.1 0.49 (0.30, 0.81) 0.50 (0.30, 0.83) 
p-value 
  
0.01 0.01 
Hospital type 
    Public 155 (59) 38.1 1 1 
Private 106 (41) 38.7 1.58 (0.96, 2.61) 1.44 (0.85, 2.45) 
p-value 
  
0.07 0.17 
Surgeon volume, resections/year 
≥ 4 142 (54) 38.0 1 1 
< 4 119 (46) 38.7 0.82 (0.46, 1.47) 0.84 (0.48, 1.47) 
p-value 
  
0.51 0.54 
Hospital volume, resections/year 
≥ 6 180 (69) 38.3 1 1 
< 6 81 (31) 38.3 0.83 (0.43, 1.60) 0.93 (0.46, 1.84) 
p-value     0.58 0.83 
a Data not shown for age at diagnosis, socioeconomic status, place of residence or tumour site; all 
p>0.15. 
b Restricted to people who had a completed resection, who were not found to have distant metastases, 
and who had complete margins data. Nine people had missing margins data. 
c Margins that were involved or clear <1 mm is the reference group. When analysing associations 
with hospital and surgeon volume, we adjusted for patient clustering using GEEs with an 
exchangeable correlation matrix. 
d Row percentages. 
d Adjustment variables: Pre-operative tumour status – hospital volume;  Hospital type – pre-
operative tumour status and hospital volume; Surgeon volume – pre-operative tumour status; 
Hospital volume – hospital type, pre-operative tumour status and surgeon volume. 
GEE, generalised estimating equation. 
 
DISCUSSION 
Consistent with the international literature, OS was worse for patients with declining performance 
status, unfavourable tumour characteristics or margins that were involved or clear < 1mm, and 
patients who had adjuvant chemotherapy treatment had better RFS. Older patients had higher one-
year mortality, but the association between age and OS diminished with time from surgery. Patients 
treated by LV surgeons had higher 90-day and one-year mortality and worse OS up to 1.5 years after 
surgery, but there were no significant associations between hospital volume and mortality or 
survival.  
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Of the tumour factors considered, lymph node positivity showed the strongest association with 
higher mortality and lower survival, consistent with expectations.86, 325 Similarly, the survival 
advantage observed for patients with stage I disease was not surprising. We did not confirm an 
association between poorly differentiated or undifferentiated tumours and worse outcomes,325-327 
most likely due to missing data for this factor. We also found no associations with tumour site; this is 
consistent with some findings,325, 343, 344 although others have found that those with tumours of the 
body or tail (versus head) had both worse328, 345, 346 and better22 survival.  
While age alone does not seem to be a contraindication to surgery,327, 347, 348 our findings suggest that 
complications have a more deleterious effect on older patients. Since patients treated by HV 
surgeons appeared to have lower rates of complication, older people should be treated by more 
experienced surgeons.  
An association between lower SES and poorer survival has been observed previously,327, 349, 350 with 
one study also showing that lower SES was associated with reduced likelihood of adjuvant 
chemotherapy treatment.327 Of all the potential mediators we considered, adjustment for 
chemotherapy treatment produced the greatest attenuation of the association between area-level SES 
and one-year mortality. However, the reduction was modest and the association remained statistically 
significant. Regardless, it is concerning that patients living in the most disadvantaged areas appeared 
to be less likely to see a medical oncologist, and potential differences in treatment access should be 
investigated further.  
Consistent with some,133, 138, 336 but not all114, 135, 351, 352 studies, we found that higher surgeon volume 
was associated with lower short-term mortality, including after adjustments for age and 
chemotherapy treatment. The magnitude of association estimated from our propensity score-adjusted 
model was similar to that obtained from a propensity-matched case-control analysis of 30-day 
mortality among patients undergoing a pancreatic resection for any cause (< 5 versus ≥ 5 
resections/year: AOR 2.04, 95% CI 1.20-3.57).133 In two studies that had a greater separation 
between LV and HV categories,138, 336 a stronger association was estimated; it remained statistically 
significant after adjustment for hospital volume suggesting that a substantial proportion of the 
apparent protective effect of hospital volume was attributable to surgeon volume. In contrast, 
surgeon volume was not statistically significant after accounting for hospital volume in another 
analysis,352 and a protective effect of hospital volume might explain null results from studies using 
data from a single HV hospital.135, 351  
Higher rates of complications may explain, in part, the higher mortality and lower survival amongst 
patients operated on by a LV surgeon.  Three quarters of the patients who died within 90 days were 
operated on by a LV surgeon, and the higher proportion of deaths from surgical complications 
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associated with LV surgeons was statistically significant. The attenuation of the association between 
surgeon volume and OS with time from surgery is consistent with complications mediating the 
relationship. Further, we found that patients who had complications fared worse in the first 8 months 
following surgery, and complications have been shown previously to increase the odds of in-hospital 
mortality.337  
Unlike many studies,114, 333-335 we did not observe poorer outcomes at LV hospitals, and it may be 
that more complicated cases are appropriately referred to HV hospitals. Indeed, HV hospitals treated 
proportionally more stage II/III cases than LV hospitals. Other explanations for our null findings 
should be considered. Most analyses of hospital volume have used a HV threshold considerably 
higher than ≥ 6 resections/year.114, 333-335 Only 5 of 50 hospitals in our study performed ≥ 11 
resections/year, the minimum volume recommended by the Leapfrog Group.353 It is possible that 
hospitals that were nominally HV in our analysis may not have had sufficiently high volumes for any 
protective effect to be apparent, although we explored a range of different thresholds and found no 
evidence of any association.  
At the time this study was performed, gemcitabine was the standard chemotherapeutic agent used in 
the adjuvant setting in NSW and QLD. Consistent with results from two phase III trials comparing 
surgery plus gemcitabine with surgery only (CONKO-001,3 JSAP-02354), we found that patients who 
received chemotherapy had significantly prolonged RFS. All three studies reported strikingly similar 
estimates of median RFS (14.3 versus 6.0 [current study], 13.4 versus 6.7 [CONKO-001], and 11.4 
versus 5.0 months [JSAP-2]) and hazard ratios (0.59 [current study], 0.55 [CONKO-001], 0.60 
[JSAP-2]). Unlike the CONKO-001 trial, neither our study (when using a standard model) nor the 
JSAP-2 trial found that chemotherapy treatment significantly improved OS, although HRs were 
again similar across all studies (0.72 [current study], 0.76 [CONKO-001], 0.77 [JSAP-2]). While 
chemotherapy treatment was an important predictor of survival ≥ 10 years from diagnosis, it was 
acknowledged that its use might be a proxy for better post-operative course and patient performance 
status.325 This may be true for our study, but results from our propensity score-adjusted models 
support the conclusion that adjuvant chemotherapy treatment improves outcomes.  
Several study limitations deserve mention. Despite our relatively large sample size, we were only 
able to explore the combined effect of surgeon and hospital volume at a rudimentary level, making it 
difficult to tease apart the relative contribution of these factors. Further, the thresholds used to define 
high- and low-volume surgeons and hospitals were relatively low. Using higher thresholds resulted 
in too few surgeons/hospitals in the high volume category to enable statistically robust analysis while 
accounting for clustering; only one surgeon performed more than 10 resections for pancreatic cancer 
per year. However we explored a range of different thresholds and our conclusion that surgeon but 
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not hospital volume influenced outcomes was unaltered. Since SES was assigned based on 
residential location, some individuals may be incorrectly classified. Despite careful adjustment, 
patient case mix might bias our estimates of associations with health service factors. To try to reduce 
this possibility, we adjusted for adjuvant chemotherapy treatment, in addition to comorbidities, when 
analysing surgical volume, mortality and survival, since it might be regarded as a surrogate for 
patients’ “fitness”.  We did not capture total lymph node positivity ratio so were unable to adjust for 
this in our analyses. 
The key strengths of this study are the relatively large sample size and the population-based design 
with patient records obtained for 96% of eligible patients.339 The use of extended Cox models 
permitted a rich assessment of patient outcomes as time from surgery elapsed, and comprehensive 
data collection allowed examination of possible mediators. 
Unlike some other studies we did not find any association with hospital volume, suggesting that 
rather than advocating a specific volume cut point guidelines may need to consider a more nuanced 
approach to advising on patient pathways, depending on the complexity of their disease. We did 
demonstrate worse survival for patients operated on by LV surgeons from the perioperative period to 
1.5 years following surgery, which may be partially explained by higher rates of complications. 
Systems should be implemented to ensure that surgeons are completing a sufficient number of 
resections to optimize patient outcomes. These findings may be particularly relevant for countries 
with a relatively small and geographically dispersed population.   
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Supplementary tables 
Table 9-13: Associations between selected exposure variables and aborted resection surgery: 
logistic regressiona. 
  N (%)b Unadjusted Adjusted 
Exposure variable All (n=365) Aborted (n=87) OR (95% CI) OR (95% CI) c 
Age at diagnosis, years 
    <60 104 (28) 25 (29) 1 1 
60-69 133 (36) 32 (37) 1.00 (0.55, 1.82) 1.00 (0.55, 1.82) 
≥70 128 (35) 30 (34) 0.97 (0.53, 1.78) 0.97 (0.53, 1.78) 
p-value 
  
0.99 0.99 
Socioeconomic status - quintiles 
   Most disadvantaged 74 (20) 12 (14) 1 1 
Second 81 (22) 21 (24) 1.81 (0.82, 4.00) 1.81 (0.82, 4.00) 
Third 67 (18) 20 (23) 2.20 (0.98, 4.94) 2.20 (0.98, 4.94) 
Fourth 75 (21) 20 (23) 1.88 (0.84, 4.19) 1.88 (0.84, 4.19) 
Least disadvantaged 66 (18) 13 (15) 1.27 (0.53, 3.01) 1.27 (0.53, 3.01) 
p-value 
  
0.31 0.31 
Place of residence 
    Major City 258 (71) 59 (69) 1 1 
Inner Regional 73 (20) 20 (23) 1.27 (0.71, 2.30) 1.27 (0.67, 2.42) 
Outer regional/remoted 32 (9) 7 (8) 0.94 (0.39, 2.29) 0.95 (0.38, 2.37) 
p-value 
  
0.70 0.73 
Tumour site 
    Head/Neck/Uncinate process 297 (83) 73 (86) 1 1 
Body/Tail 60 (17) 12 (14) 0.77 (0.39, 1.52) 0.77 (0.39, 1.52) 
p-value 
  
0.45 0.45 
Preoperative assumed tumour status 
   Confined to pancreas 148 (43) 28 (35) 1 1 
Locally advanced 199 (57) 53 (65) 1.56 (0.93, 2.61)   1.75 (1.02, 2.99) 
p-value 
  
0.09 0.04 
Any laparoscopy 
   
 
No 249 (68) 68 (78) 1 1 
Yes 116 (32) 19 (22) 0.52 (0.30, 0.92)   0.51 (0.29, 0.91) 
p-value 
  
0.02 0.02 
Any MRCP or CT (pancreas protocol) 
  
 
No 142 (39) 35 (40) 1 1 
Yes 223 (61) 52 (60) 0.93 (0.57, 1.52) 0.90 (0.55, 1.48) 
p-value 
  
0.77 0.68 
Any EUS or ERCP 
   
 
No 99 (27) 19 (22) 1 1 
Yes 266 (73) 68 (78) 1.45 (0.82, 2.56) 1.49 (0.83, 2.68) 
p-value 
  
0.21 0.18 
Hospital type 
    Public 226 (62) 55 (63) 1 1 
Private 139 (38) 32 (37) 0.93 (0.56, 1.53) 0.91 (0.54, 1.54) 
p-value 
  
0.77 0.73 
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  N (%)b Unadjusted Adjusted 
Exposure variable All (n=365) Aborted (n=87) OR (95% CI) OR (95% CI) c 
Surgeon volume, resections/year 
   ≥ 4 193 (53) 41 (48) 1 1 
< 4 171 (47) 45 (52) 1.24 (0.66, 2.30) 1.17 (0.62, 2.21) 
p-value 
  
0.50 0.62 
Hospital volume, resections/year 
   ≥ 6 245 (67) 53 (61) 1 1 
< 6 120 (33) 34 (39) 1.56 (0.86, 2.81) 1.57 (0.88, 2.82) 
p-value     0.14 0.13 
a When analysing associations with hospital and surgeon volume, we adjusted for patient clustering using 
GEEs with an exchangeable correlation matrix. 
b Column percentages. 
cAdjustment variables: Age, Socio-economic status, Tumour site – none; Place of residence – age at 
diagnosis and SES; Preoperative assumed tumour status –any laparoscopy, any MRCP or CT (pancreas 
protocol), and any EUS or ERCP; Any laparoscopy – Charlson comorbidity index, any MRCP or CT 
(pancreas protocol), any EUS or ERCP, and hospital volume; Any MRCP or CT (pancreas protocol),  Any 
EUS or ERCP – age at diagnosis, Charlson comorbidity index and hospital volume; Hospital type, Surgeon 
volume – SES; Hospital volume – age at diagnosis and Charlson comorbidity index. 
d Includes very remote locations. 
CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic 
ultrasound; GEE, generalised estimating equation; MRCP, magnetic resonance cholangiopancreatography; 
SES, socioeconomic status. 
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Table 9-14: Associations between selected exposure variables and recurrence-free survivala 
(n=261)b: Cox proportional hazards and stratified Cox modelsc. 
 
Exposure variable N (%) 
Median 
(months) 
Crude  
HR (95% CI) 
Adjusted  
HR (95% CI) d 
Age at diagnosis, years 
    <60 76 (29) 14.1 1e 1e 
60-69 98 (38) 11.8 1.10 (0.76, 1.61) 1.10 (0.76, 1.61) 
≥70 87 (33) 14.0 1.01 (0.68, 1.51) 1.01 (0.68, 1.51) 
p-value, p-trend  
 
0.85, 0.95 0.85, 0.95 
Socioeconomic status - quintiles     
Most disadvantaged 54 (21) 8.8 1 1 
Second 59 (23)  19.0 0.74 (0.46, 1.17) 0.74 (0.46, 1.17) 
Third 45 (17) 12.9 0.78 (0.47, 1.28) 0.78 (0.47, 1.28) 
Fourth 53 (20) 23.2 0.67 (0.41, 1.10) 0.67 (0.41, 1.10) 
Least disadvantaged 49 (19) 11.7 0.94 (0.58, 1.50) 0.94 (0.58, 1.50) 
p-value, p-trend  
 
0.46, 0.68 0.46, 0.68 
Place of residence  
   Major City 185 (71) 13.1 1 1 
Inner Regional 51 (20) 14.0 1.10 (0.75, 1.61) 1.08 (0.73, 1.59) 
Outer regional/remote/very remote 24 (9) 11.1 1.15 (0.68, 1.94) 1.12 (0.65, 1.94) 
p-value 
  
0.82 0.87 
Charlson comorbidity index (score)  
   Low (0) 134 (52) 13.0 1 1 
Medium (1) 77 (30) 19.0 0.82 (0.57, 1.18) 0.79 (0.54, 1.18) 
High (≥ 2)  48 (19) 9.4 1.22 (0.81, 1.83) 1.18 (0.77, 1.81) 
p-value  
 
0.23 0.25 
ECOG performance status  
   Fully active 138 (60) 21.6 1 1 
Not fully active 93 (40) 10.5 1.48 (1.06, 2.06) 1.50 (1.08, 2.10) 
p-value  
 
0.02 0.02 
TNM stage g        
I 34 (13) 22.1f 1 1 
II/III 222 (87) 11.9 1.81 (1.06, 3.08) 1.81 (1.06, 3.08) 
p-value    0.03 0.03 
Positive lymph nodes        
No 87 (34) 23.5f 1 1 
Yes 170 (66) 10.5 2.19 (1.52, 3.16) 2.19 (1.52, 3.16) 
p-value     <0.0001 <0.0001 
Poorly differentiated / undifferentiated tumour  
No 82 (63) 13.9 1 1 
Yes 49 (37) 9.0 1.34 (0.87, 2.06) 1.34 (0.87, 2.06) 
p-value    0.18 0.18 
Tumour site        
Head/Neck/Uncinate process 209 (82) 12.3 1 1 
Body/Tail 46 (18) 17.6 0.82 (0.54, 1.25) 0.82 (0.54, 1.25) 
p-value    0.35 0.35 
Hospital type  
   Public 156 (60) 12.5 1 1 
Private 105 (40) 14.0 0.99 (0.72, 1.35) 1.05 (0.74, 1.48) 
p-value  
 
0.94 0.79 
Any complication within 30 days of surgery 
No 141 (55) 14.3 1 1 
Yes 116 (45) 11.7   1.18 (0.86, 1.61) 1.15 (0.84, 1.58) 
p-value  
 
0.31 0.38 
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Exposure variable N (%) 
Median 
(months) 
Crude  
HR (95% CI) 
Adjusted  
HR (95% CI) d 
Margin status h 
Involved or clear < 1 mm 141 (56) 10.6 1 1 
Clear ≥ 1 mm 112 (44) 24.0 0.63 (0.46, 0.88) 0.62 (0.45, 0.86)  
p-value   0.01 0.005 
Treated with adjuvant chemotherapy  
   No  57 (24) 6.0 1e 1e 
Yes 177 (76) 14.3   0.52 (0.36, 0.74) 0.59 (0.39, 0.88) 
p-value  
 
0.0003 0.01 
Surgeon volume, resections/year  
   ≥ 4 142 (54) 13.0 1e 1 
< 4 119 (46) 13.1 1.04 (0.80, 1.35) 1.09 (0.82, 1.45) 
p-value  
 
0.77 0.54 
Hospital volume, resections/year  
   ≥ 6 178 (68) 12.1 1 1 
< 6 83 (32) 19.0 0.76 (0.54, 1.09) 0.71 (0.49, 1.04) 
p-value 
  
0.13 0.08 
Combined surgeon and hospital volumes, resections/year 
≥ 4 and ≥ 6 (both high) 129 (49) 13.1 1 1 
≥ 4 and < 6 13 (5) 12.5 0.85 (0.34, 2.13) 0.51 (0.15, 1.76) 
< 4 and ≥ 6 49 (19) 9.8 1.37 (0.92, 2.04) 1.37 (0.89, 2.11) 
< 4 and < 6 (both low) 70 (27) 19.0 0.83 (0.58, 1.18) 0.84 (0.59, 1.20) 
p-value    0.22 0.11 
a Median recurrence-free survival calculated using Kaplan-Meier methods.  
b Restricted to patients who had a completed resection, who were not found to have distant 
metastases during surgery, and who did not die during their acute admission.  
c Crude hazard ratios (HRs) calculated using Cox proportional hazards (PH) models. Adjusted HRs 
calculated using Cox PH or stratified Cox models. When analysing associations with hospital and 
surgeon volume, we adjusted for patient clustering using robust sandwich estimates of standard 
errors. 
d Adjustment variables: Age, Socio-economic status, TNM stage, Positive lymph nodes, Poorly 
differentiated / undifferentiated tumour, Tumour site – none; Place of residence – age at 
diagnosis, Charlson comorbidity index and adjuvant chemotherapy treatment; Charlson 
comorbidity index – age at diagnosis and socio-economic status; ECOG performance status – age 
at diagnosis and Charlson comorbidity index; Hospital type – age at diagnosis, Charlson 
comorbidity index, ECOG performance status, TNM stage and hospital volume; Any complication – 
surgeon volume and hospital volume; Margin status – age at diagnosis, Charlson comorbidity 
index, ECOG performance status and TNM stage; Treated with adjuvant chemotherapy – age at 
diagnosis, Charlson comorbidity index, ECOG performance status, TNM stage, any complication 
within 30 days of surgery and total length of stay; Surgeon volume, Hospital volume, Combined 
surgeon and hospital volumes – age at diagnosis, Charlson comorbidity index, ECOG performance 
status, TNM stage and adjuvant chemotherapy treatment. 
e PH assumption violated for exposure variable. 
f Median value not available due to censoring; mean survival given instead. 
g Only 3 people had a TNM stage III tumour. 
h “Clear margins, distance not stated” assumed to be clear ≥1 mm. 
ECOG, Eastern Cooperative Oncology Group; TNM, tumour node metastases.  
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